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General introduction

General introduction 9
EPiDEmioloGy of CERViCAl CANCER
Worldwide, cervical cancer is the fourth most common cancer in women. 
It was estimated that 528,000 women were diagnosed with cervical cancer 
in 2012 while 266,000 women died as a result of this disease. Incidence and 
mortality rates vary widely between developed and less developed regions. 
In 2012, 85% percent of the new cervical cancer cases occurred within the 
less developed regions, just as 87% of the deaths arising from cervical can-
cer. Mortality rates ranged from less than 2 per 100,000 women in Western 
Asia, Western Europe, and Australia/New Zealand, to almost 28 in Eastern 
Africa(1). The disease mainly affects young women, with a peak incidence 
at ages 40 to 55 years in unscreened women(2). 
In the Netherlands, the cervical cancer incidence and mortality have 
decreased since 1990 and 1970, although an increase in incidence was 
observed between 2004 and 2012 (Figure 1-1). In 2013, the incidence and 
mortality rate were 5.9 and 1.4 per 100,000 women-years, both standardized 
to the world’s age distribution(3). 
A prerequisite for the development of cervical cancer is infection with a 
high-risk type of the human papillomavirus (HPV)(4, 5). There are more 
than 100 HPV types of which approximately 40 are able to infect the epi-
thelium of the genital tract(6, 7). Approximately 15 of these HPV types are 
oncogenic and thus considered as high-risk HPV types(7, 8). As high-risk 
HPV is sexually transmitted, the risk of infection is strongly related with 
sexual behaviour. It increases with an earlier sexual debut and an increasing 
number of sexual partners, both for the woman and her male partner(9-11). 
The prevalence is age-dependent and reaches a maximum before the age of 
30(7, 11-14) where it can be as high as 27.4%(15). However, as most high-
risk HPV infections are transient, only 15 to 30% of them will progress to 
cervical intraepithelial neoplasia (CIN) (16-18). CIN lesions are considered 
as asymptomatic prestadia of cervical cancer and they are ranked to the 
severity of the lesion (CIN I, II, or III). Only a small part of these precursor 
stadia (approximately 1, 5, and 12% of  CIN I, CIN II, and CIN III lesions, 
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respectively(19)) will progress to cervical cancer in the absence of screen-
ing and treatment(20). Co-factors which are associated with an increased 
risk of cervical cancer are smoking, long-term oral contraceptive use, p53 
polymorphisms, and infections with other sexually transmitted diseases(9).
CERViCAl CANCER SCREENiNG
The preclinical detectable phase of cervical cancer (ie. CIN I until CIN III) 
is estimated to last on average more than ten years(21-23), which makes 
it ideal for screening. In developed countries, cervical abnormalities are 
detected by using a Pap smear. Cervix uteri exfoliated cells are collected by 
a nurse, general practitioner, or gynaecologist and examined by a cytologist 
figure 1-1. Cervical cancer incidence and mortality in the Netherlands, standardized to the 
world’s age distribution(3). 
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to identify the presence of cellular abnormalities. According to the severity 
of these abnormalities, women will either be invited for a triage test a couple 
of months later or they will be referred directly to a gynaecologist for a 
colposcopy. For the use of different cytological classification systems, and 
the correspondence between them and histological outcomes of biopsies 
taken at the gynaecologist, see Table 1-1. 
A CIN II+ lesion can be treated by local destructive therapy or by complete 
excision of the transformation zone, of which the latter is preferred accord-
ing to European guidelines(24). Treatment diminishes the risk of cervical 
cancer with 95%(25), although it increases the risk of preterm delivery, 
extremely low birth weight infants and perinatal mortality(26). As the 
majority of the lesions would not have progressed to cervical cancer(19, 20, 
22), it is important to find a balance between prevention of cervical cancer 
on the one hand and overdiagnosis and overtreatment on the other. Since 
the percentage of CIN I lesions progressing to cervical cancer is extremely 
low, Dutch guidelines advice to treat them only in exceptional cases. For 
instance, when the CIN I lesion is persistent or if adequate follow-up cannot 
be guaranteed(27).  
Table 1-1. Agreement between different cytological classification systems and histological 
outcomes(28, 29). In the Netherlands, the Pap classification was used before 1996. There-
after, the CISOE-A classification was used. Another classification system, which is interna-
tionally often used, is the Bethesda classification(30). 
Histological 
outcomes
Cytological 
outcomes according 
to Pap
Cytological 
outcomes according 
to CISOE-A
Cytological 
outcomes according 
to Bethesda
Normal 1 S1 O1 E1/E2 Negative
CIN I 2/3a1 S2/S3/S4 O3/O4 E3/4 ASC-US/ LSIL / ASC-H*
CIN II 3a2 S5 O5 E5 HSIL
CIN III 3b/4 S6 O6/O7 E6/E7 HSIL
Carcinoma Carcinoma S8/S9 O7/O8 E9 Carcinoma
*ASC-H has no official equivalent at the Pap and CISOE-A classification systems. Usually, it 
is classified in the same group as ASC-US and LSIL.
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History of screening in the Netherlands
Cervical cancer screening exists in the Netherlands since the 1970s. At that 
time no centrally organized programme was in place, but screening was 
implemented and organized per region. Since the mid-80s decentralized 
screening was offered to women aged between 35 and 53 years with a 3-year 
interval. As coverage was low and false-positivity rate was high(31-33), 
screening was reorganized in 1996: the age range was extended to ages 30 to 
60, the interval was extended from three to five years, all non-attendees re-
ceived a reminder, financing and managing was centrally organized, oppor-
tunistic screening smears were discouraged and no longer reimbursed(34), 
and the description of cervical smears by Pap terminology was replaced by 
using the more detailed CISOE-classification(35) (Table 1-1). Moreover, 
the definition of a negative smear was extended. Sole inflammation of the 
epithelium was no longer defined as a Pap 2 but as a Pap 1, which increased 
the specificity while keeping the sensitivity at a similar level(36). In addi-
tion, the triage scheme was adjusted. Women with a primary Pap 2/3a1 
were invited for cytology triage six and 18 months later and women with a 
≥Pap3a2 were referred directly to the gynaecologist. In 2002, the definition 
of a negative primary smear was again altered. The absence of endocervical 
cells was no longer a reason for a woman to be referred to triage(34).  
This reorganization and subsequent changes mainly resulted in a decreased 
percentage of women sent to follow-up, an increased compliance with 
follow-up, and a decreased average time in follow-up(34). Overall, it has 
proven that the introduction of cervical cancer screening has effectively 
reduced the incidence and mortality of cervical cancer(2, 37). 
liquid-based cytology testing and HPV triage
Approximately since 2005, the use of cytology triage testing has gradually 
been replaced by the use of cytology combined with HPV triage testing, 
which is accepted by the Dutch national guidelines for Pathology(38). With 
cytology triage testing alone, women are tested both at six and 18 months, 
independent of the result at six months. When HPV triage testing at six 
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months is added, women are referred back to the routine screening pro-
gramme if no cytological abnormalities are found and no high-risk HPV 
virus is detected (Figure 1-2). This resulted in an increased specificity as 
fewer women underwent secondary repeat testing. In addition, women will 
no longer be referred to the gynaecologist in case the cytology triage test at 
six months is classified as a Pap 2/3a1, and no HPV virus is detected, and 
the triage cytology at 18 months is classified as Pap 1 (Figure 1-2). Despite 
this change in protocol, no decrease in the number of women being referred 
to the gynaecologist was observed. Moreover, an unexpected effect of the 
addition of HPV triage testing was an increase in the rate of CIN I and CIN 
II lesions detected via triage. An explanation for this phenomenon could 
be that prior knowledge of the HPV result affected cytological classifica-
tions(39). 
Liquid-based cytology (LBC) has been developed as an alternative for 
the use of the conventional cytology Pap test as it has certain advantages, 
such as: ease of processing, reduction of unsatisfactory slides, reduction of 
time needed to read the slides and the ability of co-testing for the HPV 
virus(40-48). Conventional cytology and LBC share the same method of 
sampling cells from the cervix (ie. scraping off cells with a brush or similar 
device from the histological transition zone). LBC differs from conventional 
cytology with respect to the transfer of cells from brush to slide. With con-
ventional cytology, cells are directly smeared on a slide, while with LBC, the 
brush is first rinsed into a vial with a preservative fluid and then transported 
to the laboratory(49). In the laboratory, a uniform layer of cells is prepared 
onto the slide(50, 51). The rationale behind this is that this method of cell 
transfer results in a better representation of the entire sample as compared 
to conventional cytology where a selective proportion of the sample is 
transferred to the slide(52). In addition, this uniform monolayer is easier to 
interpret for a cytologist as compared to conventional cytology smears. The 
latter can be obscured by blood or inflammation, have a bad cell fixation 
and/or an inhomogeneous distribution of cells(49). Earlier studies have 
shown that the sensitivity to detect CIN II+ lesions is similar between con-
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ventional cytology and LBC testing(49, 52, 55-60). Because of this supposed 
similarity in CIN II+ sensitivity and the above-mentioned advantages of 
LBC over conventional cytology, the Dutch society for Pathology permitted 
the use of LBC tests SurePath and ThinPrep(38). As a result, the majority of 
Dutch laboratories processing primary screening tests switched from using 
conventional cytology to either SurePath or ThinPrep since 2000. However, 
differences in techniques are apparent between these types of LBC tests 
(Table 1-2), while the effects of these differences on their performances were 
unknown at the time. 
Recently, some of the laboratories processing primary LBC screening tests 
have implemented automated reading of these tests. This means that the 
automated reader assists the cytologist in examining the slide by pointing 
Table 1-2. Preparation and protocol differences between LBC tests SurePath and Thin-
Prep(53, 54). 
Protocol concerning: SurePath ThinPrep
Preservative liquid Ethanol based Methanol based
Collecting device The cervical specimen is 
collected using a broom like 
device with detachable head. The 
detachable head is placed in a 
vial with preservative fluid. Then, 
the vial is transported to the 
laboratory
The cervical specimen is 
collected using a Cervix Brush 
and the brush is rinsed in a vial 
with preservative fluid. Cells are 
released by pushing the brush to 
the bottom, forcing the bristles 
apart and swirling the brush 
into the fluid. Subsequently, the 
brush is discarded and the vial is 
transported to the laboratory.
Method of cell 
transfer
At the laboratory, the brush 
is discarded followed by 
centrifugation of the fluid and 
cells to isolate the cells from the 
fluid. The cells are resuspended 
in a sucrose density gradient 
followed by slide transfer using 
gravity for adherence.  A manual 
imprint system is used to 
prepare slides in advance.
At the laboratory, cells are 
isolated from the fluid by 
vacuum filtration and are 
transferred to the slide using air 
pressure for adherence. 
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out areas which need a closer look (ie. were cell abnormalities are likely to 
be present). The effect of automated reading on CIN II+ sensitivity of LBC 
tests is currently unknown as study results are heterogeneous(61-64). 
Altogether, these innovations have resulted in a mixture of using three dif-
ferent types of primary cytology tests (ie. conventional cytology, SurePath or 
ThinPrep) and a mixture of using two different triage schemes (ie. cytology 
or cytology combined with HPV triage testing) within the current Dutch 
cervical cancer screening programme (Figure 1-2). In addition, examina-
tion of LBC tests SurePath and ThinPrep can be done with or without the 
assistance of automated reading.
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figure 1-2. Screening scheme as currently used in the Netherlands. The examination of 
LBC tests SurePath and ThinPrep can be done with or without the assistance of automated 
reading. See Table 1-1 for the agreement between the Pap and Bethesda classification sys-
tem. 
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Primary HPV and self-testing 
The causality between HPV and cervical cancer makes primary HPV 
screening a good alternative to primary cytology screening. Multiple studies 
have shown that the sensitivity to detect CIN II+ or CIN III+ lesions is higher 
when using primary HPV as compared to primary cytology testing(65, 
66). Furthermore, as the negative predictive value of a primary HPV test is 
higher than that of a primary cytology test, the interval between screening 
rounds could be extended when replacing primary cytology by primary 
HPV screening without affecting its effectiveness (65, 66). It is expected that 
from 2016 onward, primary high-risk HPV testing will be implemented in 
the Dutch cervical cancer screening programme and the screening interval 
will be extended from five to ten years starting from the age of 40(67, 68). 
Consequently, women will be invited for screening at ages 30, 35, 40, 50, and 
60 years. If they do not attend screening or had a positive HPV test in the 
previous screening round, the ten-year interval will be lowered to five years. 
Triage will consist of immediate cytology co-testing and cytology testing six 
months later. If cell abnormalities are found (ie. ≥Pap 2) besides the HPV 
virus, the woman will be referred to the gynaecologist (Figure 1-3).
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figure 1-3. Future screening scheme which is expected to be used from 2016 onward.
General introduction 17
The possibility of self-sampling is another important advantage of HPV 
testing over cytology testing(69-71). This is important as self-sampling 
may increase the attendance when offered to non-attendees(72, 73). As the 
majority of the cervical cancers in the Netherlands are estimated to occur in 
non-attendees(74), it might be a promising method to decrease the cervical 
cancer incidence and mortality. Therefore, the Dutch Ministry of Health has 
decided that HPV self-sampling will be added to the primary HPV cervical 
cancer screening programme by offering it to non-attendees(67, 68). 
HPV vaccination
Since 2009, HPV vaccination has been implemented in the Dutch National 
Immunisation Programme. Twelve year old girls are vaccinated with the 
bivalent Cervarix vaccine against high-risk HPV types 16 and 18(75), which 
are responsible for more than 70% of the cervical cancer cases in Europe 
and North America(8). In addition, a catch-up campaign was organized for 
thirteen to sixteen year old girls born between 1993 and 1996)(75). Thus, 
the first vaccinated cohort will reach the screening age of 30 in 2023. As the 
coverage is approximately 60%(76) and vaccinated women are still at risk 
for cervical cancer caused by HPV types other than 16 and 18, it is expected 
that cervical cancer screening will still be necessary. The composition of 
this programme (eg. separate screening policies for vaccinated and unvac-
cinated women) is currently under investigation(77).  
moNiToRiNG of THE DuTCH CERViCAl CANCER 
SCREENiNG PRoGRAmmE
Since 1996, monitoring and evaluation is part of the cervical cancer screen-
ing programme. In that way obstacles which endanger the effectiveness of 
the programme can be identified as early as possible, using short-term (eg. 
attendance rates, the number of women referred to triage, and CIN detec-
tion rates) and long-term outcomes (eg. interval cancer rates: defined as a 
cervical cancer diagnosed after a negative primary screening smear). Sub-
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sequently, interventions can take place in order to ensure the effectiveness 
of the programme. This is of importance as the screening strategies (and 
screening tests) are based on microsimulations and assumptions which may 
differ from real-life settings. Moreover, long-term outcomes such as interval 
cancers are too rare to be examined in most clinical trials, while they can be 
assessed using population-based data. 
The national monitoring and evaluation has been performed by the Depart-
ment of Public Health of the Erasmus MC in Rotterdam. It comprises of 
publishing periodic reports (eg. in 2009, 2011, and 2013(78-80)) and cost-
effectiveness analyses examining the effects and costs of the programme 
after the reorganisation of 1996(81). 
The nationwide registry of histo- and cytopathology (PAlGA)
This database contains information on all cytological and histological ex-
aminations of the cervix uteri taken in the Netherlands, covering all Dutch 
pathology laboratories. Every woman has her own identification code, 
while date, reasoning (ie. screening or not), and results are also registered. 
This makes it possible to follow individual screening histories. Therefore, 
for most of our analyses described in this thesis, data were retrieved from 
the PALGA database. As these data contain millions of records and dozens 
of variables, SQL queries were designed to select the data needed for the 
analyses we were interested in. 
Aim of THE THESiS
The aim of this thesis is to give an overview of the effects of using new 
screening tests in the Dutch cervical cancer screening programme. In the 
first part (questions 1-4, corresponding with Chapters 2-5), we focus on the 
effects of using LBC tests SurePath and ThinPrep in the current programme. 
In the second part (questions 5-7, corresponding with Chapters 6-8), we 
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focus on the effects of non-attendance and offering HPV self-sampling to 
non-attendees in the future primary HPV programme. 
1. What is the effect of using Surepath and thinprep as primary test 
method on CIN II+ detection rates?
Although multiple studies compared the ability to detect CIN II+ 
between ThinPrep and conventional cytology(45, 49, 52, 57, 59, 60), 
only two have compared the ability between SurePath and conventional 
cytology(42, 58). In addition, none have compared the performance 
of both SurePath and ThinPrep with conventional cytology, while 
differences in protocol are present. Therefore, we examined the 
effect of using LBC tests SurePath and ThinPrep versus conventional 
cytology as primary test method within the current Dutch cervical 
cancer screening programme. All primary smears taken within 
this programme from 2000 to 2011 were analyzed using PALGA. We 
performed logistic regression analyses to examine whether CIN 
and cervical cancer detection rates differed between the types of 
cytological tests, adjusted for confounding factors.
2. are increasing CIN detection rates caused by implementation of 
LBC tests?
During the last decade, CIN I, II, and III detection rates have increased 
in the Dutch screening programme (source: PALGA). As LBC testing 
was recently implemented in the programme, we quantified the 
increase in CIN detection rates and assessed whether the increase 
was still present when adjusting for differences in types of cytology 
tests used over time. 
3. Is there a difference in sensitivity to detect progressive CIN 
lesions between Surepath, thinprep, and conventional cytology?
As in the absence of screening (and associated treatment) only a 
fraction of CIN lesions would progress to cervical cancer, detecting an 
equal or increased CIN rate is not necessarily equivalent to preventing 
equally or increased numbers of cervical cancers. To assess whether 
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the ability to detect progressive CIN lesions differs between SurePath, 
ThinPrep, and conventional cytology, we compared interval cancer 
rates between the three types of cytology tests by performing Cox 
regression analyses, adjusted for confounding factors.
4. What is the amount of overdiagnosis in the Dutch cervical cancer 
screening programme?
Cervical cancer screening is aimed at finding and treating CIN 
lesions in order to prevent the development of cervical cancer, which 
has resulted in a decrease of the cervical cancer incidence rate. 
Therefore, cervical cancer overdiagnosis is not really an issue within 
cervical cancer screening, although the detection of CIN lesions did 
increase and it is estimated that only a few of these lesions would 
have progressed to cervical cancer without treatment(19). In addition, 
the detection of  a CIN lesion is associated with a decreased quality of 
life because of the  psychosocial burden(82), and because treatment 
results in increased risks on adverse pregnancy outcomes(26). 
Therefore, we calculated the amount of overdiagnosis in cervical 
cancer upon inclusion of pre-invasive lesions using the MISCAN-
Cervix model. 
5. how many cervical cancer cases in young women can potentially 
be prevented using a more sensitive screening test at age 30?
The CIN II+ sensitivity of primary high-risk HPV testing is higher as 
compared to that of conventional cytology(65, 83), which probably 
leads to an increased prevention of cervical cancers cases and 
deaths. Notwithstanding, the CIN II+ specificity is lower(65, 83), which 
probably leads to increased numbers of triage testing and referrals 
to gynaecologist, both associated with an inevitable loss in quality of 
life(82). Nevertheless, it is expected that in general the benefits of 
primary HPV testing will outweigh the harms(84, 85). However, it is 
questionable whether this is also the case within young women aged 
below 35 years as (i) HPV infections are more often transient within 
younger women(65) and (ii) the prevalence of high-risk HPV infections 
peaks before the age of 35. To get a better understanding of the 
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potential benefit of switching from conventional cytology to a more 
sensitive screening test at young age, we estimated the proportion 
of cancer cases within 30 to 35 year old women that could have been 
prevented by using a more sensitive screening test at first screening 
at age 30. We analyzed the screening history of 30 to 35 year old 
women diagnosed with cervical cancer between 2004 and March 
2009 and assessed the percentage of cervical cancer cases that were 
preceded by a negative cytology test under the age of 35. Also, we 
assessed the percentage of cervical cancer cases without a history 
of cervical cancer screening in order to get a better understanding of 
the potential impact of increasing attendance rates as compared to 
switching to a more sensitive screening test.  
6. When is it effective to offer self-sampling to non-attendees of 
organized primary hpV screening?
Offering HPV self-sampling to non-attendees of cervical cancer 
screening could be used to increase participation rates and thereby 
decrease cervical cancer incidence and mortality. Its effect on the 
effectiveness of the programme probably not only depends on the 
increase in attendance, but also on the test characteristics of HPV 
self-sampling and on the ability to target higher underlying risk non-
attendees. Moreover, “switching” of regular attendees from office-
based to self-sampling could, given a loss in detection (ie. more loss 
to follow-up and a possible lower sensitivity), result in a decrease 
of the effectiveness of the programme. In other words, the quality-
adjusted life-years (QALYs) gained by attracting non-attendees could 
be annulled by the QALYs lost by switching of regular attendees. 
However, it is unclear at which level of switching this will happen. 
Therefore, we examined effects of parameters, such as: the relative 
CIN II+ sensitivity and specificity (self-sampling versus regular 
sampling), the extra attendance via self-sampling, the underlying risk 
of extra attendees, and the percentage of women switching. We used 
the MISCAN-Cervix model to estimate under which conditions adding 
HPV self-sampling to the primary HPV screening programme would 
be more effective (ie. QALYs would be gained). 
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7. Is lower socioeconomic status associated with an increased 
underlying cervical cancer risk?
Lower socioeconomic status (SES) is considered to be a risk factor 
for developing cervical cancer(86, 87), which might be attributed 
solely to their lower screening participation rate(88-90), but could 
also be partly due to other factors. Therefore, we included all first-
time attendees without any history of cervical examinations to 
eliminate influences of differences in screening history and uptake. 
We compared the cervical cancer risk between women living in low 
and intermediate versus high SES neighbourhoods who attended the 
organized cervical cancer screening programme between 2000 and 
2007. As the SES of a neighbourhood is indicative of the SES of its 
inhabitants, we extrapolated our results from the ecological to the 
individual level.
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AbSTRACT
Background. Within the last decade, SurePath and ThinPrep [both liquid-
based cytology (LBC) tests] have replaced conventional cytology as pri-
mary test method in cervical cancer screening programmes of multiple 
countries. The aim of our study was to examine the effect in the Dutch 
screening programme. 
Methods. All primary smears taken within this programme from 2000 to 
2011 were analyzed using the nationwide registry of histo- and cytopa-
thology (PALGA) with a follow-up until March 2013. The percentage of 
smears classified as borderline/mildly dyskaryotic (BMD) and >BMD as 
well as CIN and cervical cancer detection rates were compared between 
SurePath and ThinPrep versus conventional cytology by logistic regres-
sion analyses (adjusted for age, screening region, socioeconomic status, 
and calendar time). 
results. We included 3,118,685 conventional cytology, 1,313,731 SurePath 
and 1,584,587 ThinPrep smears. Using SurePath resulted in an increased 
rate of primary smears classified as >BMD [odds ratio (OR) = 1.12 
(95% confidence interval (CI): 1.09, 1.16)]. CIN I and II+ detection rates 
increased by 14% [OR = 1.14 (95% CI: 1.08, 1.20)] and 8% [OR = 1.08 
(95% CI: 1.05, 1.12)]. Cervical cancer detection rates were unaffected. 
Implementing ThinPrep did not result in major alterations of the cyto-
logical classification of smears, and it did not affect CIN detection rates. 
While not significant, cervical cancer detection rates were lower [OR = 
0.87 (95% CI: 0.75, 1.01)]. 
Conclusions. The impact of replacing conventional cytology by LBC as 
primary test method depends on the type of LBC test used. Only the use 
of SurePath was associated with increased CIN II+ detection, although it 
simultaneously increased the detection of CIN I.
Keywords. Cervical intraepithelial neoplasia; Liquid-based cytology; Sure-
Path; ThinPrep; Conventional cytology; Screening
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bACKGRouND 
Since the 1980s, a national cervical cancer screening programme exists in 
the Netherlands. From 1996 onward, women are invited every five years 
from ages 30 to 60 years. The screening strategy consists of primary cytology 
screening with triage by repeat cytology or triage by a combination of repeat 
cytology and human papillomavirus (HPV) testing (Figure 2-1). Despite its 
limited sensitivity(65), the conventional cytology test has long been used as 
primary test method. 
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Triage cytology test at 6 months 
 
No cytological abnormalities 
Return to routine 
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>BMD  Referral to 
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figure 2-1. Triage protocol consisting of triage cytology (A) without HPV testing, and (B) with 
HPV testing. 
HPV = Human papillomavirus; BMD = Borderline and mildly dyskaryotic smears.
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Within the last 10 to 15 years, conventional cytology has been replaced by 
liquid-based cytology (LBC) tests SurePath or ThinPrep in most of Dutch 
laboratories processing primary screening tests. Conventional cytology and 
both LBC systems share the same method of sampling cells from the cervix 
(ie. scraping off cells with a brush or similar device from the histological 
transition zone). LBC differs from conventional cytology with respect to 
the transfer of cells from brush to slide: with conventional cytology, cells 
are directly smeared on a slide, while with LBC, the brush is first rinsed into 
a vial with a preservative fluid and then transported to a laboratory(49). 
In the laboratory, a uniform layer of cells is prepared on the slide(50, 51). 
It is thought that this method of cell transfer (which differs between Sure-
Path and ThinPrep) results in a better representation of the entire sample 
as compared to conventional cytology(52). A review which evaluated the 
applicability of LBC in the Dutch cervical cancer screening programme 
concluded that further research was needed to determine the applicability 
of SurePath. Furthermore, they recommended to further analyse the costs 
and benefits of ThinPrep before deciding whether or not to implement this 
method(91). Yet, public health authorities in the Netherlands permitted use 
of both LBC systems based on perceived advantages such as: ease of process-
ing, reduction in unsatisfactory slides(40, 42, 46, 48), and time needed to 
read the slides(42, 43, 45, 47). Finally, the use of LBC allowed for easier 
application of HPV co-testing(41, 44). 
The use of conventional cytology as primary test method has also been 
replaced by the use of SurePath and/or ThinPrep in many other countries 
with and without organized cervical cancer screening programmes, such as 
Denmark, the UK, and the USA(92, 93). It is believed that the sensitivity 
of LBC for detecting cervical intraepithelial neoplasia (CIN) II+ lesions is 
similar to that of conventional cytology(55, 56). However, when stratifying 
for the type of LBC test used, many studies have been published comparing 
CIN detection between ThinPrep and conventional cytology(45, 49, 52, 
57, 59, 60), while only two studies have compared CIN detection between 
SurePath and conventional cytology(42, 58). Moreover, no studies have 
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been published comparing CIN detection rates between the three types of 
cytology tests. As the outcome of all cervix uteri cytological and histological 
tests taken within the Dutch screening programme were available [ie. are 
registered in the Dutch Pathology Register (PALGA)(94)] and we were able 
to deduce which type of primary cytology test had been used, we assessed 
whether differences in CIN detection rates were present when screened by 
SurePath or ThinPrep as compared to conventional cytology. In addition, we 
assessed the effect on cervical cancer detection rates and on the classifica-
tion of smears. 
mETHoDS
Information on all cervix uteri cytological and histological tests in the 
Netherlands registered from January 2000 until March 2013 was retrieved 
from PALGA. Women are identified through their birth date and the first 
eight letters of their (maiden) family name. This identification code enables 
linkage of tests belonging to the same woman, allowing us to follow indi-
vidual screening histories. We identified primary smears (ie. first smear of 
an episode) taken within the national cervical cancer screening programme 
between January 2000 and December 2011. A minimum duration of 15 
month follow-up was ensured as data until March 2013 were available. 
Histological confirmed CIN lesions and cervical cancer cases were identi-
fied by selecting all PALGA records that included corresponding pathology 
codes. Detection of these conditions was assigned to the type of cytology 
test used. Age was defined as the woman’s age at the time of the primary 
smear and was categorised as: 29-33, 34-38, 39-43, 44-48, 49-53, 54-58, and 
59-63 years. As women are invited every five years in the year they turn 30, 
35, .., 60 years, these age categories reflect different screening rounds. The 
cervical cancer screening programme is organized by five different screen-
ing organizations, each accounting for a geographical region (ie. screening 
region) (North, South-West, Middle-West, South and East).  Screening 
regions were coded corresponding with the place of residence at the time 
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of the primary smear. Socioeconomic status (SES) was defined (low, middle, 
high) according to the status score, which is an ecological variable based on 
the four-digit postal code of the woman’s place of residence at the time of 
the primary test(95). Status scores per four-digit postal code were provided 
by the Netherlands Institute for Social Research based on 1) mean income, 
2) percentage of households with a low income, 3) percentage of households 
with, on average, a low education, and 4) unemployment rate in 2010(96). 
Low SES corresponded with a status score lower than -1 (ie. average status 
score minus standard deviation), intermediate SES with a score of ≥-1 and 
≤1, and high SES with a score higher than 1 (ie. average status score plus 
standard deviation).
In PALGA, the type of cytology testing is not routinely registered. Therefore, 
the date of conversion was retrieved from the laboratories fixed to one of the 
quarters per year, since most labs had a phase in-phase out transition period 
of 2-4 months. This information was linked to PALGA as a proxy for which 
type of primary cytology test was used (ie. in the Netherlands, laboratories 
supply the tools for cytology and thus determine the type of cytology test 
that is used by the general practitioner). 
Type of cytology testing
With conventional cytology, cervical specimen is collected (ie. no data were 
available on the type of device or brush used), and cells are directly smeared 
from the sampling device on the slide. With SurePath, cervical specimen 
is collected using a broom like device with detachable head. The detach-
able head is placed in a vial with an ethanol based preservative fluid. At the 
laboratory, the fluid and cells are centrifuged to isolate the cells from the 
fluid. The cells are resuspended in a sucrose density gradient followed by 
slide transfer using gravity for adherence. With ThinPrep, cervical specimen 
is collected using a Cervix Brush, and the brush is rinsed in a vial with a 
methanol based preservative fluid. Cells are released by pushing the brush to 
the bottom, forcing the bristles apart, and swirling the brush into the fluid. 
Subsequently, the brush is discarded. At the laboratory, cells are isolated 
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from the fluid by vacuum filtration and are transferred to the slide using air 
pressure for adherence(53). 
Statistical analyses
Since LBC was implemented per laboratory at different points in time, 
calendar time is expected to differ between the three types of cytology tests. 
The demographic characteristics of attending women (ie. age, screening 
region, and SES) also differ between laboratories; hence, we expected that 
they also differ between the cytology tests. As age, SES, screening region, 
and calendar time are all associated with CIN and/or cervical cancer(97, 
98), they are all potential confounding factors. We used a Pearson’s chi-
squared test to assess whether their distributions differed between the types 
of cytological tests. Thus, we tested whether they were confounders or not. 
A p value of less than 0.05 was considered to be statistically significant. 
We performed logistic regression analyses to examine whether CIN and 
cervical cancer detection rates differed between the types of cytological 
tests, adjusted for confounding factors. Moreover, we assessed how these 
overall changes in CIN and cervical cancer detection rates, if present, were 
composed. First, we examined whether the rate of primary smears classi-
fied as borderline/mildly dyskaryotic (BMD) differed between the types 
of cytological tests. Second, we assessed whether CIN and cervical cancer 
detection rates in women with a BMD smear were different between the 
types of tests, which would indicate that the positive predictive value (PPV) 
of a primary BMD smear differed. Third, we combined these two steps to 
examine whether the tests differed in the fraction of primary smears both 
classified as BMD and resulting in the detection of a CIN or cervical cancer. 
By performing the same analyses for having a >BMD smear, we could assess 
whether potential differences in CIN and cervical cancer rates were (mainly) 
caused by differences in the triage (ie. those with a primary BMD smear) or 
direct referral pathway (ie. those with a primary >BMD smear). Finally, we 
assessed the overall difference in CIN and cervical cancer detection rates, 
regardless of the cytological result.
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Missing values were imputed with 10 multiple imputations for confounding 
factors. The odds ratio (OR) was interpreted as relative risk if the prevalence 
of the outcome (ie. BMD, >BMD, CIN I, CIN II, CIN III, cervical cancer or 
CIN II+) was <10% in the respective logistic regression model analysis(99). 
The software programme SPSS (version 20) was used to perform the statisti-
cal analyses.  
RESulTS  
We included 3,118,685 primary conventional cytology smears, 1,313,731 
primary SurePath smears, and 1,584,587 primary ThinPrep smears in our 
analyses. The distribution of calendar time significantly differed between 
figure 2-2. Distribution of the types of cytological tests used within the Dutch screening 
programme. The total number of primary smears where the type of cytological test was 
known varied from 441,663 in 2000 to 541,587 in 2007.
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the methods of cytology testing (p <0.001). In 2000, 94% of the primary 
cytology tests performed within the Dutch screening programme consisted 
of conventional cytology, while in 2011 this percentage has dropped to 
2% (Figure 2-2). The distribution of age, SES, and screening region also 
Table 2-1. Population characteristics. 
Conventional SurePath ThinPrep P value
N 3,118,685 1,313,731 1,584,587
Screening region <0.001
   1, n (%) 430,548 (13.8) 503,967 (38.4) 352,790 (22.3)
   2, n (%) 822,189 (26.4) 178,844 (13.6) 538,890 (34.0)
   3, n (%) 482,137 (15.5) 311,276 (23.7) 296,609 (18.7)
   4, n (%) 872,931 (28.0) 294,939 (22.5) 206,098 (13.0)
   5, n (%) 501,852 (16.1) 24,471 (1.9) 187,279 (11.8)
   Unknown, n (%) 9,028 (0.3) 234 (0.0) 2,921 (0.2)
SES <0.001
   Low, n (%) 257,544 (8.3) 156,058 (11.9) 107,983 (6.8)
   Middle, n (%) 2,574,027 (82.5) 1,045,158 (79.6) 1,331,613 (84.0)
   High, n (%) 239,623 (7.7) 87,591 (6.7) 132,439 (8.4)
   Unknown, n (%) 47,491 (1.5) 24,924 (1.9) 12,552 (0.8)
Age <0.001
   29-33 years, n (%) 428,600 (13.7) 170,699 (13.0) 195,935 (12.4)
   34-38 years, n (%) 522,173 (16.7) 191,193 (14.6) 220,462 (13.9)
   39-43 years, n (%) 533,438 (17.1) 222,906 (17.0) 271,924 (17.2)
   44-48 years, n (%) 496,856 (15.9) 219,118 (16.7) 265,672 (16.8)
   49-53 years, n (%) 446,596 (14.3) 195,127 (14.9) 243,354 (15.4)
   54-58 years, n (%) 388,637 (12.5) 171,194 (13.0) 207,405 (13.1)
   59-63 years, n (%) 302,385 (9.7) 143,494 (10.9) 179,835 (11.3)
The distributions of factors associated with CIN and/or cervical cancer detection rates 
between the three primary test methods are given. If a distribution significantly differs 
between the primary tests (which is tested with a Pearson’s Chi-Square test), the variable is 
considered to be a confounding factor. 
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Table 2-2. Logistic regression analyses on the classification of smears and histological out-
comes when tested by SurePath or Thinprep versus conventional cytology, adjusted for age, 
SES, screening region, and calendar time. 
Outcome SurePath ThinPrep
*BMD 0.96 (0.94, 0.97) 1.02 (1.01, 1.04)
¥PPV of a primary BMD smear on histological outcomes
CIN I 1.26 (1.18, 1.34) 1.03 (0.97, 1.10)
CIN II 1.16 (1.08, 1.25) 1.04 (0.97, 1.12)
CIN III 0.95 (0.88, 1.02) 0.87 (0.81, 0.94)
Cervical Cancer 0.74 (0.49, 1.12) 0.62 (0.41, 0.92)
#Fraction of primary smears both classified as BMD and resulting in the detection of the 
following histological outcomes
*CIN I 1.20 (1.13, 1.27) 1.06 (0.99, 1.12)
*CIN II 1.14 (1.07, 1.22) 1.08 (1.00, 1.15)
*CIN III 0.99 (0.92, 1.06) 0.93 (0.87, 1.00)
*Cervical Cancer 0.77 (0.51, 1.15) 0.66 (0.43, 1.00)
*>BMD 1.12 (1.09, 1.16) 0.96 (0.93, 0.99)
¥PPV of a primary >BMD smear on histological outcomes
CIN I 0.92 (0.83, 1.03) 0.86 (0.77, 0.97)
CIN II 1.06 (0.98, 1.15) 1.08 (0.99, 1.17)
CIN III 0.97 (0.91, 1.03) 1.06 (0.99, 1.13)
Cervical Cancer 0.94 (0.80 , 1.10) 0.98 (0.83, 1.15)
$Fraction of primary smears both classified as >BMD and resulting in the detection of the 
following histological outcomes
*CIN I 1.05 (0.94, 1.16) 0.83 (0.74 , 0.92)
*CIN II 1.17 (1.09, 1.27) 1.02 (0.94, 1.10)
*CIN III 1.10 (1.06, 1.15) 1.00 (0.96, 1.04)
*Cervical Cancer 1.07 (0.91, 1.24) 0.93 (0.79, 1.09)
Overall histological outcomes
*CIN I 1.14 (1.08, 1.20) 0.98 (0.93, 1.04)
*CIN II 1.14 (1.09, 1.20) 1.04 (0.99, 1.10)
*CIN III 1.06 (1.02, 1.10) 0.98 (0.94, 1.01)
*Cervical Cancer 0.99 (0.86, 1.14) 0.87 (0.75, 1.01)
Odds ratios with a 95% confidence interval are given. This table shows how the overall 
changes in CIN and cervical cancer detection rates, if present, are composed. The differ-
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significantly differed between the methods of cytology testing (Table 2-1). 
For instance, most conventional cytology tests were performed in screening 
region 4 (28%), while most SurePath and ThinPrep tests were performed in 
screening regions 1 (38.4%) and 2 (34.0%). Thus, calendar time, age, SES, 
and screening region were all considered confounding factors and missing 
values were imputed for 1.6 % of the primary smears. 
The effect of SurePath versus conventional cytology, adjusted for 
confounding factors
When comparing using SurePath with using conventional cytology as pri-
mary test method, 4% fewer primary smears were classified as BMD [OR of 
0.96 (95% confidence interval (CI): 0.94 – 0.97)], while a BMD smear more 
often led to a CIN I [OR of 1.26 (95% CI: 1.18, 1.34)] or CIN II diagnosis 
[OR of 1.16 (95% CI: 1.08, 1.25)]. Combined this led to a 20% [OR of 1.20 
(95% CI: 1.13, 1.27)] and 14% [OR of 1.14 (95% CI: 1.07, 1.22)] increase in 
the fraction of primary smears both classified as BMD and resulting in the 
detection of a CIN I or CIN II lesion (Table 2-2, for the unadjusted results 
see the Supplementary Information). 
ences in the odds of primary smears classified as BMD combined with the differences in 
the odds of the PPV of a BMD smear led to differences in the fraction of primary smears 
both classified as BMD and resulting in the detection of a CIN or cervical cancer. By per-
forming the same analyses for having a >BMD smear, we could assess whether potential 
differences in CIN and cervical cancer rates were (mainly) caused by differences in the 
triage (ie. those with a primary BMD smear) or direct referral pathway (ie. those with a 
primary >BMD smear). Altogether, this led to differences in odds of overall CIN and cervical 
cancer detection.
Bold = Significant. A p value of <0.05 was considered to be statistically significant.
BMD = Borderline and mildly dyskaryotic smears; PPV = Positive predictive value
* Odds ratio could be interpreted as detection rate ratio because the prevalence of the 
outcome was <10%.
¥ This can be interpreted as: Does a BMD or >BMD smear more often lead to the follow-
ing histological outcomes when using SurePath or ThinPrep as compared to conventional 
cytology.
# Histological outcomes detected via triage.
$ Histological outcomes detected via direct colposcopy.
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The rate of primary smears classified as >BMD increased by 12% [OR of 
1.12 (95% CI: 1.09, 1.16)], whereas a smear classified as >BMD led to a 
similar number of CIN I, CIN II, CIN III and cervical cancer diagnoses. As a 
result, the fraction of primary smears both classified as >BMD and resulting 
in the detection of a CIN II or CIN III lesion increased by 17% [OR of 1.17 
(95% CI: 1.09, 1.27)] and 10% [OR of 1.10 (95% CI: 1.06, 1.15)].
Overall, CIN I, CIN II, and CIN III detection rates increased by 14% [OR 
of 1.14 (95% CI: 1.08, 1.20)], 14% [OR of 1.14 (95% CI: 1.09, 1.20)], and 
6% [OR of 1.06 (95% CI: 1.02, 1.10)], respectively, when using SurePath as 
compared to using conventional cytology as primary test method. Cervical 
cancer detection rates were equivocal between both tests [OR of 0.99 (95% 
CI: 0.86, 1.14)]. CIN II+ detection rates increased by 8% [OR of 1.08 (95% 
CI: 1.05, 1.12)]. 
The effect of ThinPrep versus conventional cytology, adjusted for 
confounding factors
When using ThinPrep as compared to using conventional cytology as pri-
mary test method, the rate of primary smears classified as BMD increased 
by 2% [OR of 1.02 (95% CI: 1.01, 1.04)], although a primary smear classified 
as BMD less often resulted in a CIN III [OR of 0.87 (95% CI: 0.81, 0.94)] or 
cervical cancer diagnosis [OR of 0.62 (95% CI 0.41, 0.92)]. Combined this 
led to a marginally significant 8 % increase [OR of 1.08 (95% CI 1.00, 1.15)] 
in the fraction of primary smears both classified as BMD and resulting in 
the detection of a CIN II lesion. The fraction of primary smears both classi-
fied as BMD and resulting in the detection of a CIN I lesion nonsignificantly 
increased [OR of 1.06 (95% CI: 0.99, 1.12)], while the fraction both classi-
fied as BMD and resulting in the detection of a CIN III or cervical cancer 
nonsignificantly decreased [ORs of 0.93 (95% CI: 0.87, 1.00) and 0.66 (95% 
CI: 0.43, 1.00), respectively] (Table 2-2, for the unadjusted results see the 
Supplementary Information).
39SurePath leads to increased CIN II+
The rate of primary smears classified as >BMD decreased by 4% [OR of 
0.96 (95% CI: 0.93, 0.99)]. A primary smear classified as >BMD less often 
resulted in a CIN I diagnosis [OR of 0.86 (95% CI: 0.77, 0.97)], although 
it nonsignificantly resulted in more CIN II and CIN III diagnoses [ORs of 
1.08 (95% CI: 0.99, 1.17) and 1.06 (95% CI: 0.99, 1.13), respectively]. As a 
result, fraction of primary smears both classified as >BMD and resulting in 
the detection of a CIN I lesion decreased by 17% [OR of 0.83 (95% CI: 0.74, 
0.92)].
Overall, using ThinPrep as primary test method did not have a significant 
effect on CIN I [OR of 0.98 (95% CI: 0.93, 1.04)], CIN II [OR of 1.04 (95% 
CI: 0.99, 1.10)], CIN III [OR of 0.98 (95% CI: 0.94, 1.01)] (Table 2-2) or CIN 
II+ detection rates [OR of 0.99 (95% CI: 0.96, 1.02)]. Cervical cancer detec-
tion rates were nonsignificantly lower [OR of 0.87 (95% CI: 0.75, 1.01)]. 
DiSCuSSioN
Using SurePath versus conventional cytology as primary test method re-
sulted in a 12% increase in the rate of primary smears classified as >BMD. 
The rate of primary smears classified as BMD decreased by 4% and women 
with a primary BMD smear were more often diagnosed with CIN I or II. 
Combined this led to increased fractions of primary smears both classified 
as BMD and resulting in the detection of a CIN I or CIN II lesion, and to 
increased fractions of primary smears both classified as >BMD and result-
ing in the detection of a CIN II or CIN III lesion. Altogether, the detection 
of CIN II+ increased by 8% accompanied by a 14% increase in the detection 
of CIN I. Cervical cancer rates were unaffected. The comparison of using 
ThinPrep versus conventional cytology did not result in such findings, 
although the sensitivity to detect cervical cancers might be lower. 
Given the differences in preparation between both LBC methods, it is 
possible that the sensitivity for CIN II+ differs between them as well. For 
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instance, it was shown that the cell yield is larger when the collecting device 
was retained instead of discarded from the vial with preservative fluid(100, 
101), meaning that if the protocol is followed the cell yield is larger when 
using SurePath (ie. collecting device is retained) than when using ThinPrep 
(ie. collecting device is discarded). Therefore, the probability of transferring 
abnormal cells from the cervical specimen (if present) to the slide is probably 
larger when using SurePath. The study of Rask et al. seems to confirm this, 
since they found that replacing conventional cytology by SurePath resulted 
in a significant 31% increase in cytological abnormalities within 23-29 aged 
women, while replacing conventional cytology by ThinPrep resulted in a 
nonsignificant 11% decrease(92). 
Our research demonstrated that CIN II+ detection rates are similar between 
ThinPrep and conventional cytology, which is compatible with results of 
previous studies. For instance, the observed CIN II+ detection rate ratio of 
0.99 (95% CI: 0.96, 1.02) fits with the pooled relative CIN II+ sensitivity 
of 1.03 (95% CI: 0.97, 1.09) as reported in the meta-analysis of Arbyn et 
al. (ie. our point estimate lies within the 95% CI)(55). However, that ratio 
was based on seven studies comparing LBC with conventional cytology of 
which two did not use ThinPrep as LBC test method. When only focusing 
on the included ThinPrep studies, we found and calculated (ie. using data 
provided in the study) CIN II+ detection rate ratios of 1.17 (95% CI: 0.87, 
1.56)(57), 0.97 (95% CI: 0.61, 1.55)(60), 0.95 (95% CI: 0.62, 1.48)(52), and 
1.09 (95% CI: 0.80, 1.48)(59), which were all compatible to the detection 
rates observed in the present study. The CIN II+ detection rate ratio of the 
fifth included ThinPrep study was not provided nor could be calculated(45). 
Furthermore, the largest randomized controlled trial performed so far, 
including almost 90,000 participants, found a CIN II+ detection rate ratio 
of 1.00 (95% CI: 0.84, 1.20)(49) which also fits our data. When focusing on 
studies comparing SurePath with conventional cytology, only one previous 
study matched our criteria (ie. providing a CIN II+ detection rate ratio, or 
data needed to calculate it, at a cut-off of ASCUS or BMD)(58). Again, their 
data [ie. a CIN II+ detection rate of 1.01 (95% CI: 0.76, 1.33)] fitted with ours 
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[ie. a ratio of 1.08 (95% CI: 1.05, 1.12)] (ie. our point estimate lies within the 
reported 95% CI). 
It is expected that from 2016 onward, primary cytology screening will be 
replaced by primary HPV screening in the Dutch cervical cancer screening 
programme. If high-risk HPV is present, a reflex cytology triage test will be 
carried out on the same sample followed by another triage test six months 
later, if the reflex cytology triage test shows no abnormalities. If one of these 
smears is classified as ≥BMD, the woman will be referred to the gynaecologist 
for colposcopy, otherwise she will be referred to routine screening. Whether 
our results can be extended from a primary screening to a triage population 
depends on the performance of the cytology tests on (i) fluid remnant after 
primary HPV testing in HPV-positive women (in case of  reflex triage test-
ing), and (ii) directly taken material in (previously) HPV-positive women 
(in case of triage testing at six months). Although prior knowledge of the 
HPV status influences the interpretation of cytological smears(102, 103), 
we assume this effect to be similar for the three types of cytology tests. If 
true, we expect the differences in sensitivity between Surepath, ThinPrep, 
and conventional cytology in a triage population to be equivalent to the dif-
ferences in a primary screening population. However, this assumption has 
not been tested yet. In addition, because conventional cytology cannot be 
performed on fluid remnant after primary HPV testing(50, 55), our results 
of comparing SurePath and ThinPrep with conventional cytology cannot be 
extended to reflex triage testing. As data of Cuzick et al. suggested that the 
performance of HPV assays depends on the type of LBC test used(104), it 
is also possible that the performance of LBC tests on fluid remaining after 
HPV testing depends on the type of HPV assay used. Thus, more research 
is needed to assess which combination of primary HPV test and secondary 
reflex LBC test has the highest CIN II+ sensitivity. 
We were the first who compared CIN and cervical cancer detection rates 
between Surepath, ThinPrep and conventional cytology.  Furthermore, we 
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included more than six million primary smears, and we showed its effect in 
real practice instead of in a strictly controlled setting. 
At the same time, the lack of a more controlled setting is one of the limita-
tions of our study. As ThinPrep and SurePath were used in different women, 
differences in demographic factors were inevitable. Although we were able 
to correct for confounders age, screening region, SES, and calendar time, 
we were not able to correct for other potential confounding factors such 
as screening history or compliance with the given advice. Both could have 
resulted in biased effect estimates if their distribution differed between the 
types of cytology tests. In addition, no data are present whether cytology 
triage testing at six months was combined with HPV testing. Because of the 
possibility of co-testing, it is likely that the use of HPV triage is correlated 
with the use of primary LBC testing. As it is known that more CIN I and 
CIN II lesions are detected when cytology triage is combined with HPV(39), 
it is probable that the increased sensitivity of SurePath to detect CIN I and 
CIN II was partly caused by the simultaneous use of HPV testing. However, 
the entire increase in CIN III detection rates when comparing Surepath 
with conventional cytology, and for a large part also the increase in CIN II 
detection rates, is caused by an increase of primary smears being classified 
as >BMD. Therefore, we still believe that SurePath results in increased CIN 
II+ detection rates although it might be accompanied by a smaller increase 
in CIN I detection than estimated. Also, we did not have individual data 
on which type of primary test was used. Therefore, we combined the date 
of the primary smear and the quarter of the year within which the labora-
tory introduced the LBC test as proxy for the type of cytology test that was 
used. This means that primary screening smears taken during this quarter 
could have been misclassified, resulting in slightly underestimated effects. 
Another shortcoming of the study was that we were not able to correct for 
the use of automated reading, although this has only been introduced in 
relatively few Dutch laboratories. As study results on the effect of automated 
screening are heterogeneous, it is unknown how this affected our effect 
estimates. If automated reading does not affect the sensitivity for CIN II+, 
as shown by Klug and Palmer et al.(61, 62), our estimates are not biased. If 
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automated reading results in a decreased sensitivity for CIN II+, as shown 
in the MAVARIC study(63), we might have underestimated the effect of 
using SurePath and ThinPrep on CIN II+ detection rates. If it results in an 
increased sensitivity, we might have overestimated the effects. At last, we did 
not correct for possible learning curve effects, as the aim of our study was 
to examine the effect of using SurePath and ThinPrep in routine-practice, 
which also includes a possible learning effect.  
Our results indicate that the widespread use of SurePath as primary test 
method has led to an increased probability to detect both CIN I and CIN 
II+ lesions. As only a small fraction of CIN I lesions progress to cancer, 
increased CIN I detection is often regarded as increased overdiagnosis. In 
contrast, CIN II+ lesions are associated with a substantial cancer risk and 
are therefore often considered as clinically relevant. However, whether the 
increased probability to detect CIN II+ lesions indeed corresponds with an 
increased sensitivity for progressive lesions remains to be investigated. If 
this is the case, using SurePath would in due time result in a decrease of 
the incidence and mortality of cervical cancer, thereby increasing the health 
benefits of the screening programme. If not, it would only lead to increased 
burden and harms through overdiagnosis (and treatment) of regressive CIN 
lesions. The widespread use of ThinPrep as primary test method did not lead 
to changes in CIN II+ detection rates, although cervical cancer detection was 
nonsignificantly lower. Whether these results imply a decreased sensitivity 
for progressive CIN II+ lesions is unknown. For evidence as to whether the 
detection of progressive CIN II+ lesions is higher with any of the LBC tests 
than with conventional cytology, cervical interval cancer rates have to be 
compared.
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AbSTRACT
Background. Over the last decade, cervical intraepithelial neoplasia (CIN) 
detection has increased in the Netherlands. We investigated the underly-
ing mechanism by quantifying the increase, and analyzing patterns of 
CIN and cervical cancer detection over time. 
Methods. We observed annual CIN and cervical cancer detection rates per 
10,000 primary smears within the Dutch screening programme for 2000 
to 2011. Joinpoint analyses were performed to determine changes in time 
trends, logistic regression analyses to assess the relative risk of calendar 
time on histological outcomes, adjusted for demographic factors and 
type of primary cytology test used. 
results. Trends of increased detection occurred for all CIN grades (ie. 
detection rates increased from 17.8 to 36.1, from 21.0 to 35.5, and from 
43.4 to 64.6 for CIN I, II, and III from 2003 to 2009). After adjusting for 
demographic factors, detection rates were still 2.11 [95% confidence in-
terval (CI): 1.95, 2.29], 1.79 (95% CI: 1.66, 1.92), and 1.59 (95% CI: 1.50, 
1.67) times higher in 2009. When also adjusting for the type of cytology 
test, detection rates were 1.90 (95% CI: 1.62, 2.22), 1.48 (95% CI: 1.22, 
1.79), and 1.55 (95% CI: 1.39, 1.73) times higher. No trends in cervical 
cancer detection rates were found.
Conclusions. The implementation of liquid-based cytology contributed 
to the CIN increase. If some of these extra detected CIN are regressive 
this leads to overdiagnosis. Other factors, such as an increased cervical 
cancer risk, and implementation of imaging-assisted reading, could also 
have contributed. 
Keywords. Cervical cancer; Screening; Trend; Cervical intraepithelial neo-
plasia 
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bACKGRouND
Cervical intraepithelial neoplasia (CIN) is considered a preclinical precur-
sor of cervical cancer and is graded (CIN I, II, and III) by the severity of 
the dysplasia(105, 106). The long total duration of the detectable preclini-
cal dysplastic stage [ie. more than 10 years on average(21-23)] means that 
screening is an appropriate approach for cervical cancer prevention. A na-
tional cervical cancer screening programme has existed in the Netherlands 
since the 1980s, with women aged 30–60 invited every five years since 1996. 
Despite its limited sensitivity(65), cytology is still utilized as the primary 
screening and triage test. After a borderline or mildly dyskaryotic (BMD) 
result (ie. corresponding to ASC-H of the Bethesda classification), women 
are invited for triage cytology tests six [with or without high-risk human 
papillomavirus (HPV) testing] and 18 months later (see the Supplementary 
Information for a detailed triage protocol). For a worse result (ie. >BMD), 
women are immediately referred to a gynaecologist. According to the guide-
lines, CIN II and III are always treated, while CIN I is only treated when 
persistent(107). The Dutch screening programme achieves a cervical smear 
coverage of almost 80%(80). 
During the last decade, CIN detection rates have rapidly increased in the 
Dutch screening programme(80). It is important to reveal the underlying 
mechanism, so that possible adjustments to the screening programme can 
be made in order to ensure its effectiveness. We therefore quantified the 
increase in CIN detection rates, unadjusted and adjusted for differences in 
demographic factors and types of cytology tests used over time. In addition, 
we analyzed patterns of CIN detection by age, screening region, and the 
cytological classification of smears. Furthermore, we studied cervical cancer 
detection rates and the cytological classification of smears over time. 
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mETHoDS 
Data collection
Information on all cervix uteri cytological and histological tests in the 
Netherlands registered from January 2000 until March 2013 were retrieved 
from the nationwide network and registry of histology and cytopathology 
PALGA(94). Women were invited every five years in the year they turn 30, 
35, .., 60 so that attendance occurs in age groups 29-33, 34-38, …, 59-63. 
These women are identified through their birth date and the first eight let-
ters of their (maiden) family name. This identification code enables linkage 
of the woman’s tests, allowing us to follow individual screening histories. 
We identified primary smears (ie. first smear of an episode) taken within the 
national screening programme between January 2000 and December 2011, 
which ensures a minimum follow-up of 15 months after a primary smear. 
Histologically confirmed CIN lesions or cervical cancer cases following pri-
mary smears were identified by selecting all PALGA records that included 
corresponding pathology codes. Detection of these conditions was assigned 
to the calendar year of the primary smear. Age was defined as the age at the 
primary smear, and was categorized as: 29– 33, 34–38,..., 59–63. The cervical 
cancer screening programme is organized by five different screening orga-
nizations, each accounting for a geographical region (ie. screening region) 
(North, South-West, Middle-West, South, and East). Screening regions were 
coded corresponding with the place of residence at the time of the primary 
smear. Women were stratified to low, intermediate or high socioeconomic 
status (SES) according to their status score, which is an ecological variable 
based on the four-digit postal code of the woman’s place of residence at 
the time of the primary test(95). Status scores per four-digit postal code 
were provided by the Netherlands Institute for Social Research(96) based 
on (i) mean income, (ii) percentage of households with a low income, (iii) 
percentage of households with, on average, a low education, and (iiii) un-
employment rate in 2010. Low SES corresponded with a status score lower 
than -1 (ie. average status score minus standard deviation), intermediate 
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SES with a score of ≥-1 and ≤1, and high SES with a score higher than 1 (ie. 
average status score plus standard deviation). 
The type of primary cytology test used (ie. conventional cytology, SurePath, 
or ThinPrep) was based on the date of the primary smear, the laboratory 
involved, and the date of conversion from the laboratory. This conversion 
date was retrieved from the laboratories and fixed to one of the quarters per 
year, as most laboratories had a phase in-phase out transition period of 2-4 
months, and this information was linked to PALGA as a proxy for which 
type of primary cytology test was used. 
Statistical analyses
Annual CIN and cervical cancer detection rates were calculated as the num-
ber of diagnoses per 10,000 primary smears, allocated to the calendar year 
of the primary smear, unstratified and stratified by cytological classification 
(ie. BMD or >BMD). CIN was defined as all histological neoplastic lesions 
in the cervix similar to CIN I, CIN II, or CIN III, including glandular neo-
plasia (such as adenocarcinoma in situ). The annual rate of smears classified 
as BMD and >BMD were also calculated.
Joinpoint analyses were performed to identify time trends, using the Join-
point Regression Programme (version 4.0.4.) from the Statistical Research 
and Applications Branch of the US National Cancer Institute(108). Annual 
percent changes (APCs) with their corresponding 95% confidence intervals 
(CIs) were calculated by fitting a regression line to the natural logarithm of 
the rates using calendar time as independent variable [ie. y = ax + b where y 
= ln(rate) and x = calendar year, then APC = 100 * (e^a-1)]. 
We performed logistic regression analyses to examine whether the rate of 
smears classified as BMD or >BMD increased over time (ie. for the period 
depicted by joinpoint analysis), unadjusted and adjusted for differences in 
demographic factors (ie. age, screening region, and SES) and differences in 
types of cytology tests used over time. As the effect of the type of primary 
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cytology used could differ between age groups(92) and laboratories, we 
included two-way interaction terms between the type of primary cytology 
test and age, and between the type of primary cytology test and screening 
region (ie. as proxy for the laboratories involved).  
Similar analyses were performed to assess whether CIN and cervical cancer 
detection rates increased over time. Missing values were imputed with 10 
multiple imputations for the type of primary cytology test used, screening 
region, and SES (ie. 15.2% of the cases had one or more missing values). 
The odds ratio (OR) was interpreted as relative risk if the prevalence of the 
outcome was <10%(99). The software programme SPSS (version 20) was 
used to perform statistical analyses. 
RESulTS
Out of 6,470,400 primary cytology tests in the screening programme from 
2000 to 2011, there were 16,837 CIN I (26.0 per 10,000 primary smears), 
17,193 CIN II (26.6 per 10,000 primary smears), 34,380 CIN III (53.1 per 
10,000 primary smears), and 2,180 cervical cancer (3.4 per 10,000 primary 
smears) diagnoses.
The average CIN I detection rate decreased from 2000 to 2004 by 6.3% (95% 
CI: -10.7, -1.6) per year (Figure 3-1), followed by an average increase of 
15.7% (95% CI: 10.7, 20.9) per year from 2004 to 2009. CIN II detection rates 
increased from 2000 to 2005 by 3.8% (95% CI: 1.4, 6.3) annually, and from 
2005 to 2009 by 11.8% (95% CI: 6.9, 16.9). Average CIN III detection rates 
decreased by 5.6% (95% CI: -10.6, -0.3) from 2000 to 2003, then increased 
by 6.6% (95% CI: 4.2, 9.1) per year from 2003 to 2009. From 2009 onward, 
no significant annual changes were detected for all CIN grades. There were 
no significant trends for cervical cancer detection over the studied period 
[APC of 1.2 (95% CI: -0.3, 2.8)]. 
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figure 3-1. Trends in crude CIN and cervical cancer detection rates as observed within 
the national screening programme. Joinpoints are depicted by larger symbols. The annual 
percent changes are given with their 95% confidence interval for the periods depicted by 
joinpoint analyses (eg. CIN I detection decreased by 6.3% per year from 2000-2004 and in-
creased by 15.7% from 2004-2009). Bold estimates are statistically significant
Table 3-1. Relative risk of CIN I, CIN II, CIN III, and cervical cancer in 2009 compared with 
2003, unadjusted and adjusted for confounding factors. 
CIN I CIN II CIN III Cervical cancer
Model 1 2.03 (1.88, 2.19) 1.69 (1.57, 1.82) 1.49 (1.41, 1.57) 1.10 (0.89, 1.35)
Model 2 2.11 (1.95, 2.29) 1.79 (1.66, 1.92) 1.59 (1.50, 1.67) 1.12 (1.01, 1.25)
Model 3 1.90 (1.62, 2.22) 1.48 (1.22, 1.79) 1.55 (1.39, 1.73) 1.05 (0.70, 1.59)
Odds ratio given can be interpreted as relative risk as the prevalence of the outcomes is 
<10%. The 95% confidence interval is given in brackets. Bold = Significant. A p value of 
<0.05 was considered to be statistically significant. 
Model 1 = The effect of calendar time.
Model 2 = The effect of calendar time adjusted for demographic factors age, screening 
region, and SES. 
Model 3 = The effect of calendar time adjusted for demographic factors age, screening 
region, and SES + type of primary cytology test used. Two-way interaction terms between 
screening region and the type of primary cytology test used, and age and the type of pri-
mary cytology test used were also included. 
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Between 2003 and 2009 the detection rate increased for CIN I from 17.8 
to 36.1 diagnoses per 10,000 primary smears (Figure 3-1), for CIN II from 
21.0 to 35.5, and for CIN III from 43.4 to 64.6. This corresponds with a 
2.11 (95% CI: 1.95, 2.29), 1.79 (95% CI: 1.66, 1.92), and 1.59 (95% CI: 1.50, 
1.67) times increased probability of being diagnosed with CIN I, CIN II, 
or CIN III, respectively, when adjusted for differences in demographic fac-
tors (Table 3-1). When also adjusting for the type of primary cytology test 
used, these relative risks were 1.90 (95% CI: 1.62, 2.22), 1.48 (95% CI: 1.22, 
1.79), and 1.55 (95% CI: 1.39, 1.73), respectively. The probability of being 
diagnosed with cervical cancer did not change over time.
Table 3-2. Relative risk of CIN I, CIN II, and CIN III in 2009 compared with 2003, per age 
group and screening region. 
CIN I CIN II CIN III
Age group
   29-33 2.28 (1.72, 3.02) 1.50 (1.15, 1.96) 1.74 (1.46, 2.07)
   34-38 2.10 (1.54, 2.86) 1.13 (0.79, 1.62) 1.38 (1.10, 1.72)
   39-43 1.59 (1.05, 2.39) 1.57 (1.15, 2.15) 1.60 (1.22, 2.10)
   44-48 1.74 (1.21, 2.50) 1.93 (1.31, 2.84) 1.55 (1.17, 2.06)
   49-53 1.83 (1.24, 2.70) 1.43 (0.87, 2.37) 1.60 (1.09, 2.35)
   54-58 1.78 (1.09, 2.93) 2.33 (1.18, 4.61) 1.07 (0.59, 1.97)
   59-63 1.04 (0.49, 2.23) 1.06 (0.41, 2.76) 0.74 (0.35, 1.57)
Screening 
region
   1 1.83 (1.49, 2.25) 1.34 (1.09, 1.64) 1.26 (1.08, 1.45)
   2 1.95 (1.42, 2.67) 1.54 (1.13, 2.09) 1.67 (1.36, 2.04)
   3 2.46 (1.29, 4.68) 1.81 (0.68, 4.82) 1.79 (0.97, 3.33)
   4 1.84 (1.43, 2.37) 1.21 (0.92, 1.60) 1.92 (1.60, 2.29)
   5 1.53 (1.01, 2.33) 2.06 (1.45, 2.92) 1.44 (1.12, 1.86)
Adjusted for age (if applicable), screening region (if applicable), SES, and the type of prima-
ry cytology test used. Two-way interaction terms between screening region and the type of 
primary cytology test used (if applicable), and age and the type of primary cytology test used 
(if applicable) were also included. Odds ratio given can be interpreted as relative risk as the 
prevalence of the outcomes is <10%. The 95% confidence interval is given in brackets. Bold 
= Significant. A p value of <0.05 was considered to be statistically significant.
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Trends seemed similar between most age groups for all CIN grades (Supple-
mentary Information). When adjusting for demographic factors and the 
type of primary cytology test used, no significant differences in increased 
CIN detection rates seemed were found between age groups (ie. 95% CIs did 
overlap) (Table 3-2). Between screening regions, the trends differed slightly 
(Supplementary Information). When adjusting for demographic factors and 
the type of primary cytology test used, the increase in CIN III detection 
rates seemed to differ between the screening regions (ie. 95% CI did not 
overlap) (Table 3-2). 
When restricting analyses to CIN detected via triage, trends of increased 
CIN I, CIN II, and CIN III detection occurred over time (Figure 3-2a). After 
adjustment for confounders, the probability of a CIN I, II, or III diagnosis 
was 1.94 (95% CI: 1.62, 2.32), 1.56 (95% CI: 1.25, 1.96), and 1.76 (95% CI: 
1.44, 2.15) times higher in 2009 compared with 2003 (data not shown). 
The detection of cervical cancer via triage did not increase over time [OR 
of 0.69 (95% CI: 0.21, 2.27)]. The increase in CIN detected via triage was 
mainly explained by a 77% increased probability of primary smears being 
classified as BMD [OR of 1.77 (95% CI: 1.59, 1.98)] (data not shown-see 
Figure 3-3 for BMD detection rates per year and results of the joinpoint 
analysis). A BMD smear did not lead to a significant change in CIN I [OR of 
1.11 (95% CI: 0.95, 1.30)], CIN II [OR of 0.84 (95% CI: 0.69, 1.03)], or CIN 
III detection rates [OR of 0.99 (95% CI: 0.80, 1.23)] (data not shown). Re-
stricting analyses to CIN detected via direct referral yielded similar results. 
Trends of increased CIN I, II, and III detection occurred (Figure 3-2b). The 
probability of being diagnosed with CIN I, II, or III increased from 2003 to 
2009 [ORs of 1.66 (95% CI: 1.26, 2.20), 1.33 (95% CI: 1.04, 1.71), and 1.47 
(95% CI: 1.30, 1.67), respectively], but the probability of being diagnosed 
with cervical cancer was unaffected [OR of 1.06 (95% CI: 0.68, 1.65)] (data 
not shown). The increase in CIN detected via direct referral was mainly 
explained by a 41% increased probability of primary smears being classified 
as >BMD [OR of 1.41 (95% CI: 1.27, 1.58)] (data not shown – see Figure 3-3 
for >BMD detection rates per year and results of the joinpoint analysis). 
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figure 3-2. Trends in crude CIN and cervical cancer detection rates as observed within the 
national screening programme via (A) triage (ie. indirect referral to the gynaecologist) or via 
(B) direct referral to the gynaecologist. Joinpoints are depicted by larger symbols. The an-
nual percent changes are given with their 95% confidence interval for the periods depicted 
by joinpoint analyses (eg. when detected via triage, CIN I detection increased by 17.7% per 
year from 2004-2009 while CIN III detection increased by 8.8% per year). Bold estimates are 
statistically significant.
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A >BMD smear did not lead to increased CIN I [OR of 1.19 (95% CI: 0.89, 
1.58)], CIN II [OR of 0.93 (95% CI: 0.74, 1.17)], or CIN III detection rates 
[OR of 1.08 (95% CI: 0.91, 1.27)] (data not shown).
DiSCuSSioN
In the Dutch screening programme trends of increased detection occurred 
for all CIN grades from 2003–2005 to 2009. When adjusted for differences in 
the distribution of demographic factors, the probability of having a CIN I [ie. 
OR of 2.11 (95% CI: 1.95, 2.29)], CIN II [ie. OR of 1.79 (95% CI: 1.66, 1.92)], 
or CIN III diagnosis [ie. OR of 1.59 (95% CI: 1.50, 1.67)] was still consider-
ably higher in 2009 as compared with 2003. When also adjusting for the type 
figure 3-3. Trends in crude abnormal cytological detection rates (BMD and >BMD) as ob-
served within the national screening programme. Joinpoints are depicted by larger symbols. 
The annual percent changes are given with their 95% confidence intervals for the periods 
depicted by joinpoint analyses (eg. BMD decreased by 6.2% per year from 2000-2004 and 
increased by 10.6% from 2004-2011).  Women with a BMD outcome receive triage advice; 
women with a >BMD outcome receive direct referral advice. Bold estimates are statistically 
significant.
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of primary cytology test used, these relative risks were 1.90 (95% CI: 1.62, 
2.22), 1.48 (95% CI: 1.22, 1.79), and 1.55 (95% CI: 1.39, 1.73), respectively. 
Overall, the increase in CIN detection did not seem to significantly differ 
between age groups and screening regions, except for the increase in CIN 
III detection rates among the screening regions. Trends of increased CIN 
detection still existed when restricting analyses to CIN detected via triage 
or via direct referral, mainly explained by increased probabilities of smears 
being classified as BMD or >BMD (ie. increased probabilities of women 
receiving a triage or direct referral advice). No trends in CIN detection 
rates were found from 2009 to 2011, and no significant trends have yet been 
detected for cervical cancer over time.
Although the increasing trend of CIN detection rates seems to have been 
temporary (ie. until 2009), CIN detection rates remained at this increased 
level afterwards. As a consequence, the number of treated CIN lesions in-
creased from approximately 3500 in 2000 (70 per 10,000 primary smears) to 
5000 in 2011 (100 per 10,000 primary smears) (ie. assuming that all CIN II 
and III lesions are treated, and 500,000 women attend screening each year). 
The total increase in CIN detection is probably caused by multiple fac-
tors, including an increased risk of developing cervical cancer. However, it 
is unlikely that the strong increase in CIN detection rates could have been 
caused solely by an increased prevalence of risk factors (eg. changes in sex-
ual behaviour, smoking, or long-term oral contraceptive use). The gradual 
implementation of liquid-based cytology contributed to a small extent to 
the CIN increase, although this effect could be underestimated if the effect 
of switching to liquid-based cytology differed between laboratories. The in-
teraction between screening region (ie. proxy for the laboratories involved) 
and the type of primary cytology test used seems to confirm this, and could 
partly explain the increase in the number of cytological smears classified as 
BMD or >BMD, although the implementation of imaging-assisted reading 
could also have contributed(92). Increased attendance of previously un-
screened women may also have contributed to the CIN increase, although 
coverage rates of the screening population did not increase from 1998 to 
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2006(29). Increased CIN detection rates may have been a compensation for 
the observed previous decrease in CIN detection. This decrease was prob-
ably the effect of a period with increased screening intensity from 1996 to 
1998, when the age range eligible for screening was extended from 35-53 
years to 30-60 years and several extra birth cohorts were invited(34, 109). 
Finally, the screening protocol may occasionally be violated by performing 
co-testing (ie. primary cytology combined with primary high-risk HPV-
testing), which could explain a small part of the CIN increase(110).
Changes in the distribution of demographic factors (age, screening 
region, and SES) did not explain the increase in CIN detection. Changes 
in registration method or completeness are also unlikely explanations, as 
definitions and methods of data collection in PALGA are unchanged over 
the past decade. Although the interobserver agreement among pathologists 
is lower for CIN I and CIN II than for CIN III(111, 112), there are currently 
no data that suggest any changes over time. In addition, the positive predic-
tive value of a direct referral did not significantly increase. It is unlikely that 
a late effect of a higher cytology cut-off (ie. due to the introduction of the 
CISOE-A classification in 1996(28)) has contributed to the CIN increase, 
as the increase was also observed in new participants of the screening pro-
gramme (ie. aged 29-33). In addition, no significant differences in increased 
CIN detection rates have been observed between age groups.
Contrary to CIN trends, trends in cervical cancer detection rates have not 
yet been observed. Future trends of cervical cancer incidence may help 
to understand the underlying mechanism causing increased CIN detec-
tion rates. An increased sensitivity to detect, and therefore treat, CIN will 
eventually lead to lower cervical cancer incidence and mortality, assuming 
that a proportion of the extra detected CIN is clinically relevant. If not, 
it would only lead to increased burden and harms through overdiagnosis 
(and treatment) of regressive CIN lesions. An increased underlying risk of 
cervical cancer and, therefore, progressive CIN lesions, will probable lead to 
increased cervical cancer incidence and mortality.
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Our results agree with those of a Danish study which found a strong 
increase in the number of CIN I, II, and III diagnoses(113). The Danish 
authors concluded that the increase was too sudden and strong to be caused 
by biological factors, such as an increase in HPV prevalence. In Finland 
the CIN detection rate decreased from 37.8 per 10,000 primary smears in 
2006 to 32.5 in 2009(114). In the UK the percentage of abnormal smears in 
women aged 25-64 increased from 5.2% in 2004-2005 to 6.7% in 2009-2010 
and decreased to 5.8% in 2011-2012(115). These variations in trends among 
European countries do not explain the observed trend in the Netherlands, 
and may indicate regional and national changes in the screening programme 
(eg. a new primary screening test), rather than changes in biological factors.
A limitation of our study was that we could not correct for differences in 
follow-up time after a positive primary smear. The individual follow-up 
period varied from 48 (ie. primary smear taken before April 2009) to 15 
months (ie. primary smear taken in December 2011). The latter follow-up 
might have been too short for women with a primary BMD smear who were 
invited for multiple repeat cytology testing six and 18 months later. As the 
number of CIN I, II, and III lesions detected after these multiple repeat tests 
were 27.2, 16.5, and 7.4% of the total CIN I, II, and III detection (source: 
PALGA), low-grade CIN rates might have been somewhat underestimated 
in 2011. Also, we could not correct for difference in lost to follow-up (ie. 
women who did not comply with the given advice) over time, but its effect 
on the CIN increase would be negligible as the increase in CIN detection 
rates is mainly explained by an altered distribution of cytological classifica-
tions. 
In the Netherlands, trends of increased detection were present for all CIN 
grades from 2003-2005 to 2009, although they were not (yet) detected 
for cervical cancer. The gradual implementation of liquid-based cytol-
ogy caused some of the increase in CIN detection rates. This could lead 
to lower incidence and mortality of cervical cancer, if a proportion of the 
extra detected CIN are clinically relevant. If they are not, it would only lead 
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to increased burden and harms through overdiagnosis (and treatment) of 
regressive CIN lesions. Other factors, such as an increased risk of develop-
ing cervical cancer and implementation of imaging-assisted reading, could 
also have contributed to the increased CIN detection rates.
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figure 3-S1. Triage protocol consisting of triage cytology (A) without HPV testing, and (B) 
with HPV testing. HPV = Human papillomavirus; BMD = Borderline and mildly dyskaryotic 
smears.
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figure 3-S2. Trends in crude (A) CIN I, (B) CIN II, and (C) CIN III detection rates as observed 
within the national screening programme, per age group. Joinpoints are depicted by larger 
symbols. 
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Table 3-S1. Trends of CIN I, II and III detection rates per age group as given by joinpoint 
analyses. 
Outcome Age group Period APC (95% Confidence Interval)
29-33 2000-2004
2004-2011
-1.1 (-8.3, 6.8)
16.1 (13.2, 19.1)
34-38 2000-2003
2003-2011
-4.2 (-16.9, 10.5)
12.4 (9.3, 15.5)
39-43 2000-2004
2004-2011
-3.5 (-14.3, 8.8)
12.6 (7.7, 17.7)
CIN I
44-48 2000-2003
2003-2009
2009-2011
-10.2 (-21.9, 3.3)
15.4 (9.3, 21.9)
1.9 (-16.4, 24.1)
49-53 2000-2003
2003-2011
-17.6 (-30.3, -2.5)
11.0 (7.3, 14.8)
54-58 2000-2004
2004-2011
-11.8 (-24.6, 3.1)
12.3 (5.5, 19.6)
59-63 2000-2011 3.0 (-1.8, 7.9)
29-33 2000-2006
2006-2009
2009-2011
5.1 (3.4, 6.8)
17.5 (8.6, 27.2)
-3.1 (-10.0, 4.3)
34-38 2000-2011 7.4 (5.9, 8.9)
39-43 2000-2011 9.6 (8.0, 11.3)
CIN II 44-48 2000-2011 10.2 (8.6, 11.8)
49-53 2000-2011 10.0 (7.9, 12.1)
54-58 2000-2011 7.7 (3.8, 11.7)
59-63 2000-2011 5.7 (1.7, 9.9)
29-33 2000-2004
2004-2011
0.1 (-5.0, 5.4)
7.0 (4.9, 9.1)
34-38 2000-2003
2003-2011
-5.4 (-14.0, 4.1)
5.3 (3.1, 7.6)
39-43 2000-2011 5.0 (3.1, 6.9)
CIN III
44-48 2000-2005
2005-2008
2008-2011
2.5 (-0.8, 5.9)
18.0 (4.6, 33.1)
-1.5 (-6.7, 3.9)
49-53 2000-2011 6.9 (4.5, 9.3)
54-58 2002-2011
2002-2011
-21.9 (-45.8, 12.6)
4.7 (1.3, 8.3)
59-63 2000-2011 2.0 (-1.0, 5.2)
Bold = Significant annual percent changes were present within that period of time. 
A p value of <0.05 was considered to be statistically significant.
APC = Annual percent change.
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figure 3-S3. Trends in crude (A) CIN I, (B) CIN II, and (C) CIN III detection rates as observed 
within the national screening programme, per screening region. Joinpoints are depicted by 
larger symbols. 
Table 3-S2. Trends of CIN I, II and III detection rates per screening region as given by join-
point analyses.
Outcome Screening region Period APC (95% Confidence Interval)
1 2000-2002
2002-2008
2008-2011
-22.2 (-36.5, -4.6)
11.3 (6.3, 16.6)
0.7 (-7.8, 9.9)
2 2000-2004
2004-2009
2009-2011
-3.1 (-11.2, 5.8)
17.0 (8.7, 25.9)
4.6 (-13.0, 25.8)
CIN I 3 2000-2011 13.0 (8.6, 17.5)
4 2000-2002
2002-2007
2007-2011
-15.1 (-30.8, 4.3)
1.9 (-5.1, 9.4)
16.1 (9.5, 23.2)
5 2000-2005
2005-2011
-8.4 (-18.2, 2.6)
13.9 (5.6, 22.8)
1 2000-2011 5.9 (4.5, 7.3)
2 2000-2011 6.2 (4.5, 7.8)
CIN II 3 2000-2011 10.6 (8.5, 12.7)
4 2000-2011 8.1 (6.3, 9.9)
5 2000-2006
2006-2011
0.9 (-3.0, 5.0)
15.8 (11.1, 20.8)
1 2000-2002
2002-2011
-15.5 (-30.9, 3.4)
3.9 (1.9, 5.9)
2 2000-2003
2003-2009
2009-2011
-3.4 (-8.0, 1.4)
5.3 (3.3, 7.5)
-6.9 (-14.8, 1.6)
CIN III 3 2000-2003
2003-2011
-5.4 (-12.4, 2.1)
7.8 (6.1, 9.4)
4 2000-2004
2004-2009
2009-2011
-2.4 (-5.3, 0.6)
10.9 (7.9, 14.0)
-3.9 (-11.3, 4.0)
5 2000-2005
2005-2011
-3.4 (-6.6, -0.0)
8.4 (5.8, 11.0)
Bold = Significant annual percent changes were present within that period of time. A p value 
of <0.05 was considered to be statistically significant. 
APC = Annual percent change. 
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AbSTRACT
Background. Several studies have compared cervical intraepithelial 
neoplasia (CIN) II+ detection rates between conventional cytology and 
liquid-based cytology tests SurePath and/or ThinPrep. As detecting more 
CIN does not necessarily mean preventing more cervical cancers, we ex-
amined the incidence of interval cancers (ie. cervical cancers diagnosed 
after a negative primary smear) in the Dutch cervical cancer screening 
programme. 
Methods. All primary negative screening smears taken within this pro-
gramme from 2000 to March 2012 were analyzed using the nationwide 
registry of histo- and cytopathology (PALGA), stratified by the type of 
cytology test used (ie. SurePath, ThinPrep, or conventional cytology), 
with a follow-up until March 2013. The 72-month cumulative incidence 
of interval cancers was calculated for each screening method. Cox regres-
sion analyses were performed to assess the hazard ratio (HR), adjusted 
for calendar time, age, screening region, and socioeconomic status. In 
addition, we stratified for the reason of the cervical examination prior 
that led to the interval cancer diagnosis (ie. clinically or screen-detected). 
results. We included 5,924,474 primary negative screening smears, re-
sulting in 23,833,123 women-years. The 72-month cumulative interval 
cancer incidence was 66.8 [95% confidence interval (CI): 56.7, 78.7], 58.5 
(95% CI: 54.6, 62.7), and 44.6 (95% CI: 37.8, 52.6) per 100,000 negative 
ThinPrep, conventional cytology, and SurePath smears, respectively. 
When compared to conventional cytology, the overall hazard of interval 
cancer was 17% lower [HR = 0.83 (95% CI: 0.70, 0.99)] for SurePath, 
caused by a 26% lower hazard [HR = 0.74 (95% CI: 0.59, 0.91)] of a clini-
cally detected interval cancer. For ThinPrep, the overall hazard was on 
average 20% higher [HR = 1.20 (95% CI: 1.01, 1.41)], caused by a 58% 
higher hazard of a screen-detected interval cancer [HR = 1.58 (95% CI: 
1.19, 2.08)]. 
Conclusions. The interval cancer rate was lowest after a negative SurePath 
smear and highest after a negative ThinPrep smear. This strongly suggests 
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that the sensitivity to detect progressive CIN lesions is highest when us-
ing SurePath and lowest when using ThinPrep as primary test method. 
Keywords. Cervical cancer; Interval cancer; False-negative smear; LBC; 
SurePath; ThinPrep; Conventional cytology; Screening
bACKGRouND
The use of conventional cytology as primary test method has been replaced 
by the use of liquid-based cytology (LBC) in many countries with organized 
cervical cancer screening programmes, such as the UK, the Netherlands, 
and Denmark(92, 93). The main advantages of using LBC instead of con-
ventional cytology are facilitating co-testing [the residual material can be 
tested for the presence of the human papillomavirus (HPV)](41, 44) and 
reducing the number of slides of unsatisfactory quality(40, 42, 46, 48, 116). 
In addition, it is believed that the sensitivity of LBC for detecting cervical 
intraepithelial neoplasia (CIN) II+ lesions is similar to that of conventional 
cytology(55, 56). However, although many studies have been published 
comparing CIN detection between ThinPrep and conventional cytology(45, 
49, 52, 57, 59, 60), only two studies have compared CIN detection between 
SurePath and conventional cytology(42, 58). Therefore, we compared CIN 
II+ detection rates between these three types of cytology tests in our previ-
ous study, including more than six million smears taken within the Dutch 
cervical cancer screening programme(117). While the use of SurePath led to 
an 8% increased detection of CIN II+ as compared to conventional cytology, 
the use of ThinPrep did not affect CIN II+ detection rates. These results were 
compatible with results of other studies. In our previous study we showed 
that our point estimates of the CIN II+ detection rate ratios lied within the 
95% confidence interval (CI) of those from other studies comparing CIN 
II+ detection rates between SurePath or ThinPrep and conventional cytol-
ogy(117). Furthermore, a recently published study by Rebolj et al. confirmed 
our findings(64). When applying the same reading technology, they found 
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increased CIN II+ detection rates when using SurePath, while these were 
unaffected when using ThinPrep. 
As in the absence of screening (and associated treatment) only a fraction of 
CIN would progress to cervical cancer, detecting more CIN lesions is not 
necessarily equivalent to preventing more cervical cancers. If the increase 
of detected CIN lesions would be mainly regressive, this increase would not 
translate into altered carcinoma incidence. To assess whether the ability to 
detect progressive CIN lesions differs between different types of LBC tests 
and conventional cytology, the probability of a cervical cancer diagnosis 
shortly after a negative primary screening smear (ie. interval cancer) has to 
be compared. Whereas detecting more progressive CIN lesions will lead to 
fewer interval cancers, detecting more regressive CIN lesions will not. As 
the incidence of interval cancers is rare [6-year cumulative incidence rate 
of 48 per 100.000 negative smears (95% CI: 43, 54)](36), such a comparison 
can only be feasible if performed by an observational population-based 
study where a large number of smears can be evaluated. 
The Netherlands is one of many countries with an organized cervical cancer 
screening programme where primary conventional cytology testing has 
been replaced by primary LBC testing. Here, organized cervical cancer 
screening exists since the 1980s and women aged between 30 and 60 years 
have been invited every five years since 1996. The screening strategy consists 
of primary cytology screening with cytology triage, the latter either alone 
or in combination with HPV testing. All cervix uteri cytological and histo-
logical tests taken inside and outside the Dutch screening programme are 
registered in the Dutch Pathology Register (PALGA)(94) and women can be 
traced even when they moved around the country. By using these data, we 
were able to assess any differences in interval cancer risk between different 
types of LBC tests (ie. SurePath and ThinPrep) and conventional cytology, 
thereby indicating whether there is a possible difference in sensitivity to 
detected progressive CIN lesions. In addition, we stratified for the reason of 
cervical examination prior to the interval cancer diagnosis (ie. clinically or 
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screen-detected). Moreover, possible differences in overdiagnosis rates were 
assessed by comparing CIN detection rates. 
mETHoDS
Information on all cytological and histological examinations of the cervix 
uteri taken in the Netherlands between January 2000 and March 2013 were 
available and retrieved from PALGA. Multiple quality checks ensured the 
reliability of the retrieved data(29, 118). Women were identified through 
their birth date and the first eight letters of their (maiden) family name. This 
identification code enables linkage of multiple tests belonging to the same 
woman, allowing us to follow individual screening histories. We identified 
and selected episodes starting with a negative primary screening smear 
taken within the Dutch screening programme between January 2000 and 
March 2012. Women with a primary smear of unsatisfactory quality fol-
lowed by a negative smear within the same episode were also selected. An 
episode was defined as starting with a primary test followed by one or more 
secondary tests in case the result was abnormal (ie. at least borderline mild 
dyskaryosis) or of unsatisfactory quality. Unless the follow-up of a primary 
test had already been completed according to guidelines, tests taken within 
four years following a primary test were considered as follow-up or second-
ary tests(38). All other tests were seen as primary tests. 
Negative primary screening smears were stratified by the type of cytology 
test used (ie. SurePath, ThinPrep, or conventional cytology). Since PALGA 
does not register this routinely, regional coordinating pathologists obtained 
conversion dates (ie. fixed to the first date of the quarter) from individual 
laboratories part of their region (ie. five regions covering 44 laboratories). 
This information was linked to (i) the pathology laboratory involved, and 
(ii) the examination date as a proxy for which type of primary cytology test 
was used (ie. in the Netherlands, laboratories supply the general practitio-
ners with cytology kits and thus determine the type of cytology used).  
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Follow-up lasted for a period of six years, or until the next episode started, 
or the end of the database was reached (March 2013), whichever came first. 
We chose for a period of six years because it covers the next screening round 
which is scheduled to take place five years after a negative screening smear. 
Histologically confirmed cervical cancer cases were identified by select-
ing all PALGA records that included pathology codes describing invasive 
cancers originating in the cervix uteri. These codes were manually checked 
to avoid over-counting both of non-invasive lesions and primary cancers 
originating elsewhere. 
Since women in the Netherlands are invited for screening in the year they 
turn 30, 35, …, and 60, age was categorized as: 29-33, 34-38, …, and 59-63 
years at the time of the negative primary cytological smear. Calendar year 
was also defined at the time of the negative cytological smear. The Dutch 
screening programme is organized by five screening organizations, each 
covering a geographical region (ie. screening region; North, South-West, 
Middle-West, South and East). Screening region was determined by a 
woman’s place of residence at the time of the negative smear. Socioeconomic 
status (SES), categorized as low, middle, or high, was defined by the status 
score. This is an ecological variable based on the household characteristics 
of the four-digit postcode area where the woman was living at the time of the 
primary test(95). Status scores per four-digit postal code were provided by 
the Netherlands Institute for Social Research(96) based on 1) mean income, 
2) percentage of households with a low income, 3) percentage of households 
with, on average, a low education, and 4) unemployment rate in 2010. Low 
SES corresponded with a status score lower than -1 (ie. average status score 
minus standard deviation), intermediate SES with a score of ≥-1 and ≤1, and 
high SES with a score higher than 1 (ie. average status score plus standard 
deviation).
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Statistical analyses
Laboratories implemented LBC testing at different points in time. Therefore, 
follow-up (FU) and calendar time were expected to differ between the three 
types of cytology tests. As demographic characteristics of screened women 
(ie. age, screening region, and SES) probably differed between laboratories, 
we expected them to differ between the types of cytology tests as well. Since 
age, SES, screening region and calendar time were all associated with CIN 
and/or cervical cancer detection rates(86, 87, 97, 98), they were all potential 
confounding factors. We used a Pearson’s chi-squared test to test whether 
their distributions differed between the types of cytological tests. Thus, we 
tested whether they were confounders or not. A p value of less than 0.05 was 
considered to be statistically significant.
Cumulative incidence and hazard ratio
For each type of test, the cumulative interval cancer incidence per 100,000 
negative cytological screening smears was calculated. Differences in FU 
time were taken into account and the 95% CIs were estimated by non-
parametric Kaplan-Meier product-limit estimator for log(hazard)(36)
(119). Cox regression analyses were performed to compare the hazard of an 
interval cancer between the types of cytology tests, also taking differences 
in FU time into account and adjusting for confounding factors. In addition, 
we stratified for the reason (i.e. screen-detected when programme smear, or 
clinically in all other cases, which includes opportunistic screening as well 
as direct biopsies) of the cervical examination that led to the interval cancer 
diagnosis. Missing values were imputed with 10 multiple imputations for 
confounding factors. Time dependencies of the hazard ratios (HRs) were 
statistically tested by splitting the total follow-up time in two periods with 
a roughly equal number of cases. Subsequently, HRs were assessed for each 
time period. If the sum of the deviance of both sub-models was significantly 
lower than the deviance of the original model, the hazard ratio was time-
dependent as it differed significantly between the time periods.
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Difference in CIN detection rates and 72-month cumulative interval cancer 
incidence per 100,000 (negative) primary screening smears
We assessed the difference in CIN detection rates per 100,000 SurePath and 
100,000 ThinPrep smears (ie. as compared to the CIN detection rates per 
100,000 conventional cytology smears) and we compared it with the dif-
ference in the 72-month cumulative interval cancer incidence per 100,000 
SurePath and ThinPrep negative smears. Information on the calculation 
of the difference in detection rates per 100,000 primary screening samples 
can be found in the Supplementary Material. The 72-month cumulative 
incidence rates for SurePath and ThinPrep were calculated by multiplying 
the distribution of the 72-month cumulative incidence rate for conventional 
cytology with the distribution of the adjusted HRs for SurePath and Thin-
Prep versus conventional cytology, as obtained by Cox regression.
RESulTS
Within the follow-up period, 1,042 interval cancers were diagnosed after 
3,028,865 negative conventional cytology smears, 231 interval cancers were 
diagnosed after 1,303,817 negative SurePath smears, and 328 interval can-
cers were diagnosed after 1,591,792 negative ThinPrep smears (Table 4-1). 
This corresponds with the diagnoses of 7.6, 4.8, and 6.3 cervical cancers per 
100,000 women-years, respectively.
Crude cumulative incidence, taking differences in the duration of FU time 
into account
As compared with conventional cytology, the 12-, 24-, 36-, 48-, 60- and 
72-month cumulative interval cancer incidences were significantly lower 
for SurePath smears (Figure 4-1). When SurePath was compared with Thin-
Prep, all but the 24-month cumulative incidences were significantly lower 
for SurePath. No significant difference was detected between ThinPrep and 
conventional cytology. The 72-month cumulative incidence was 44.6 (95% 
CI: 37.8, 52.6) after 100,000 negative SurePath smears, 58.5 (95% CI: 54.6, 
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Table 4-1. Baseline characteristics.
Conventional SurePath ThinPrep P value
Negative primary smears, n 3,028,865 1,303,817 1,591,792
Women-years at risk 13,796,018 4,835,917 5,201,188
Interval cancers, n 1,042 231 328 <0.001
FU time <0.001
   0-1 years, n (%) 208,668 (6.9) 73,905 (5.7) 95,563 (6.0)
   1-2 years, n (%) 105,945 (3.5) 191,027 (14.7) 321,784 (20.2)
   2-3 years, n (%) 129,165 (4.3) 187,410 (14.4) 311,295 (19.6)
   3-4 years, n (%) 203,768 (6.7) 189,063 (14.5) 284,262 (17.9)
   4-5 years, n (%) 920,825 (30.4) 334,677 (25.7) 339,590 (21.3)
   5-6 years, n (%) 1,460,494 (48.2) 327,735 (25.1) 239,298 (15.0)
Age <0.001
   29-33, n (%) 411,873 (13.6) 167,015 (12.8) 193,998 (12.2)
   34-38, n (%) 503,889 (16.6) 187,179 (14.4) 217,213 (13.6)
   39-43, n (%) 516,728 (17.1) 218,559 (16.8) 267,194 (16.8)
   44-48, n (%) 482,822 (15.9) 218,476 (16.8) 267,585 (16.8)
   49-53, n (%) 434,620 (14.3) 192,594 (14.8) 240,801 (15.1)
   54-58, n (%) 381,312 (12.6) 173,572 (13.3) 219,277 (13.8)
   59-63, n (%) 297,621 (9.8) 146,422 (11.2) 185,724 (11.7)
Screening region <0.001
   1, n (%) 417,594 (13.8) 498,554 (38.2) 353,757 (22.2)
   2, n (%) 797,228 (26.3) 176,577 (13.5) 537,844 (33.8)
   3, n (%) 472,708 (15.6) 306,500 (23.5) 293,197 (18.4)
   4, n (%) 845,727 (27.9) 297,858 (22.8) 210,042 (13.2)
   5, n (%) 486,976 (16.1) 24,085 (1.8) 193,971 (12.2)
   Unknown, n (%) 8,632 (0.3) 243 (0.0) 2,981 (0.2)
SES <0.001
   Low, n (%) 248,097 (8.2) 153,494 (11.8) 108,492 (6.8)
   Middle, n (%) 2,501,696 (82.6) 1,038,602 (79.7) 1,337,521 (84.0)
   High, n (%) 232,658 (7.7) 87,193 (6.7) 132,863 (8.3)
   Unknown, n (%) 46,414 (1.5) 24,528 (1.9) 12,916 (0.8)
Calendar time <0.001
   2000-2003, n (%) 163,1520 (53.9) 162,014 (12.4) 26,499 (1.7)
   2004-2007, n (%) 118,6547 (39.2) 435,108 (33.4) 404,603 (25.4)
   2008-2012*, n (%) 210,798 (7.0) 706,695 (54.2) 116,0690 (72.9)
*Until 31 March 2012. 
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62.7) after 100,000 negative conventional cytology smears, and 66.8 (95% 
CI: 56.7, 78.7) after 100,000 negative ThinPrep smears. 
Confounding factors
Large and significant differences in the distributions of FU time, screening 
region, and calendar time were observed. For instance, almost 80% of the 
negative conventional cytology smears had a FU time of at least four years, 
while for SurePath and ThinPrep this was the case for slightly more than 
50 and 35% of the negative smears. Small but significant differences were 
also present in the distributions of SES and age (Table 4-1). Thus, FU time, 
figure 4-1. Comparing the crude cumulative interval cancer incidence per 100,000 nega-
tive primary screening smears between conventional cytology, SurePath, and ThinPrep. The 
95% confidence intervals are depicted by vertical lines. A p value of < 0.05 was considered 
to be statistically significant.
*Significant difference between SurePath and conventional cytology. 
#Significant difference between SurePath and ThinPrep. 
No significant differences between ThinPrep and conventional cytology were detected.
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screening region, calendar time, SES, and age were all considered confound-
ing factors when comparing the occurrence of interval cancers between the 
three testing methods. Missing values were imputed for 1.6% of the primary 
negative smears. 
Cox regression analyses of interval cancers, taking differences in the 
duration of FU time into account and adjusted for confounding factors 
When comparing SurePath with conventional cytology, adjusted for con-
founding factors, the hazard of an overall interval cancer was significantly 
lower [HR of 0.83 (95% CI: 0.70, 0.99)] (Table 4-2). This decreased hazard 
was mainly caused by a decreased hazard of a clinically detected interval 
cancer [HR of 0.74 (95% CI: 0.59, 0.91)], the hazard of a screen-detected 
interval cancer was similar to that of conventional cytology [HR of 0.98 
Table 4-2. Cox regression analyses of interval cancer, overall and stratified by reason of the 
cervical examination that led to the interval cancer diagnosis. Differences in FU were taken 
into account and hazard ratios are shown unadjusted and adjusted for age, SES, screening 
region, and calendar time. 
Unadjusted OR (95%  CI) Adjusted OR (95%  CI)
Overall
   SurePath versus CC 0.74 (0.64, 0.85) 0.83 (0.70, 0.99)
   ThinPrep versus CC 1.07 (0.95, 1.22) 1.20 (1.01, 1.41)
   SurePath versus ThinPrep 0.68 (0.57, 0.81) 0.72 ( 0.60, 0.86)
Clinically detected
   SurePath versus CC 0.70 (0.59, 0.84) 0.74 (0.59, 0.91)
   ThinPrep versus  CC 1.03 (0.88, 1.20) 1.03 (0.92, 1.14)
   SurePath versus ThinPrep 0.68 (0.55, 0.84) 0.75 ( 0.59, 0.94)
Screen-detected
   SurePath versus  CC 0.80 (0.64, 1.02) 0.98 (0.74, 1.29)
   ThinPrep versus  CC 1.16 (0.93, 1.44) 1.58 (1.19, 2.08)
   SurePath versus  ThinPrep 0.68 (0.51, 0.91) 0.65 ( 0.47, 0.89)
Bold = Significant. A p value of <0.05 was considered to be statistically significant.
CC = Conventional cytology
80 Chapter 4
(95% CI: 0.74, 1.29)]. All HRs were not time-dependent (ie. the HRs did not 
differ within the six year time period; p = 0.449 for HR of overall interval 
cancer; p = 0.590 for HR of clinically detected interval cancer; p = 0.448 for 
HR of screen-detected interval cancer).
When comparing SurePath with ThinPrep, adjusted for confounding factors, 
the hazard of an overall interval cancer was significantly lower [HR of 0.72 
(95% CI: 0.60, 0.86)]. This decreased hazard was both caused by a decreased 
hazard of a clinically detected interval cancer [HR of 0.75 (95% CI: 0.59, 
0.94)] and a decreased hazard of a screen-detected interval cancer [HR of 
0.65 (95% CI: 0.47, 0.89)]. All HRs were not time-dependent (p = 0.781 for 
HR of overall interval cancer; p = 0.661 for HR of clinically detected interval 
cancer; p = 0.853 for HR of screen-detected interval cancer).
When comparing ThinPrep with conventional cytology, adjusted for con-
founding factors, the hazard of an overall interval cancer was on average 
significantly higher [HR of 1.20 (95% CI: 1.01, 1.41)]. This effect seemed to 
differ over time (p = 0.051), with a HR of 1.03 (95% CI: 0.82, 1.29) in the 
first 44 months after the negative screening smear and a HR of 1.43 (95% 
CI: 1.12, 1.83) thereafter. This overall increased hazard was caused by an 
increased hazard of a screen-detected interval cancer [HR of 1.58 (95% CI: 
1.19, 2.08)], the hazard of a clinically detected interval cancer was unaffected 
[HR of 1.03 (95% CI: 0.92, 1.14)]. These HRs were not time-dependent (p 
= 0.210 for HR of clinically detected interval cancer; p = 0.401 for HR of 
screen-detected interval cancer).
Difference in CIN detection rates and 72-month cumulative interval cancer 
incidence per 100,000 (negative) primary screening smears, adjusted for 
confounding factors 
The use of SurePath versus conventional cytology as primary test method 
resulted in 94.4 (95% CI: +68.9, +120.6) extra CIN diagnoses per 100,000 
screening smears, while the 72-month cumulative interval cancer incidence 
decreased by 9.7 (95% CI: -13.6, -4.8) (Table 4-3). The use of ThinPrep ver-
Cervical cancer incidence after a negative cytological screening smear 81
sus conventional cytology showed quite different results. While the number 
of CIN diagnoses did not change significantly, the 72-month cumulative in-
terval cancer incidence increased by 11.1 (95% CI: +4.1, +20.9) per 100,000 
negative screening tests.
DiSCuSSioN
The interval cancer incidence rate among the three cytology modalities was 
highest for conventional cytology and lowest for SurePath. The 72-month 
cumulative interval cancer incidence, when also taking differences in FU 
time into account, was again lowest for SurePath but highest for ThinPrep. 
When we also adjusted for confounding factors, the overall interval cancer 
risk was 17% lower for SurePath in comparison to conventional cytology, 
which was caused by a 26% lower risk for a clinically detected interval can-
Table 4-3. The increase (+) or decrease (-) in CIN detection rates and 72-month cumula-
tive interval cancer incidence per 100,000 (negative) SurePath or ThinPrep smears versus 
100,000 (negative) conventional cytology smears. These numbers were corrected for dif-
ferences in the distribution of follow-up time (in case of interval cancers), age, screening 
region, SES, and calendar time. The 95% confidence intervals are given. 
Base-case: CC* SurePath versus CC ThinPrep versus CC
CIN I 216.1 +30.1
(+18.1, +42.8)
-3.5
(-14.3, +7.9)
CIN II 220.0 +31.2
(+19.0, +44.1)
+9.4
(-2.1, +21.5)
CIN III 495.0 +30.3
(+12.0, +49.3)
-12.2
(-29.6, +5.9)
Total CIN 931.0 +94.4
(+68.9, +120.6)
-6.8
(-30.6, +17.6)
Interval cancer 58.5
(54.6 to 62.7)
-9.7
(-13.6, -4.8)
+11.1
(+4.1, +20.9)
Bold = Significant. A p value of <0.05 was considered to be statistically significant. 
CC = Conventional cytology; CIN = Cervical intraepithelial neoplasia
*Observed CIN detection rate and 72-month cumulative interval cancer incidence per 
100,000 (negative) conventional cytology smears.
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cer. The use of SurePath resulted in ten fewer interval cancers per 100,000 
primary smears, while the number of CIN lesions increased by 94. The 
overall interval cancer risk was 20% higher for ThinPrep in comparison to 
conventional cytology, but it differed over time. Within the first 44 months 
after the negative screening test, the risks were comparable. Thereafter, the 
risk was 43% higher when using ThinPrep. Both the overall increased risk 
and the difference over time is due to a 58% higher risk for a screen-detected 
interval cancer when using ThinPrep (ie. the recommended Dutch screen-
ing interval is five years and thus 60 months). The use of ThinPrep resulted 
in 11 additional interval cancers per 100,000 negative primary smears. 
In our previous study, using the same data as in our current study, we 
showed that the detection of CIN II+ was increased by using SurePath, while 
it was unaffected by using ThinPrep(120). As the use of SurePath resulted in 
decreased interval cancer rates, this indicates that at least part of the extra 
detected CIN lesions were progressive. As the use of ThinPrep resulted in 
increased interval cancers, this indicates that although similar numbers of 
CIN lesions were detected fewer of them were progressive. These differences 
in sensitivity to detect progressive CIN lesions are most likely caused by 
differences between the techniques of the LBC tests, such as: the extent 
of fixation, the technique of taking a representative sample from the vial, 
and the retention of the brush (ie. the collecting device) in the fluid(53, 
54). Studies have shown that retaining the brush, as is done when using 
SurePath, is associated with an increased cell yield as compared to rins-
ing and discarding the brush, as is done when using ThinPrep(100, 101). 
Therefore, the ability to transfer abnormal cells may differ between SurePath 
and ThinPrep, possibly resulting in a difference in sensitivity. Moreover, as 
the thoroughness of rinsing the brush in the vial with preservative fluid, 
and therefore the cell yield(101), might differ between clinicians, it is pos-
sible for the interobserver agreement of ThinPrep to be lower than that of 
SurePath. Thus, the differences in sensitivity to detect progressive lesions 
might differ more between laboratories using ThinPrep than SurePath. In 
addition, the interobserver agreement of conventional cytology is prob-
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ably lower than that of SurePath and ThinPrep as the quality of the cell 
transfer, and therefore the quality of the conventional cytology smear, can 
differ between clinicians. Thus, how much there is to gain when replacing 
conventional cytology by another primary test method could differ between 
clinicians and therefore, between laboratories. In conclusion, the difference 
in sensitivity to detect progressive lesions between SurePath and ThinPrep 
versus conventional cytology might differ between clinicians and therefore, 
between laboratories. 
If we take the most recent distribution of cytology testing into account 
(ie. obtained in the first quarter of 2012), each year 325,000 women are 
screened by ThinPrep and therefore prone to 36 extra interval cancers while 
175,000 women are screened by SurePath and therefore protected against 
17 of them. However, as the risk for a clinically detected interval cancer 
was unaffected by ThinPrep, the extra found interval cancers are probably 
diagnosed in an early stage where clinical symptoms are absent or rarely 
present. Therefore, the negative effects of using ThinPrep are probably less 
pronounced on the interval cancer mortality than on the incidence. On the 
other hand, the protective effect of SurePath on interval cancer mortality is 
probably more pronounced than on the incidence as we found that SurePath 
was primarily protective for clinically detected interval cancers. As no data 
on mortality were available, we were not able to estimate the effects of LBC 
implementation on interval cancer mortality. While our results may be less 
relevant for the future of the Dutch cervical cancer screening programme 
(ie. it is expected that from 2016 onward, primary cytology screening will 
be replaced by primary  HPV screening(67)), they certainly can be relevant 
to other countries with organized primary cytology screening programmes 
who have switched to using SurePath and/or ThinPrep or will switch in the 
near future.  
An important drawback of cervical cancer screening is the diagnosis and 
treatment of CIN lesions that would never have progressed to clinical 
cervical cancer in the absence of screening. With the use of SurePath, the 
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prevention of ten extra interval cancers is accompanied by the detection of 
94 extra CIN lesions. Therefore, when including CIN diagnoses in the defi-
nition, the increased sensitivity to detect progressive CIN lesions also led to 
increased overdiagnosis rates according to the following definition: number 
of extra diagnoses with screening divided by total number of diagnoses in a 
population with screening. As both the number of excess diagnoses and the 
number of diagnoses in the population increased by 84, the ratio increased 
and therefore the overdiagnosis rate. How the use of SurePath will affect 
the number of QALYs gained, and therefore the effectiveness of the Dutch 
cervical cancer screening programme, is beyond the scope of this article.
This study is the first that compared interval cancer rates between two 
different types of LBC tests and conventional cytology, thereby examining 
differences in sensitivity to detect progressive CIN lesions. In addition, we 
examined the drawbacks of LBC implementation by comparing indicators 
of overdiagnosis. 
Our study has some limitations, many of which are linked to the fact 
that this was not a randomized trial. First, differences in the distribution 
of demographic factors were present since the study did not take place in 
a controlled setting. Although we were able to correct for FU time, age, 
screening region, SES, and calendar time, we were not able to correct for 
other potential confounders such as a woman’s screening history. This may 
have resulted in biased effect estimates if the distribution differed between 
the types of cytology tests. The fact that no large differences in age and 
SES were found was reassuring. Second, as the risk of a screen-detected 
interval cancer was increased for ThinPrep and the FU time was too short 
for most women with a negative primary ThinPrep smear to be invited 
for the next screening round, this would mean that the overall risk of an 
interval cancer was underestimated for ThinPrep. However, as we corrected 
for differences in the distribution of calendar time, which is linked to FU 
time, we believe  this underestimation would be minimal. Indeed, when we 
only selected women attending screening within six years after a negative 
primary ThinPrep smear (data not shown), we found a slightly higher risk of 
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a screen-detected interval cancer than before, which seems to confirm our 
statement that we minimally underestimated our screen-detected and over-
all risk for ThinPrep. As no difference in screen-detected interval cancer risk 
was found between SurePath and conventional cytology, (shortage in) FU 
time had no influence on the overall interval cancer risk for SurePath. Third, 
we were not able to correct for the use of automated reading, although the 
possible influence would be small given that automated reading has only 
been introduced in relatively few Dutch laboratories. Moreover, as multiple 
studies demonstrated that CIN II+ detection were unaffected(61, 62, 64) or 
slightly decreased(63) by adding automated assisted reading to the use of 
ThinPrep or SurePath, we do not believe our estimated were significantly 
biased. Fourth, as we did not have an unique identification code [ie. identi-
fication code was based on the first eight letters of the (maiden) family name 
and birth date], tests belonging to different women may have been allocated 
to a single woman (so-called fusions). However, we think it is unlikely that 
these fusions would be correlated with the type of cytology test used. Fifth, 
we did not have individual data on which type of primary test was used. 
Therefore, we used date of the primary cytological smear and conversion 
date (ie. fixed to the first date of the quarter) of the laboratory examining 
the smear to deduce which type of cytology test was used. This means that 
negative primary screening smears taken during this quarter may have been 
misclassified, leading to a slight underestimation of the effects. Sixth, we 
were not able to censor follow-up for death and migration. However, since 
mortality rates are relatively low at screening ages(121), and demography 
was relatively similar between the groups, we do not expect this has biased 
our results. Seventh, we did not correct for possible learning curve effects, 
since the aim of our study was to examine the effect of using SurePath and 
ThinPrep in routine practice, which also includes a possible learning effect. 
In conclusion, the use of SurePath versus the use of conventional cytology 
as primary test method was associated with lower interval cancer rates, 
strongly suggesting that the sensitivity to detect progressive CIN lesions is 
higher. The use of ThinPrep versus the use of conventional cytology was 
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associated with higher interval cancer rates, strongly suggesting that the 
sensitivity to detect progressive CIN lesions is lower. Our findings should 
urge reconsideration for the assumed lack of difference in test characteris-
tics between LBC and conventional cytology. 
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SuPPlEmENTARy iNfoRmATioN
In this Supplementary Material, we describe the material and methods that 
were used to determine the difference in CIN detection rates per 100,000 
primary screening smears. 
Selecting data from PAlGA: CiN lesions
We identified primary smears taken within the national cervical cancer 
screening programme between January 2000 and December 2011. As data 
until March 2013 were available to us, a minimum duration of 15 months 
follow-up was ensured. Histologically confirmed CIN lesions were identi-
fied by selecting all PALGA records that included corresponding pathology 
codes. Subsequently, lesions were linked to the type of  cytology test used. 
Age, screening region, SES, and calendar year at the time of the primary 
smear were assessed in similar ways as in the main analysis. 
Statistical analyses: CiN lesions
We compared CIN detection rates per 100,000 SurePath and 100,000 Thin-
Prep smears with CIN detection rates per 100,000 conventional cytology 
smears. As confounding factors are present, comparing observed CIN de-
tection rates was not sufficient. Therefore, we calculated CIN detection rates 
Table 4-S1. Factors to calculate the adjusted CIN detection rates for SurePath and Thin-
Prep. Given factors are odds ratios comparing SurePath and ThinPrep with conventional 
cytology, adjusted for age, screening region, SES and calendar time.
SurePath versus CC 
(95% CI)
ThinPrep versus CC
(95% CI)
CIN I 1.14 (1.08, 1.20) 0.98 (0.93, 1.04)
CIN II 1.14 (1.09, 1.20) 1.04 (0.99, 1.10)
CIN III 1.06 (1.02, 1.10) 0.98 (0.94, 1.01)
Total CIN 1.10 (1.07, 1.13) 0.99 (0.97, 1.02)
Bold = Significant. A p value of <0.05 was considered to be statistically significant.
CC = Conventional cytology; CIN = Cervical intraepithelial neoplasia. 
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per 100,000 SurePath and ThinPrep smears by multiplying the observed 
CIN detection rates per 100,000 conventional cytology smears with the ad-
justed odds ratios for SurePath and ThinPrep versus conventional cytology, 
as obtained in our previous study (Table 4-S1(117)). These odds ratios were 
adjusted for differences in the distribution of age, screening region, SES, and 
calendar time between the three cytology tests.
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AbSTRACT
Background. Early detection of cancer prevents cancer deaths if an effective 
treatment is available for the early stage at detection. A drawback of mass 
screening is overdiagnosis. The potential harm of overdiagnosis depends 
on its frequency and the consequences of diagnosis and treatment. There 
is much debate on the topic of overdiagnosis in screening for breast 
cancer, but less so on overdiagnosis in screening for cervical cancer. 
Methods. We estimated overdiagnosis rates by microsimulation for breast 
cancer screening and for cervical cancer screening, using a cohort run 
of women born in 1982 with lifelong follow-up. Overdiagnosis estimates 
were made analogous to two definitions formed by the UK 2012 breast 
screening review. Pre-invasive disease was included in both definitions. 
results. Whereas breast cancer screening averted 1.3% of invasive cancers 
and 21% of related deaths, cervical cancer screening averted 55% of 
cervical cancers and 59% of related deaths. Breast cancer overdiagnosis 
rate was estimated at 2.5%, when including pre-invasive disease. Cervi-
cal cancer overdiagnosis rate was 74.8%, when including pre-invasive 
disease. For women of all ages in breast cancer screening, an excess of 
207 diagnoses per 100,000 women was found with screening, compared 
to an excess of 3,999 diagnoses per 100,000 women in cervical cancer 
screening.
Conclusions. For breast cancer, the frequency of overdiagnosis in screening 
is relatively low, but its consequences are evident. For cervical cancer, the 
frequency of overdiagnosis in screening is high, because of detection of 
pre-invasive disease, but the consequences per case are relatively small 
due to less invasive treatment. This illustrates that it is necessary to pres-
ent overdiagnosis in relation to disease stage and consequences. 
Key words. Breast cancer screening; Cervical cancer screening; Pre-invasive 
disease; Overdiagnosis; Microsimulation
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bACKGRouND
The purpose of cancer screening is to prevent cancer death by detecting a 
(pre)cancerous lesion early, when treatment is still a viable option and more 
effective(122). Screening advances the diagnosis of disease to an earlier age, 
resulting in a higher incidence just after the initiation of screening. After the 
upper age limit of screening, the incidence rate will drop(123). 
Breast cancer screening detects invasive breast cancer and ductal carcinoma 
in situ (DCIS), which are both considered a cancer diagnosis(124). The 
number of breast cancer diagnoses has increased since the introduction of 
screening, due to both lead time and changes in underlying risk. In a mature 
cervical cancer screening programme, the screen detection of invasive can-
cer is rare due to the higher frequency of detection of precursor lesions, thus 
altering the natural history of those lesions that are progressive. Screening 
for cervical cancer mostly detects cervical intraepithelial neoplasia (CIN), 
which is not regarded as a cancer diagnosis. The incidence rate of cervical 
cancer had been decreasing prior to the introduction of screening and has 
continued to decrease since the introduction of screening(125, 126). Given 
the fact that screening for colorectal cancer will also focus on detecting 
precancerous lesions, it is expected that the incidence of invasive colorectal 
cancer will decrease after screening is introduced(126). 
The downside of early detection is the possibility of detecting abnormalities 
that would never have become clinically apparent in the absence of screen-
ing(127). This may occur because abnormalities spontaneously regress, as is 
described for cervical cancer(128-130), or because they remain indolent, as 
is described for breast cancer(131, 132). The detection of such an abnormal-
ity is called overdiagnosis, and most overdiagnoses lead to overtreatment. 
Overdiagnosis has been the topic of a fierce debate in breast cancer screen-
ing(127). In cervical cancer screening, overdiagnosis is usually quantified as 
a lack of specificity for clinically significant disease. 
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The impact of overdiagnosis depends on its frequency and its consequences. 
In breast cancer screening, the overdiagnosis rate is relatively low(127). In 
cervical cancer screening, the overdiagnosis rate is usually not established. 
The consequence of overdiagnosis is unnecessary treatment which is inher-
ently harmful. The consequences of overdiagnosis in breast cancer screening 
are more severe than those in overdiagnosed non-progressive CIN lesions in 
cervical cancer screening. For an individual patient the name of the disease 
carries weight as well. 
We aimed to exemplify the impact of overdiagnosis by comparing these two 
screening programmes, which have been implemented for several decades 
in the Netherlands; for cervical cancer since 1985 (ie. currently, women 
aged 30-60 are invited every five years), and for breast cancer since 1990 (ie. 
currently, women aged 50-74 are invited every two years)(133, 134). 
In literature, estimates of overdiagnosis in breast cancer screening vary from 
4-54%(127, 135-138). The proper estimate of overdiagnosis has been the 
topic of many debates and the cause of many misunderstandings. We chose 
to use the definitions put forward by the UK independent review panel(139). 
This is the first study aiming to compare different screening programmes by 
addressing the potential amount and composition of overdiagnosed cases 
in the same overdiagnosis framework. As more types of cancer will become 
eligible for screening, we hope that in the future balanced reports will 
elucidate the impact of any cancer screening on the advanced cancer rate 
and disease-specific mortality, while also publishing the properly estimated 
extent of overdiagnosis.
mETHoDS
The MISCAN model is a microsimulation model. This means the model 
simulates all individual life histories in a population. We have a model for 
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breast cancer screening (MISCAN-Breast) and a model for cervical cancer 
screening (MISCAN-Cervix)(127, 140). In order to obtain a representative 
population, the models are fitted with a birth table and a life table. Each 
life history has its own probability of developing a (pre)cancerous lesion. In 
MISCAN-Breast, this probability is determined by fitting model parameters 
hazard, onset, and incidence, to data on incidence without screening from 
the Dutch Cancer Registry(141). In MISCAN-Cervix, the model is fitted 
to incidence data from the Dutch Cancer Registry and data on detection 
obtained from PALGA(141). From each state the disease may progress to 
the next stage by a semi-Markov progression model (Figure 5-1). In MIS-
CAN-Breast, screening is implemented in the model using data on gradual 
roll-out, attendance rate, and re-attendance rate in the Dutch screening 
programme. Sensitivity, stage distribution, and distribution of sojourn-time 
were estimated by fitting these parameters to data on incidence and stage 
distribution in situations with (1991-2010) and without screening (1990). 
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figure 5-1. Progression in the MISCAN model. Every woman starts at the top left, where 
she has no cancer. From there she may progress through the different stages of cancer. If 
the cancer is detected by screening, the woman moves to the bottom of the graph (screen-
detected). If the cancer is clinically detected she moves to the far right of the graph (clini-
cally detected).
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MISCAN-Breast assumes a 1.4% annual percentage change in underlying 
incidence(142). Mortality reduction in the breast cancer model is based on 
the results of the Swedish trials(143). The mortality reduction in the cervical 
cancer model is based on observational data, provided by the Dutch Cancer 
Registry and PALGA over the period 1998 to 2007. 
The impact of screening on an individual life history is illustrated by 
Figure 5-2, in which there are five different women, and each has a scenario 
with and without screening. Dark grey cells represent the negative effects of 
screening, while light grey cells represent the positive effects of screening. 
Woman number 1 will benefit from screening. In situation 1A, there is no 
mass screening. She will have an onset of cancer; this cancer will grow and 
develop up to the point when she develops symptoms. The cancer will be 
clinically diagnosed and she will die from this cancer. In situation 1B, there 
is mass screening. The woman will have the same onset and the same pre-
clinical disease phase, but now mass screening will detect her cancer before 
she develops symptoms. Therefore, the disease is in a less advanced state 
and treatment is successful. She has gained life-years and will die of other 
causes than cancer. Woman number 2 does not benefit from screening. 
Like woman number 1, she has an onset of cancer, followed by a preclinical 
disease phase. This phase however, would extend beyond her lifespan. She 
will never be diagnosed with cancer in the situation without screening (2A). 
In the situation with screening (2B) the cancer will be detected by screening 
and she will be treated accordingly. She will still die at the same time, but 
now she has lost several quality-adjusted life-years (QALYs) due to the fact 
that she had a cancer diagnosed. Woman number 3 develops a pre-invasive 
disease that will progress to a clinically detected cancer, but she will not 
die from this cancer (3A). She will also not gain any life-years by screening 
(3B). Woman number 4 has a type of cancer with an obvious pre-invasive 
precursor state (ie. CIN in cervical cancer). In this case the preclinical phase 
is divided into two phases, one with preclinical pre-invasive disease and one 
with preclinical cancer. The preclinical-pre-invasive state will progress to 
preclinical cancer, which becomes clinically detected and leads to cancer-
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related death in the situation without screening (4A). When this woman is 
screened (4B) while her disease is in the pre-invasive phase and her condi-
tion is detected, she may be cured completely. Thus, cancer was prevented 
and she benefits from screening. Woman number 5 does not benefit from 
screening; she has a preclinical-pre-invasive disease that will not progress, 
or may even regress back to normal without screening (5A). Screening (5B) 
will give her a diagnosis of pre-invasive disease, but she will not gain any 
life-years.
MISCAN-Breast assumes a regression rate of 2%, and a progression rate of 
11%, for DCIS(144). MISCAN-Cervix has six different disease paths, five 
assume regression, and assumes progression from onset to invasive disease. 
Each woman has an age-dependent probability of ending up in one of the 
disease paths. 
We performed a cohort run using our breast cancer and cervical cancer 
models. The cohort consisted of 10,000,000 women, all born in 1982. The 
year 1982 was chosen so all women were 30 years and invited for cervical 
cancer screening in 2012, the most recent year with complete data. The 
number of simulated women alive in 2012 was also chosen as the denomina-
tor to convert raw data to rates. Between 2012 and 2032 (the year all women 
are invited to breast cancer screening for the first time) approximately 2% of 
the simulated women die of all-cause mortality (including cancer). Follow-
up was completed for ages 30-100 years. Output measures were: number of 
diagnoses during entire follow-up in the situation without screening and 
in the situation with screening, and the number of diagnoses during the 
screening ages in the situation without screening and in the situation with 
screening. All results are presented per 100,000 women aged 30 in 2012 and 
stratified by precancer (DCIS for breast cancer and CIN grades I, II, and III 
for cervical cancer) and invasive cancer. 
To estimate overdiagnosis we used the definitions set forward by the UK 
Independent review panel, which are: (i) “from the population perspective, 
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the proportion of all cancers ever diagnosed in women invited to screening 
that are overdiagnosed”, and (ii) “from the perspective of a woman invited 
to screening, the probability that a cancer diagnosed during the screening 
period represents overdiagnosis”(139). To be able to address all diagnoses 
in the programme, we extend the definitions above to include pre-invasive 
lesions, such as CIN I, II, and III.
These definitions translate into the following calculations: 
1. From the population perspective: Number of extra diagnoses with 
screening/Total number of diagnoses in a population with screening. For the 
purpose of comparison we used ages 30-100 years. No significant amount of 
cancers occur before the age of 30. 
2. From an individual perspective: Number of extra diagnoses with 
screening/Total number of diagnoses in women of screening age. For breast 
cancer screening this age range is 49-75 years. For cervical cancer screening 
this age range is 29-60 years, but we used 29-64 years because the diagnostic 
process in cervical cancer screening may take some time due to follow-up. 
The number of extra diagnoses with screening is the difference between 
the total number of diagnoses in women aged 0-100 without screening and 
the total number of diagnoses in women aged 0-100 with screening. When 
we consider overdiagnosis, we included pre-invasive disease. If we had not 
included pre-invasive disease, overdiagnosis measures would not have ap-
plied.
RESulTS
All results are given per 100,000 women aged 30 in 2012. The model pre-
dicted 1,669 cervical neoplasia diagnoses (Table 5-1) and 13,210 breast can-
cer diagnoses per 100,000 women without screening (Table 5-2). Screening 
added 3,999 cervical neoplasia diagnoses and 207 breast cancer diagnoses. 
The extra cervical diagnoses were 4,920 extra CIN lesions, which cannot be 
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clinically detected, and 921 (-55.2%) fewer cervical cancer diagnoses. The 
extra breast cancer diagnoses were the result of 376 extra DCIS diagnoses 
(+61.7%), and 169 fewer invasive cancers (-1.3%). 
From a population perspective, the breast cancer overdiagnosis rate was 
estimated to be 1.5%. The cervical cancer overdiagnosis rate varied from 
70.6%, when including all CIN and invasive diagnoses, to 50.0%, when in-
cluding only CIN III and invasive disease. From the individual perspective, 
the breast cancer overdiagnosis rate was 2.5%. Cervical cancer overdiagno-
sis rate varied from 74.8%, when including all CIN and invasive diagnoses, 
Table 5-1. Number of cervical cancer cases per 100,000 women aged 30 years in 2012 in the 
situations with versus without screening.
 Without screening With screening
Clinically detected
Clinically 
and screen-
detected
Screen-
detected
Clinically 
detected
Diagnoses during entire life (ages 30-100 years)
   CIN I 0 1,138 1,138 0
   CIN II 0 1,189 1,189 0
   CIN III 0 2,593 2,593 0
   Cervical cancer 1,669 748* 117 632
   Total diagnoses 1,669 5,668 5,037 632
    Cervical cancer 
death
644 266
Diagnoses during screening (ages 30-64 years)
   CIN I 0 1,138 1,138 0
   CIN II 0 1,189 1,189 0
   CIN III 0 2,593 2,593 0
   Cervical cancer 1,138 424 117 307
   Total diagnoses 1,138 5,344 5,037 307
CIN = Cervical intraepithelial neoplasia
*The total of screen-detected and clinically detected cervical cancers do not add up as a 
result of rounding 
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Table 5-2. Number of breast cancer cases per 100,000 women aged 30 years in 2012 in the 
situations with versus without screening.
 Without screening With screening
Clinically detected
Clinically 
and screen-
detected
Screen-
detected
Clinically 
detected
Diagnoses during entire life (ages 30-100 years) 
   DCIS 610 985 531 454
   Breast cancer 12,600 12,431 3,523 8,908
   Total diagnoses 13,210 13,417 4,055 9,362
   Breast cancer death 4,637 3,668
Diagnoses during screening (ages 49-75 years) 
   DCIS 364 746 531 215
   Breast cancer 7,286 7,447 3,523 3,924
   Total diagnoses 7,650 8,194 4,055 4,139
DCIS = Ductal carcinoma in situ
Table 5-3. Cervical cancer and breast cancer overdiagnosis rates including different (pre-)
stadia and stratified by perspective. 
(Pre)stadia included as 
overdiagnosis
Population perspective: 
Excess diagnoses / Lifetime 
diagnoses
Individual perspective: 
Excess diagnoses / 
Screening age diagnoses
CIN I, II, and III + cervical 
cancer
70.6% 74.8%
CIN II, and III + cervical 
cancer 63.2% 68.0%
CIN III + cervical cancer 50.0% 55.4%
DCIS + breast cancer 1.5% 2.5%
Overdiagnosis rates were calculated by using the numbers of cases per 100,000 women 
given in Tables 5-1 and 5-2. Excess diagnoses were calculated by subtracting all diagnoses 
in women aged 30-100 in the situation without screening from all diagnoses in women aged 
30-100 in the situation with screening. 
Diagnoses are considered to be lifetime diagnoses when detected in women aged 30-100. 
Diagnoses are considered to be screening age diagnoses when detected in women aged 
30-64 for cervical cancer, and in women aged 49-75 for breast cancer. 
CIN = Cervical intraepithelial neoplasia; DCIS = Ductal carcinoma in situ.
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to 55.4%, when including only CIN III and cervical cancer (Table 5-3). The 
number of cervical cancer deaths reduced by 59% in the situation with 
screening (ie. from 644 to 266 deaths per 100,000 women). The number 
of breast cancer deaths reduced by 21% (ie. from 4,637 to 3,668 deaths per 
100,000 women). 
DiSCuSSioN
Both breast cancer screening and cervical cancer screening prevent cancer-
specific mortality at the expense of overdiagnosis, when the detected pre-
invasive lesions are included in its definition.
The burden of overdiagnosis depends on its frequency and its consequences. 
Although the overdiagnosis frequency is high in cervical cancer screening 
relative to breast cancer screening, the impact is limited because treatment is 
minimally invasive. For CIN I most often no treatment is necessary, and for 
CIN II or CIN III a loop excision or conisation may be done in an out-patient 
setting(145). These procedures have relatively limited risks, and no apparent 
cosmetic impact. However, cold knife conisation and large loop excision may 
be associated with preterm delivery, low birth weight, caesarean section, and 
preterm rupture of the membranes in future pregnancies(146-148). For breast 
cancer screening, the frequency is low relative to cervical cancer screening, 
but the impact is higher due to more invasive treatment. The treatment of 
DCIS consists of lumpectomy or even mastectomy, in some cases followed by 
radiation therapy(149, 150). The risks of these treatments include (rare) stan-
dard operation risks (haemorrhage or infection) and the risk of generalized 
anaesthesia. Additionally, the cosmetic result of these procedures has signifi-
cant impact(150). The perception of the individual also needs to be taken into 
account. The information provided with each diagnosis, whether it is cancer 
or pre-invasive disease, is crucial to the impact of this event. The decision to 
count a diagnosis as overdiagnosis has to be related to its severity, treatment 
warranted, and on the impact of the information provided at diagnosis. 
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Our estimates for overdiagnosis of breast cancer were different from those 
previously published using the MISCAN model. This is a direct result of 
using cohort runs instead of simulating a realistic population. If we run 
our model with a population aged 0-100, we obtain an overdiagnosis rate 
directly comparable to that of De Gelder et al.(127). This rate is: from a 
population perspective, for all diagnoses 4.6%; and from an individual 
perspective, for all diagnoses 8.1%(127, 135-138). For cervical cancer no 
comparable numbers were published. 
Our analysis for cervical cancer screening was performed on the current 
situation (ie. primary conventional cytology testing with cytology triage) 
in the Netherlands. However, over the last years most laboratories have 
added a test to detect human papillomavirus (HPV) infections in the triage 
phase which slightly increases CIN I and CIN II detection(39). In addition, 
most laboratories processing primary screening tests have switched from 
using conventional cytology to liquid-based cytology tests SurePath and 
ThinPrep. Rozemeijer et al. have shown that CIN II+ detection rates increase 
by using SurePath, while they are unaffected by using ThinPrep(117). This 
means that overdiagnosis rates are probably somewhat higher in the cur-
rent Dutch situation than estimated in our study. Also, it is expected that 
from 2016 onward, cervical cancer screening will be further modified in the 
Dutch programme. Primary cytology will then be replaced by primary HPV 
screening with cytology triage. Furthermore, women will be invited for 
screening five times in their lifetime(151). On the one hand there is a risk of 
increasing overdiagnosis by detecting disease at yet an earlier stage, on the 
other hand overdiagnosis may decrease due to less screening examinations 
in a lifetime. 
Internationally breast cancer screening programmes vary. In the USA many 
women are annually screened for breast cancer from the age of 40,  despite 
the recommendation made by the United States Preventive Services Task 
Force (USPSTF)(152), while in the UK women are invited from ages 50-
70 every three years (ie. the programme is currently extending to include 
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women aged 47-73)(153). In addition, cervical cancer screening pro-
grammes also vary. In some countries, such as Finland, the cervical cancer 
screening programme is comparable to that of the Netherlands and women 
are invited seven times a lifetime, while in the UK, Sweden and Denmark 
women are invited for screening 12, 13, and 13 times a lifetime starting at 
the ages of 25, 23, and 23, respectively(154-156). Therefore, our estimated 
overdiagnosis rates for both breast and cervical cancer screening may be 
different in other countries. They are expected to increase for screening 
programmes with increasing number of screening examinations and for 
screening programmes with an earlier onset of screening. With each added 
screening round overdiagnosis may increase, also for younger women. In 
fact more non-progressive CIN is found in younger women than in older 
women(21). 
Looking towards the future, if we were to analyse the data for colorectal 
cancer screening we would expect results in between those of breast cancer 
and cervical cancer screening, depending on the screening test being used. 
Faecal occult blood tests, especially the older guaiac tests but also the newer 
immunochemical tests, have a lower sensitivity for early, pre-invasive disease 
than endoscopy. The most sensitive test will find more pre-invasive disease, 
which will need less invasive treatment but also more often would not have 
developed into clinical disease. Thus, the frequency of overdiagnosis would 
be high but the per case consequences would be low. 
In order to compare the two programmes, which offer screening at different 
ages, we performed a cohort run. Although this results in a lifetime estimate 
of harms and benefits, it remains hypothetical as the homogeneity of a 
cohort never resembles a real population. Mathematical modelling requires 
assumptions made in the model on natural history of cancer. The mean 
duration of sojourn time and the probability of progression are interchange-
able in the model, the assumptions used have influenced the overdiagnosis 
estimate(157). 
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We have compared the burden of screening for two of the population can-
cer screening programmes currently in use in the Netherlands. For breast 
cancer, overdiagnosis estimates are relatively low, but the consequences for 
overdiagnosed women are significant. On a population level, these conse-
quences are, however, quite small. For cervical cancer, overdiagnosis esti-
mates of pre-invasive disease are high, but the consequences are relatively 
small due to less invasive treatment. Screening eligible women should not 
only be informed about the potential benefits from screening, but also about 
the probability, and its potential harms, from being overdiagnosed.
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AbSTRACT 
Background. The human papillomavirus (HPV) DNA test has higher sen-
sitivity than cytology for cervical cancer screening. Therefore, cervical 
cancer cases that are missed by cytology could potentially be identified 
if we use primary HPV testing. Studies showed that HPV screening is 
the preferred primary test at age 35 and over. Given the high prevalence 
of harmless HPV infections, the use of HPV testing at younger age is 
less obvious. The number of cancers in young age is often mentioned to 
indicate the possible benefits of a more sensitive test. We actually esti-
mated the proportion of those cases that is potentially preventable in the 
Netherlands by the use of a more sensitive screening test at first screening 
age 30, given that the more sensitive test is used at age 35 and over.
Methods. We analyzed the screening history of women diagnosed with 
cervical cancer in the period 2004 to March 2009, using data from the 
Dutch Pathology Register.
results. Only 15-30% (two to four cases per 100,000 women) of the cases 
was preceded by negative cytology under age 35 and therefore could have 
been prevented by a more sensitive test at age 30.
Conclusions. The lower the screening coverage and the shorter the screen-
ing interval in those screened at young age, the smaller the gain of a more 
sensitive test. So, as long as the current screening pattern is not changed, 
the majority of the cervical cancer cases at young age would still occur 
even when applying a more sensitive test at the younger ages.
Keywords. Cervical cancer; Screening; Human papillomavirus DNA test; 
Cytology; Young women
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bACKGRouND
Mass screening for cervical cancer has been operational for women from 
age 30 years onward in the Netherlands since 1996(34). Nevertheless, 
still approximately 700 women are diagnosed with cervical cancer annu-
ally in the Netherlands, of which 160 cases in the age group 30-39(158). 
Some of these cases were diagnosed based on symptoms while unscreened 
or were detected by their first screening moment(74). In these women, 
lack of screening test sensitivity did not play a role. However, some cases 
had screening but tested negative(74), which might well be due to lack of 
sensitivity of, in the current situation, cytological screening. Meta-analyses 
and pooled analyses have established that human papillomavirus (HPV) 
DNA tests have higher sensitivity than cytology for detecting high-grade, 
clinically relevant, cervical intraepithelial (CIN) lesions(83, 159). Therefore, 
cervical cancer cases that are missed by cytology could have been identified 
if we had used primary HPV DNA testing as the primary screening test. 
Several studies showed that HPV screening is the preferred primary test at 
age 35 and over(84, 85, 160-164). HPV testing is less specific than cytology 
because it can detect harmless HPV infections. As these are considerably 
more prevalent in young women, the net benefits of using HPV testing 
under age 35 is less obvious(165, 166). Frequent screening at a young age 
detects many transient infections, cytological and histological abnormalities 
and every screening round adds to unnecessary triage, overdiagnosis, and 
overtreatment as a consequence. Conversely, the number of life-years gained 
per extra death prevented in young women is high, and the prevention of 
cervical cancer incidence and mortality at young age is valuable. 
The goal of this study is to estimate how many cases are potentially prevent-
able in the Netherlands by the use of a more sensitive screening test before 
the age of 35, assuming that this more sensitive test is (already) offered after 
the age of 35 years. To this end, we analyzed the screening history of women 
with cervical cancer diagnosed in the period January 2004 to March 2009, 
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using data from the Dutch national pathology file that includes cervical 
cytology and histological results(94). 
mETHoDS
To analyse the screening history of women diagnosed with cervical cancer 
in the period January 2004 to March 2009, we used data from the Dutch 
nationwide network and registry of histo- and cytopathology (PALGA). The 
registration began in the late 1970s and achieved practically complete cover-
age of pathology laboratories in 1990. The network registers cervical smears 
and biopsies taken in all settings: primary smears within the screening 
programme, opportunistic screening, smears and biopsies taken because 
of medical complaints, and secondary (diagnostic and follow-up) tests, 
regardless of whether they are taken or read by public or private healthcare 
providers and laboratories.
In the PALGA network, women are identified through their birth date and 
the first four letters of their (maiden) family name. This identification code 
enabled linkage of multiple tests belonging to the same woman, allowing 
us to follow the individual screening and disease histories. The problem of 
false identity matches was avoided by excluding women with 0.5% most 
common maiden names in the analyses(167). The implicit assumption used 
here is that the screening histories and the commonness of surnames are 
not associated.
Registered screening histories were organized into screening episodes. An 
episode starts with a primary test (a smear or a biopsy) followed by second-
ary tests in case this test was abnormal (at least borderline dyskaryosis) or of 
unsatisfactory quality. Follow-up or secondary tests were defined as the tests 
made within four years following the primary test, unless the follow-up of 
this primary smear had already been completed according to the guidelines 
(eg. with two consecutive negative smears after a borderline dyskaryotic 
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smear, or three consecutive negative smears after histologically confirmed 
CIN). All other tests were considered to be primary tests.
Analyses
Analyses were performed for different age groups, that is, 30-35 years, 30-40 
years, and ≥30 years. The definition of age is the age of a woman at the end 
of the calendar year. This is because in the Netherlands women are invited 
to participate in screening during the year they become 30, 35, 40, 45, 50, 
55 or 60 years. Therefore, some women are still 29, 34, and so forth, at the 
time they are being screened. Age groups were based on the fact that women 
below the age of 30 are not invited to participate into screening. In general, 
since women are screened with an interval of five years, the age group 30-35 
years will show the interval cases that are missed at the first screening round. 
The age group 30-40 years will show the interval cases and cases picked up 
at the second screening round, that are missed at the first screening round.
We wanted to estimate how many cases were possibly the result of a failure 
of cytological screening [ie. a normal cytological result while a cancer 
(precursor) is present] performed before the age of 35, and could possibly 
have been prevented if a more sensitive test had been used, by analyzing 
the screening history of women with cervical cancer. To this end, we first 
identified cervical cancer cases diagnosed at ages 30-35 years, 30-40 years, 
and ≥30 years by selecting all PALGA records that included pathology codes 
for cervical cancer between 2004 and March 2009. For these women, we 
reviewed the free text of all histology reports in PALGA. Age of diagnosis 
was defined as the age at the date of the first registered pathology code for 
cervical cancer in PALGA. 
Of all cervical cancer cases diagnosed in women aged 30-35 years, we 
first excluded those diagnosed at the first episode in a woman’s lifetime 
(Figure 6-1). If the cancer was diagnosed at the first episode, it could not 
have been found earlier using a more sensitive test. Second, we analyzed 
whether the primary cytology test of the episode prior to the episode in 
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which the cancer was diagnosed, was performed before the age of 35 years 
(Figure 6-1). If the previous episode started after the age of 35 years, we 
assumed that these cases were not the result of a false negative cytological 
test performed before the age of 35 years and therefore could not potentially 
be diagnosed earlier by HPV screening before the age of 35 years. Third, of 
the cases diagnosed in the second or later episode in a woman’s lifetime and 
with a previous episode starting before the age of 35 years, we excluded those 
cases with an abnormal cytological result before the age of 35 (Figure 6-1). 
For these cases, the cancer (precursor lesion) was not missed by the primary 
cytological test, but by the follow up, like false-negative follow-up or no 
(complete) follow-up. If we assume a similar triage test in case of primary 
HPV testing and primary cytological testing, these cases would also not 
have been diagnosed by follow up after a positive HPV test. If there were 
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figure 6-1. Analyses of screening history of women diagnosed with cervical cancer at age 
30-35 years, in the period January 2004 to March 2009 (n = Number of cases; Q = Question). 
‘Excluded’ means that these cases could not have been prevented using a more sensitive 
test at age 30.
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only negative cytological results before the age of 35 years, these cases (or 
their precursors) were possibly missed due to a false-negative test. These 
cases represent the cases that are potentially preventable by the more sensi-
tive HPV test before age 35.
To explore the probability that the lesion was missed by the cytological 
test, we analyzed what the interval was between the date of first test of the 
episode in which the cancer was diagnosed and the date of the primary test 
of the previous episode. The shorter the interval, the more likely the lesion 
was already present at the time of screening. In other words, if the interval 
was short after a normal cytological result, the chance that the (pre)cancer 
had been missed by the preceding cytological test would be larger than if 
the interval was longer. Furthermore, we did the same subsequent analyses 
for women diagnosed with cervical cancer aged 30-40 years, and for women 
aged ≥30 years.
We calculated the percentage of cases that could potentially be prevented 
per age group, by dividing the number of cervical cancer cases that could 
possibly be prevented per age group and interval, by the number of cervical 
cancer cases diagnosed per age group. We calculated 95% binomial propor-
tion confidence intervals using an exact method. We estimated the number 
of cervical cancer cases that could potentially be prevented per year and 
age group in the Netherlands using a more sensitive test before the age of 
35 years, by multiplying the number of cancers diagnosed in 2011 in the 
Netherlands Cancer Registry(158) with the calculated percentage of cases 
that could be prevented. We calculated the crude rate of the number of 
cancer cases per 100,000 women using the Dutch female population in the 
specific age groups in the period 2011-2012(168). 
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RESulTS
After the exclusion of the 0.5% most common surnames, 226 diagnosed 
cervical cancer cases were still registered in PALGA in the period January 
2004 to March 2009 in women aged 30-35 years, 583 in women aged 30-40 
years, and 2,426 in women aged ≥30 years (Figure 6-1, Table 6-1). Of the 
women aged 30-35 years, 67% had never been screened before the cancer 
was diagnosed. Of the remaining 33% (75 cases), 74 cases (99%) had the 
last cytological test before the episode in which the cancer was diagnosed, 
before the age of 35 years. In 63 of these 74 cases (85%), no cytological 
abnormality was found at that last screening test. In 83% (n = 52) of these 
cases, the interval between the first test of the episode in which cervical 
cancer was diagnosed and the previous primary smear was less than ten 
years, in 63% (n = 40) it was less than five years (Table 6-2).
In women aged 30-40 years, 583 cervical cancer cases were diagnosed 
(Table 6-1). Of these women, 49% were never screened before the cancer 
was diagnosed. Of the remaining 51% (297 cases), 207 cases (70%) had the 
Table 6-1. Analyses of screening history of women diagnosed with cervical cancer in the 
period January 2004 to March 2009, by age at cancer diagnosis (following the decision tree 
as presented in Figure 6-1 for age group 30-35 years)
Age of cervical cancer diagnoses
30-35 years 30-40 years ≥30 years
Total cervical cancer cases, n 226 583 2,426
(a) Cases with a previous 
episode with a primary smear, n 
(% of total)
75 (33) 297 (51) 1,377 (57)
(b) Of (a), the cases of which 
the last primary smear was 
performed <35 years, n (% of 
total)
74 (33) 207 (36) 318 (13)
(c) Of (b), the cases with only 
normal smear results <35 years, 
n (% of total)
63 (28) 160 (27) 219 (9)
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last cytological test before the episode in which the cancer was diagnosed, 
before the age of 35 years. In 160 of these 207 cases (77%), no cytologi-
cal abnormality was found at the last screening test performed before the 
cancer was diagnosed. In 82% (n = 131) of these cases, the interval between 
the first test of the episode in which cervical cancer was diagnosed and the 
previous primary smear was less than ten years, in 51% (n = 82) it was less 
than five years (Table 6-2).
In women aged ≥30 years, 2,426 cervical cancer cases were diagnosed 
(Table 6-1). Of these women, 43% were never screened before the cancer 
was diagnosed. Of the remaining 57% (1,377 cases), 318 cases (23%) had the 
last cytological test before the episode in which the cancer was diagnosed, 
before the age of 35 years. In 219 of these 318 cases (69%), no cytologi-
cal abnormality was found at the last screening test performed before the 
cancer was diagnosed. In 65% (n = 142) of these cases, the interval between 
the first test of the episode in which cervical cancer was diagnosed and the 
previous primary smear was less than ten years, in 37% (n = 82) it was less 
than five years (Table 6-2).
In Table 6-3 and Figure 6-2, we show how many cases are potentially pre-
ventable per year and age group, by the use of a more sensitive screening test 
before the age of 35 years. If we assume that the lesion was already present at 
Table 6-2. Number of cervical cancer cases of which all previous cytology was under age 35 
and negative in the period January 2004 to March 2009, by age at cancer diagnosis and the 
interval between the date of first test of the episode in which the cancer was diagnosed and 
the date of the primary test of the last previous episode.
Age of cervical 
cancer 
diagnoses
≤5 years, 
n (%)
≤10  years,
n (%)
≤15 years,
n (%)
Total,
n (%)*
30-35 years 40 (63) 52 (83) 61 (97) 63 (100)
30-40 years 82 (51) 131 (82) 151 (94) 160 (100)
≥30 years 82 (37) 142 (65) 184 (84) 219 (100)
*Row (c) in Table 6-1. 
116 Chapter 6
Table 6-3. Nationwide annual number of cancer cases per 100,000 women (Source: Nether-
lands Cancer Registry) of which the last previous cytology was under age 35 and negative, 
and that therefore could potentially have been prevented with a more sensitive test at age 
30, by age at cancer diagnosis and interval since that last negative smear.
Age at cancer diagnosis
30-35 years 30-40 years ≥30 years
Total incidence in 2011
   Cases 73 164 711
   Cases per 100,000  
   women
14.5 15.6 12.9
Preventable incidence in 2011
Interval ≤5 years
   % cases 
   (95% CI)
18%
(12.7, 22.7)
14%
(11.2, 16.9)
3%
(2.7, 4.1)
   Cases 13 23 21
   Cases per 100,000 
   women
2.6 2.2 0.4
Interval ≤10 years
   % cases 
   (95% CI)
23%
(17.5, 28.5)
22%
(19.1, 25.9)
6%
(4.9, 6.8)
   Cases 17 36 43
   Cases per 100,000 
   women
3.3 3.4 0.8
Interval ≤15 years
   % cases 
   (95% CI)
27%
(21.2, 32.8)
26%
(22.3, 29.5)
8%
(6.5, 8.6)
   Cases 20 43 57
   Cases per 100,000  
   women
3.9 4.1 1.0
All intervals
   % cases 
   (95% CI)
28%
(22.0, 33.7)
27%
(23.8, 31.1)
9%
(7.9, 10.2)
   Cases 20 44 64
   Cases per 100,000  
   women
4.1 4.2 1.2
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the screening moment less than five years before the cancer was diagnosed, 
2.6 cancer cases per 100,000 women (18%, 95% CI: 12.7, 22.7) per year 
are missed and potentially preventable in age group 30-35 years. For the 
age groups 30-40 and ≥30 years, 2.2 (14%) and 0.4 (3%) cases per 100,000 
women are potentially preventable per year. If we assume that the lesion was 
already present at the screening moment less than ten years before the can-
cer was diagnosed, 3.3 cases per 100,000 women (23%, 95% CI: 17.5, 28.5) 
are annually potentially preventable in age group 30-35 years, 3.4 (22%, 95% 
CI: 19.1, 25.9) in age group 30-40 years and 0.8 (6%, 95% CI: 4.9, 6.8) in age 
group ≥30 years. For a screening moment ≤15 years before the cancer was 
diagnosed, these figures are 3.5 (27%, 95% CI: 21.2, 32.8), 4.1 (26%, 95% 
CI: 22.3, 29.5), and 1.0 (8%, 95% CI: 6.5, 8.6) cases per 100,000 women per 
year, for age groups 30-35, 30-40, and ≥30 years, respectively. If all screening 
moments before the cancer was diagnosed are considered, regardless of the 
9% (95% CI: 7.9, 10.2) 
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figure 6-2. Maximum proportion of cervical cancer cases of which the last previous cytology 
was under age 35 and negative, and that therefore could potentially have been prevented 
with a more sensitive test at age 30, by age group and interval since that last negative smear 
(Table 6-3).  
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interval of the previous test and the cancer diagnoses, these figures are 4.1 
(28%, 95% CI: 22.0, 33.7), 4.2 (27%, 95% CI: 23.8, 31.1), and 1.2 (9%, 95% 
CI: 7.9, 10.2) cases per 100,00 women per year for age groups 30-35, 30-40, 
and ≥30 years, respectively.
DiSCuSSioN
We showed that only 9% of the women aged ≥30 years who were diagnosed 
with cervical cancer in recent years could potentially have benefited from a 
more sensitive test (than the Pap smear) also at age 30 instead of having this 
more sensitive test only from age 35 onward. The other women with cervical 
cancer either did not attend cervical screening before the cancer diagnoses 
(43%), attended screening only after age 35 (44%), or already had a positive 
test before age 35 using the less sensitive Pap smear (4%). Women in the 
latter categories would not have benefited from having had a more sensitive 
test offered instead of a Pap smear. Depending on the age at diagnosis and 
the interval since that last negative Pap smear considered, the percentage of 
cases that could potentially have been avoided by offering a more sensitive 
test varies from 3% in women aged ≥30 years with an interval of less than 
five years, to 28% in all women aged 30-35 years. This shows the maximum 
possible benefit when performing HPV testing at all screening ages (includ-
ing age 30) compared to only at the ages over 35 years. Furthermore, the 
achieved benefit must be balanced with the relatively high positivity-rate of 
HPV testing at age 30 compared to the rate in older ages.
There are two explanations for a normal cytological test result in the episode 
before cervical cancer is diagnosed: (i) there is no neoplasia present yet, (ii) 
the lesion is present but missed by the test. The interval between the first 
manifestation of CIN I and the development of clinical cervical cancer is 
estimated to be on average 15 years(21, 169-171). Therefore, explanation 
two becomes less probable when the normal test result took place more than 
ten years before cervical cancer was diagnosed, and even less so in case of an 
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interval of more than 15 years. For the tests performed less than ten years 
before cancer diagnosis, and especially for the tests performed less than five 
years before diagnosis, however, explanation two seems most likely, mean-
ing that a more sensitive test in principle could have detected the present 
lesions. We showed that, if we assume that the lesion was already present at 
the screening moment less than ten years before the cancer was diagnosed, 
3.3 (23%) cases per 100,000 women have been annually missed and are 
potentially preventable in age group 30-35 years, 3.4 (22%) in age group 
30-40 years and 0.8 (6%) in age group ≥30 years. Note that these figures are 
a maximum and one would have to assume 100% sensitivity to prevent them 
all by the alternative test. Although the HPV test is more sensitive than the 
Pap test, it is not 100% sensitive(159). 
The presented proportions of cervical cancer cases that can be prevented 
by a more sensitive test at age 30 are representative for the Netherlands. 
The question is to what extent they are applicable for other countries. This 
depends on several factors, such as the coverage of the screening pro-
gramme at young age, the frequency of screening, and the sensitivity of the 
cytological test in the specific situation. For example, in the United States, 
the percentage of young women that undergo screening is higher than in 
the Netherlands(172), therefore the probability that women had a previous 
primary smear before the cancer was diagnosed is higher. This would re-
sults in a higher number of potentially preventable cases. Conversely, as the 
frequency of screening is also higher in the United States compared to the 
Netherlands(172), the probability that a lesion was missed in a pre-invasive 
stage is lower. This would result in a lower number of potentially prevent-
able cases. 
Test-positive rates are up to three times higher with HPV DNA screening 
than with cytology(173). HPV DNA screening consequently also causes 
more false-positive tests, that is, positive screening tests without underlying 
(clinically relevant) CIN or cervical cancer. These women will have unneces-
sary follow-up, such as repeat testing or a referral for colposcopy, which have 
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important psychosocial consequences(174). Moreover, most women with 
high-grade CIN are of reproductive age, which will be picked up by HPV 
DNA screening applied <35 years of age. Treatment of CIN is associated 
with a small but real increase in risk of pregnancy-related morbidity, such 
as premature delivery (<37 weeks), low birth weight (<2500 g) and preterm 
prelabour rupture of membranes(26, 146, 175). These disadvantages must 
be weighed against the advantages of the extra cervical cancer cases that are 
potentially preventable by using a more sensitive screening test.
In the Netherlands, all smears and histologically diagnosed cervical cancer 
cases are in principle registered in PALGA. However, the total number of 
women aged ≥30 years with an incident cervical cancer in 2004-2008 in 
PALGA differs from the number published by the Cancer Registry (+14%). 
Nevertheless, PALGA is the only comprehensive registry in the Netherlands 
that links the cancer cases with their screening history. 
In the future, studying interval cancers by stage would be useful, to get more 
insight into the cause of the occurrence of the cancer after a negative screen-
ing test. For example, low stage tumours are more likely newly developed 
tumours (not missed by the screening test). Unfortunately, tumour stage has 
not yet been included in the PALGA registry. To determine the total effect of 
applying a more sensitive screening test at younger ages, next to the effect on 
the cervical cancer incidence, the effect on cervical cancer mortality needs 
to be estimated. Currently, cervical cancer mortality is not included in the 
PALGA registry. In the future, we intend to link cervical cancer mortality 
to screening history to improve the evaluation of different cervical cancer 
screening methods.  We showed that 43% of the cervical cancer patients did 
not attend screening before they were diagnosed. Some of these cases could 
possibly have been prevented by offering an HPV self-test to non-attending 
women. It has been shown that offering an HPV self-test to non-responding 
women increases the screening participation rate with approximately 
6%(73). Furthermore, 25% of the women who never had been screened 
before, did attend the HPV self-test(176). 
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HPV vaccination was recently introduced in the Dutch National Immunisa-
tion Programme (NIP). In 2009, a catch-up programme was started for girls 
born between 1993 and 1996. Vaccination of the first NIP cohort (ie. girls 
born between January 1, 1997 and August 31, 1997) started in April 2010. 
As all women born after 1992 have been or will be invited for HPV vaccina-
tion, vaccinated women will reach the initial screening age (ie. 30 years) in 
2023. As it is expected that the cervical cancer incidence will decrease as 
a result of the vaccination, in the future, we need to reconsider the cost-
effectiveness of screening, and especially HPV screening. Determining the 
effectiveness of screening programmes for vaccinated women will require 
a separate analysis that can be performed when more is known about the 
long-term effectiveness of HPV vaccination.
In conclusion, we showed that the total incidence of cervical cancer at young 
screening age is not a good indicator for the potential gain when applying 
a more sensitive test at young age. For the Dutch situation, only 15-30% of 
all cases diagnosed in age group 30-40 years were preceded by a negative 
cytology based screening test and could therefore potentially have been 
prevented by a more sensitive screening test at age 30, for example, an HPV 
test. As long as the current screening pattern is not changed, the majority of 
the cervical cancer cases at young age would still occur even when applying 
a more sensitive screening test at the younger screening ages. The lower the 
screening coverage and the shorter the screening interval in those screened 
at young age, the lower the preventable proportion.
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AbSTRACT
Background. Human papillomavirus (HPV) self-sampling might be a 
promising method to increase effectiveness of primary HPV screening 
programmes when offered to non-attendees. However, effectiveness 
could decrease if regular attendees “switch” to self-sampling, because 
self-sampling test characteristics may be inferior. We examined under 
which conditions the harms would outweigh the benefits.
Methods. The MISCAN-cervix model was used to estimate quality-adjusted 
life-years (QALYs) gained and costs of offering HPV self-sampling to 
non-attendees. We varied the relative CIN II+ sensitivity and specificity 
(self-sampling versus regular sampling), extra attendance, risk of extra 
attendees, and the switching percentage.
results. Without switching, offering self-sampling is (cost-)effective under 
every studied condition. If the attendance due to self-sampling increases 
by ≥6 percentage points, higher primary underlying risk women (un-
screened women who will never attend regular screening) attend and the 
relative CIN II+ sensitivity and specificity are ≥0.95, it is (cost-)effective 
to offer self-sampling to non-attendees, even if all regular attendees 
switch. If the relative sensitivity decreases to 0.90 combined with either 
the absence of higher primary underlying risk women or a 3 percentage 
points extra attendance, QALYs are lost when more than 20 to 30% of the 
regular attendees switch.
Conclusions. Offering self-sampling will gain health effects if the relative 
CIN II+ sensitivity is ≥0.95, unscreened attendees are recruited, and the 
total attendance increases by ≥6 percentage points. Otherwise, switch-
ing of regular attendees may decrease the total effectiveness of the 
programme. 
Impact. Self-sampling needs to be implemented with great care and 
advantages of office-based sampling need to be emphasized to prevent 
switching. 
Keywords. Self-sampling; Human papillomavirus; Cervical cancer screen-
ing; Microsimulation; Effectiveness; Non-attendees
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bACKGRouND
In the Netherlands, cervical cancer incidence and mortality have decreased 
in the past decades to 6.5 and 1.3 per 100,000 women-years (age-adjusted to 
the World Population) in 2012(177). The introduction and improvements of 
the screening programme played a considerable role in this decrease(178). 
Since 1996, Dutch women of ages 30 to 60 years are invited to attend cervi-
cal cancer screening every five years. From 2016 onward, primary cytol-
ogy will be replaced by primary high-risk human papillomavirus (HPV) 
testing(179), because the sensitivity for detecting CIN II+ lesions is higher 
when using HPV testing(65) and HPV testing can be performed on self-
samples(69, 70). Although the current screening participation rate ranges 
from 65 to almost 70% [source: Dutch Network and National Database for 
Pathology (PALGA)(94)], it has been estimated that more than half of the 
invasive cervical cancers occur in women who did not participate in the 
previous six years. Moreover, some of these women had never been screened 
at all(74). This shows that addressing non-attendance can increase the ef-
fectiveness of the programme considerably. 
Self-sampling devices, with which women can collect cervical cells them-
selves, have been developed recently. As self-sampling is more woman-
friendly and less time consuming than letting a clinician, general practitio-
ner, or midwife collect cervical cells, it probably increases participation in 
screening. Indeed, the Dutch PROHTECT study has shown that offering a 
self-sampling HPV test to non-attendees of the programme increased the 
overall screening participation rate by about 6 percentage points(73, 180). 
However, the gain in effectiveness of the programme [ie. gain in quality-
adjusted life-years (QALYs)] probably not only depends on the increase in 
attendance, but also on the test characteristics of HPV self-sampling and 
on the ability to target higher risk non-attendees. It is likely that unscreened 
women (who were invited at least once but were never screened) have higher 
risks on developing cervical cancer than one-time non-attendees (who missed 
the last screening round, but have been screened in the past). Nevertheless, 
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including any non-attendee will probably increase the effectiveness of the 
programme. However, “switching” of regular attendees from office-based to 
self-sampling could, given a loss in detection (ie. more loss to follow-up, 
possible lower sensitivity), result in a decrease of the effectiveness of the 
programme (ie. losing QALYs). In other words, the QALYs gained by at-
tracting non-attendees could be annulled by the QALYs lost by switching of 
regular attendees. It is unclear at which level of switching this will happen. 
The aim of this study is to examine the effectiveness of offering HPV self-
sampling to non-attendees of a primary HPV screening programme. We 
modelled effects of parameters such as the relative CIN II+ sensitivity and 
specificity (self-sampling versus regular sampling), the extra attendance via 
self-sampling, and the risk of extra attendees. Given that the percentage of 
women who will switch from office-based to self-sampling is unknown, we 
determined the percentage of switching that would result in a decrease of 
the total effectiveness of the programme (ie. harms outweigh the benefits, 
QALYs are lost). We also examined the circumstances (ie. limits) under 
which it would not be cost-effective to offer HPV self-sampling to non-
attendees. 
mETHoDS  
We used the MISCAN-Cervix model to estimate benefits, harms, and costs 
of offering a self-sampling HPV test to non-attendees(181). For detailed in-
formation on the model specifications, see the Supplementary Information.
Assumptions for screening and triage
The screening policy considered is primary HPV screening with cytol-
ogy triage, as will be implemented in the Netherlands(182) (Figure 7.1-1). 
Women will be invited for screening at ages 30, 35, 40, 50, and 60 years. In 
addition, women will be invited at ages 45, 55 and 65 years if they not attend 
screening or have a positive HPV test in the previous screening round.
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HPV positive 
Immediate cytology triage test 
*Compliance self-sampling users = 92% 
#Compliance office-based sampling users = 100%  
 
No cytological 
abnormalities 
Cytology triage test at 6 months 
*Compliance self-sampling users = 68% 
#Compliance office-based sampling users = 92% 
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HPV negative 
Return to routine 
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programme 
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Colposcopy 
*Compliance = 97% 
 
Colposcopy 
*Compliance = 66% 
 
HPV test 
(self-sampling or office-based sampling) 
 
No cytological 
abnormalities 
 
BMD or worse 
figure 7.1-1. Triage strategy and compliance assumptions after a positive self-sampling 
and office-based sampling HPV test. We assumed that the compliance (ie. attendance for 
triage and colposcopy) behaviour does not differ between self-sampling, future, and current 
office-based sampling users. 
*Compliance rates of the first triage test (ie. immediate cytology triage), second triage test 
(ie. cytology triage at 6 months), and of colposcopy are assumed equal to those observed 
within the current programme. 
#The first triage test (ie. immediate cytology triage) after a positive office-based sampling 
test will be performed using co-collection, so the compliance will automatically be 100%. 
Compliance with the second triage test (ie. cytology triage at 6 months) is assumed to be 
equal to the first triage test in the current programme.  
 HPV = Human papillomavirus; BMD = Borderline and mildly dyskaryotic smears.
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Assumptions for attendance
For HPV office-based sampling, we assumed an age-dependent overall 
65% attendance rate as currently observed within the Dutch cytologi-
cal screening programme (source: PALGA). On the basis of the findings 
of the PROHTECT trial (offering self-sampling to non-attendees after an 
opting-out letter), we assumed that a self-sampling kit was sent to 85% of 
the non-attendees(183), which resulted in an extra overall attendance of 6 
percentage points(73). We assumed that 29% of these extra attendees are 
higher primary risk women (ie. unscreened women who will never attend 
via office-based sampling and who have a 1.7 times higher primary underly-
ing risk for developing cervical cancer than women who are willing to attend 
office-based sampling) which is equal to the proportion in non-attendees 
65% 
6% 
29% 35% 
Extra attendees 
Final non-attendees 
 
Non-attendees 
29%  of the extra attendees 
and final non-attendees 
consist of higher primary risk 
women Regular 
attendees 
figure 7.1-2. Distribution of regular attendees, non-attendees and extra attendees within 
the screening population. After receiving a screening invitation 65% of the invited women 
will attend via office-based sampling (ie. regular attendees) and 35% will not attend (ie. non-
attendees). After a HPV self-sampling test has been offered to the non-attendees, 17% of 
them will attend (ie. extra attendees; = 6% of the screening population) and 83% will not (ie. 
final non-attendees; = 29% of the screening population). 29% of the non-attendees consist 
of higher primary risk women ( = 10% of the screening population). We assumed that the 
proportion of higher primary risk women in the extra attendees and final non-attendees 
stayed equal to that in the non-attendees ( = 1.7% of the screening population are higher pri-
mary risk women who attend via self-sampling, 8.3% are higher primary risk women who do 
not attend). Office-based sampling users consist of regular attendees, while self-sampling 
users consist of extra attendees and, in case of switching, of (part of the) regular attendees. 
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(ie. 10% / 35% = 29%) (Figure 7.1-2). In addition to their increased primary 
underlying risk, these women also have an increased cervical cancer risk 
due to never attending regular screening. 
We assumed that the loss to follow-up after a positive self-sampling test was 
higher than after a positive office-based sampling test. On the basis of the 
observed data (source: PALGA), we assumed that 92% of the women comply 
with the first triage invitation and 68% with the second. With office-based 
sampling, the collected material can be used both for primary HPV and 
direct cytology triage testing (co-collection). Therefore, the first and only 
triage invitation is six months after the positive screening test. This results 
in a compliance of 100% for immediate cytology triage testing and 92% for 
triage testing six months after the positive office-based sampling test. In 
case of self-sampling, co-collection is not possible and women receive their 
first and second triage invitation directly and six months after the positive 
screening test. This results in a compliance of 92% for immediate cytology 
triage testing and 68% for triage testing six months after the positive self-
sampling test (Figure 7.1-1). 
As no data were available, we considered the two most extreme “switching” 
scenarios in the base-case analyses: no regular attendees and all regular at-
tendees switch from office-based to self-sampling.
base-case assumptions for test characteristics
The test characteristics of self-sampling were based on the assumption that a 
validated PCR test was used, as for instance the GP5+/6+(65, 184). According 
to the recent meta-analysis of Arbyn and colleagues(185), the point estimate 
for the relative sensitivity of CIN II+ when comparing self-sampling with 
office-based sampling is approximately 0.95, whereas the point estimate for 
the relative specificity is probably higher than 1.00. Therefore, we assumed 
a 5 percentage points lower sensitivity for high-risk HPV infections when 
self-sampling (ie. 80 versus 85%), and an equal specificity of 100% (ie. the 
true but uncertain value of specificity is probably somewhat lower than 
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100% due to cross-reactivity with low-risk HPV types and contamination). 
By including fast clearing high-risk HPV infections, we were able to model 
a lack of specificity. 
As women in our model can have multiple lesions at the same time, the 
CIN II+ sensitivity not only depends on the sensitivity for a high-risk 
HPV infection, but also on the specificity. Therefore, a 5 percentage points 
lower sensitivity for high-risk HPV infections and an equal specificity 
corresponds with a 0.95 relative CIN II+ sensitivity. On the other hand, the 
specificity for a CIN II+ lesion depends on the specificity and sensitivity for 
a high-risk HPV infection. As the prevalence of high-risk HPV infections 
in women without CIN II+ is higher in young women and relatively more 
young women use self-sampling, a 5 percentage points lower sensitivity for 
high-risk HPV infections and an equal specificity corresponds with a 0.99 
relative CIN II+ specificity. 
Assumptions for costs and utilities
Table 7.1-1 presents the inputs for utilities and costs used in the analyses. 
Utilities were based on (inter)nationally published data(186). The unit costs 
were estimated from a societal perspective. As compared to office-based 
sampling, self-sampling was assumed to be less expensive, but the costs of 
immediate cytology triage were higher. Diagnostic costs of women referred 
for colposcopy, treatment costs, and costs of palliative care were equal be-
tween the two tests and were derived from previous cost studies performed 
in the Netherlands(187). 
Cost-effectiveness analysis
We assumed that the evaluated alternative screening policies (ie. primary 
HPV screening with and without offering HPV self-sampling to non-attend-
ees) started in 2013 and continued until all women reached the final screen-
ing age. The costs and effects of the simulated screening programmes were 
counted from 2013 onward until all simulated women (ie. born between 
1953 and 1992) had died. We also simulated the last three screening rounds 
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Table 7.1-1. Model inputs: Costs and utilities under base-case assumptions. 
Parameter
Utility loss
Costs in 2 Fraction Duration 
Invitation 4.85
Primary office-based sampling test
Programme1 2.68 / 2.95
 0.006 2 weeks
Organisation 12.50
Office-based  sampling 12.09
Laboratory 29.00
Time/travel 6.28
Total 62.55 / 62.82
Primary self-sampling test
Self-sampling kit2 6.00
0.006 2 weeks
Programme 2.68
Organisation 12.50
Laboratory 29.00
Time3 2.76
Total 52.94
Immediate cytology triage test after positive office-based  sampling4
Laboratory5 30.27 N.A. N.A.
Total 30.27
Immediate cytology triage test after positive self-sampling
Organisation 10.00
0.006 2 weeks
Office-based  sampling 12.09
Laboratory 32.27
Time/travel 6.28   
Total 60.64
Cytology triage test at 6 months
Organisation 10.00
0.006 0.5 year
Office-based  sampling 12.09
Laboratory 32.27
Time/travel 6.28   
Total 60.64
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before 2013 (ie. primary cytology screening with cytology triage), because 
they can influence the effectiveness of the screening programme after 2013. 
Table 7.1-1. (continued)
Parameter
Utility loss
Costs in 2 Fraction Duration 
Diagnosis and treatment of pre-invasive stages
False-positive referral 296 0.005 0.5 year
CIN grade I 924 0.03 0.5 year
CIN grade II 1,368 0.07 1 year 
CIN grade III 1,602 0.07 1 year 
Diagnosis and treatment of cancer
FIGO 1A 5,246 0.062 5 years 
FIGO 1B 12,440 0.062 5 years
FIGO 2+ (screen-detected) 12,261 0.28 5 years 
FIGO 2+ (clinically detected) 11,451 0.28 5 years 
Terminal care 27,859 0.712 1 month
Costs are in 2012 prices.  N.A. = Not applicable. 
1  As the total programme costs were fixed, the costs per test were dependent on the num-
ber of women participating in the screening programme. As this number was higher with 
the inclusion of the self-sampling test, the costs per test were lower in the situation with 
versus without self-sampling. 
2  We assumed that 85% of the non-attendees received the self-sampling kit of A6.00 at 
home, irrespective of whether they used it or not. This price was estimated based on 
personal communication with multiple developers of brush and lavage HPV self-sampling 
kits. The remaining costs (eg. laboratory, organisation, etc.) were only taking into account 
among women who actually attended via self-sampling. 
3  Given that it was not required to go to the general practitioner’s office, we assumed that 
women who attended via self-sampling spent half of the time to screening (12.76 instead 
of 15.52) as compared with women who attended via office-based sampling, while travel 
costs (10.76) were absent. 
4  Co-collection-based analysis was possible after positive office-based sampling and, 
therefore, women did not have to go to the general practitioner´s office for the immediate 
cytology triage test. 
5  We assumed that part of the material costs (12.00) was already included in the price of 
the office-based sampling test. Therefore, laboratory costs of immediate cytology triage 
after a positive office-based sampling test were lower than after a positive self-sampling 
test. 
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We simulated ten million women for each strategy. Future costs and health 
effects [life-years (LYs) lived and utility losses] were discounted towards the 
year 2013 at an annual rate of 3%. We computed the net costs and number 
of QALYs gained by screening as the difference between the simulations 
with and without screening. The incremental cost-effectiveness ratio (ICER) 
was defined as the increase in costs per additional (QA)LY gained when 
self-sampling would be offered to non-attendees as compared to no such 
offer. The cost-effectiveness threshold was set to €20,000 per QALY gained, 
based on decisions of the Dutch government(188), and to €50,000, which is 
often used in an international perspective(189). 
multivariate sensitivity analyses
The relative CIN II+ sensitivity and specificity can differ from the estimates 
we used in our base-case analysis, as there is uncertainty about the true 
value [eg. the 95% confidence interval (CI) for the pooled relative sensi-
tivity and specificity when using the GP5+/6+ is 0.89 to 1.01 and 0.95 to 
1.29, respectively(185)]. In addition, they depend on the type of HPV DNA 
test used(185), meaning that the values could be different when another 
validated HPV DNA test is used. Therefore, we choose to set the sensitivity 
for a high-risk HPV infection equally, 5, and 10 percentage points lower for 
self-sampling as compared to office-based sampling. The specificity was set 
equally, 5, and 15 percentage points lower. As the CIN II+ sensitivity and 
specificity depend on both the sensitivity and specificity for high-risk HPV 
infections, the CIN II+ sensitivity and specificity varied slightly between dif-
ferent combinations of self-sampling test characteristics for high-risk HPV 
infections. This resulted in a relative CIN II+ sensitivity that varied between 
0.89 and 1.02, and a relative CIN II+ specificity that varied between 0.84 and 
1.00. 
The relative CIN II+ sensitivity and specificity are expected to have a major 
influence on the effectiveness of the programme, especially when women 
switch. Therefore, we determined the percentage of women switching 
(0%, 10%, …., 90%, 100%) for which offering self-sampling is no longer 
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effective (ie. QALYs are lost) or cost-effective (ie. ICER is larger than the 
cost-effectiveness threshold). In addition, we varied the loss in quality of life 
associated with cytology triage, the costs of the self-sampling kit, the extra 
attendance via self-sampling, and the attendance of higher primary risk 
women women (ie. unscreened women who will never attend office-based 
sampling) and their underlying risk for cervical cancer. 
Utility loss associated with cytology triage. True estimates of the utility loss 
due to having cytology triage are unavailable. Especially if self-sampling 
is associated with a lower specificity, this may influence the effectiveness 
of offering self-sampling. Therefore, we studied the effect of assuming no 
utility loss to 0.012 per week for being in triage (base-case: 0.006 per week).
Costs. The total price of a self-sampling kit depends on many factors (eg. 
type of self-sampling device, possibility to achieve economies of scale, and 
on-going innovations for the self-sampling test). Therefore, we varied unit 
self-sampling kit costs from €3.50 to €10.00 (base-case: €6.00).
Attendance via self-sampling. We varied the extra attendance rate due 
to self-sampling from 3 to 10 percentage points (base-case: 6 percentage 
points). Furthermore, we varied the proportion of higher primary risk 
women in extra attendees from 0 to 50% (base-case: 29%). 
Underlying risk for cervical cancer of “higher primary risk” women. We 
assumed that all women have the same underlying risk for cervical cancer 
(base-case: “higher primary risk” women have a 1.7 times higher underlying 
risk as compared with regular attendees), although “higher primary risk” 
women still have an increased cervical cancer risk due to never attending 
regular screening.
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RESulTS 
base-case scenario
Table 7.1-2 presents the undiscounted effects and costs per 100,000 
simulated women when offering HPV self-sampling to non-attendees of 
a primary HPV screening programme. Without switching, offering self-
sampling increased the number of triage tests and false-positive referrals 
for colposcopy (+7.5% and +5.7%, respectively) and decreased the number 
of cervical cancer cases and deaths by 7.0% and 9.2%, respectively. Because 
the costs increased by only 5.5%, it was not only effective (+12.1% QALYs 
gained) but also cost-effective (ICER of €2,115 per QALY gained) to add 
self-sampling to the programme (Table 7.1-3).
As the sensitivity of self-sampling was lower than that of office-based sam-
pling and because the probability of being lost to follow-up after a positive 
self-sampling test was higher than after a positive office-based sampling 
test, switching resulted in a decrease of the number of triage tests and 
subsequently false-positive referrals, an increase of the number of cervical 
cancers, and a decrease in the number of cervical cancer deaths prevented 
Table 7.1-3. Discounted simulated effects and costs (both 3% per year) of providing non-
attendees with a self-sampling test in a primary HPV screening programme under the base-
case scenarios, per 100,000 simulated women. 
Base-case scenario, n (% versus no self-sampling)
No switching 100% switching
LYs gained 1,746 (+12.1) 1,573 (+1.0)
QALYs gained 1,880 (+12.1) 1,701 (+1.4)
Costs in 2 8,184,676 (+5.5) 6,687,767 (-13.8)
ICER: Costs in 2 per LY gained 2,276 Cost-saving
ICER: Costs in 2 per QALY gained 2,115 Cost-saving
Cost-saving = Cervical cancer screening was both more effective and less costly with versus 
without offering HPV self-sampling test to non-attendees. LYs = Life-years; QALYs = Quality-
adjusted life-years; ICER = Incremental cost-effectiveness ratio.
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figure 7.1-3. The effect of switching and the relative CIN II+ sensitivity and specificity on (A) 
the number of QALYs gained, (B) extra costs, and (C) ICER. Results are given per 100,000 
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and QALYs gained. Still, when all women switched it was effective and cost-
saving to offer self-sampling (Table 7.1-2 and 7.1-3).
multivariate sensitivity analyses
Without switching, a decrease in the CIN II+ sensitivity of self-sampling 
mainly resulted in fewer QALYs gained (Figure 7.1-3a), whereas a decrease 
in the CIN II+ specificity mainly resulted in increased costs (Figure 7.1-3b). 
Both resulted in a higher ICER (Figure 7.1-3c). However, even when the 
relative sensitivity and specificity were inferior to that of office-based sam-
pling (ie. 0.89-0.91 and 0.84-0.85, respectively), QALYs were gained and the 
ICER was below the threshold of €20,000 per QALY gained, if no women 
switched.  
In all scenarios, switching resulted in fewer QALYs gained (Figure 7.1-3a). 
This effect was larger in case the relative sensitivity was lower than 1.00. 
However, even when the test characteristics of self-sampling were inferior 
to that of office-based sampling, QALYs were only lost when more than 60% 
of the women switched (Table 7.1-4). When they were slightly inferior (ie. 
0.95-0.97 relative sensitivity and 0.94-0.95 relative specificity) or similar 
(ie. 1.01-1.02 relative sensitivity and 0.99-1.00 relative specificity), it was 
effective under every switching scenario. If self-sampling specificity was 
inferior, the costs of offering HPV self-sampling increased with increasing 
simulated women (3% discounting for costs and effects). The relative CIN II+ sensitivity and 
specificity (self-sampling versus office-based sampling) are indicated by the sensitivity and 
specificity in the legend. 
(C) The combined effect of sensitivity, specificity and switching on the ICER is only shown 
when adding a self-sampling test resulted in a gain of QALYs as compared with primary 
HPV screening alone. Therefore, a negative ICER (ie. cost-saving) is also dominating (ie. 
primary HPV screening with offering a self-sampling test to non-attendees was both more 
effective and less costly than primary HPV screening alone). 
*Beyond this level of switching, offering a self-sampling test resulted in a loss of QALYs as 
compared to primary HPV screening alone. 
Black dashed line = Primary HPV-screening without offering self-sampling to non-attend-
ees. 
When is it effective to offer self-sampling to non-attendees? 139
Ta
bl
e 
7.
1-
4.
 F
or
 w
ha
t s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
do
es
 o
ff
er
in
g 
se
lf
-s
am
pl
in
g 
to
 n
on
-a
tt
en
de
es
 le
ad
 to
 a
 lo
ss
 in
 Q
A
LY
s?
R
el
at
iv
e 
C
IN
 II
+ 
se
ns
iti
vi
ty
 a
nd
 
sp
ec
ifi
ci
ty
 (s
el
f v
er
su
s 
of
fic
e-
ba
se
d 
sa
m
pl
in
g)
B
as
e-
ca
se
U
til
ity
 lo
ss
 d
ue
 to
 
cy
to
lo
gy
 tr
ia
ge
Ex
tr
a 
at
te
nd
an
ce
  
(p
er
ce
nt
ag
e 
po
in
ts
)
* U
nd
er
ly
in
g 
ri
sk
 o
f 
hi
gh
er
 p
ri
m
ar
y 
ri
sk
 
w
om
en
%
 E
xt
ra
 a
tt
en
de
es
 
co
ns
is
tin
g 
of
 h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
 
Se
ns
iti
vi
ty
Sp
ec
ifi
ci
ty
**
0.
00
0
0.
01
2
10
3
**
* A
ve
ra
ge
50
0
1.
01
0.
99
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
>6
0
1.
01
0.
94
In
d.
In
d.
In
d.
In
d.
>9
0
In
d.
In
d.
>5
0
1.
02
0.
84
In
d.
In
d.
In
d.
In
d.
>7
0
>8
0
In
d.
>4
0
0.
95
0.
99
In
d.
In
d.
In
d.
In
d.
>5
0
>6
0
In
d.
>3
0
0.
96
0.
95
In
d.
In
d.
>9
0
In
d.
>5
0
>5
0
In
d.
>3
0
0.
97
0.
85
>8
0
In
d.
>7
0
In
d.
>4
0
>4
0
In
d.
>2
0
0.
89
1.
00
>7
0
>7
0
>7
0
In
d.
>4
0
>4
0
In
d.
>2
0
0.
90
0.
95
>7
0
>7
0
>7
0
In
d.
>3
0
>3
0
>9
0
>2
0
0.
91
0.
85
>6
0
>8
0
>5
0
>9
0
>3
0
>3
0
>8
0
>1
0
Fo
r 
ev
er
y 
sc
en
ar
io
 th
e 
m
in
im
um
 s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
is
 g
iv
en
 u
nd
er
 w
hi
ch
 it
 is
 n
o 
lo
ng
er
 e
ffe
ct
iv
e 
(ie
. Q
AL
Ys
 a
re
 lo
st
) t
o 
of
fe
r 
se
lf-
sa
m
pl
in
g 
to
 n
on
-a
tt
en
de
es
. T
he
 s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
va
ri
es
 b
et
w
ee
n 
0 
(ie
. e
ve
n 
w
he
n 
no
 w
om
en
 s
w
itc
h 
it 
is
 n
ot
 e
ffe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
, >
90
 (i
e.
 
w
he
n 
m
or
e 
th
an
 9
0%
 o
f t
he
 w
om
en
 s
w
itc
h 
it 
is
 n
ot
 e
ffe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
 to
 in
de
pe
nd
en
t (
in
d.
; i
e.
 in
de
pe
nd
en
t o
f h
ow
 m
an
y 
w
om
en
 
sw
itc
h,
 it
 is
 a
lw
ay
s 
ef
fe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
.  
B
as
e-
ca
se
 a
ss
um
pt
io
ns
: U
til
ity
 lo
ss
 d
ue
 to
 c
yt
ol
og
y 
tr
ia
ge
 =
 0
.0
06
 p
er
 w
ee
k,
 e
xt
ra
 a
tt
en
da
nc
e 
= 
6 
pe
rc
en
ta
ge
 p
oi
nt
s,
 u
nd
er
ly
in
g 
ri
sk
 o
f h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
 a
s 
co
m
pa
re
d 
w
ith
 th
e 
re
st
 o
f t
he
 s
cr
ee
ni
ng
 p
op
ul
at
io
n 
= 
1.
7 
tim
es
 h
ig
he
r,
 %
 o
f h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
 in
 e
xt
ra
 a
tt
en
d-
ee
s 
= 
29
%
. T
he
se
 v
ar
ia
bl
es
, i
f n
ot
 v
ar
ie
d,
 w
er
e 
he
ld
 c
on
st
an
t a
t t
he
ir
 b
as
e-
ca
se
 le
ve
l. 
* U
nd
er
ly
in
g 
ri
sk
 fo
r 
de
ve
lo
pi
ng
 c
er
vi
ca
l c
an
ce
r. 
**
B
ec
au
se
 a
 h
ig
he
r 
ut
ili
ty
 lo
ss
 fo
r 
pr
im
ar
y 
th
an
 tr
ia
ge
 te
st
in
g 
do
es
 n
ot
 s
ee
m
 r
ea
lis
tic
 w
e 
al
so
 a
ss
um
e 
no
 u
til
ity
 lo
ss
 fo
r 
pr
im
ar
y 
te
st
in
g.
 
**
* A
ve
ra
ge
 =
 E
qu
al
 to
 th
e 
re
st
 o
f t
he
 s
cr
ee
ni
ng
 p
op
ul
at
io
n.
 
140 Chapter 7.1
Ta
bl
e 
7.
1-
5.
 F
or
 w
ha
t s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
is
 o
ff
er
in
g 
se
lf
-s
am
pl
in
g 
to
 n
on
-a
tt
en
de
es
 n
ot
 (c
os
t-
)e
ff
ec
tiv
e?
R
el
at
iv
e 
C
IN
 II
+  s
en
si
tiv
ity
 
an
d 
sp
ec
ifi
ci
ty
 (s
el
f v
er
su
s 
of
fic
e-
ba
se
d 
sa
m
pl
in
g)
B
as
e-
ca
se
U
til
ity
 lo
ss
 d
ue
 to
 
cy
to
lo
gy
 tr
ia
ge
C
os
ts
 o
f s
el
f-
sa
m
pl
in
g 
ki
t i
n 
2
Ex
tr
a 
at
te
nd
an
ce
 
(p
er
ce
nt
ag
e 
po
in
ts
)
* U
nd
er
ly
in
g 
ri
sk
 o
f h
ig
he
r 
pr
im
ar
y 
ri
sk
 
w
om
en
%
 E
xt
ra
 a
tt
en
de
es
 
co
ns
is
tin
g 
of
 h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
Se
ns
iti
vi
ty
Sp
ec
ifi
ci
ty
**
0.
00
0
0.
01
2
3.
50
10
10
3
**
* A
ve
ra
ge
50
0
1.
01
0.
99
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
>6
0
1.
01
0.
94
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
>9
0
In
d.
In
d.
>2
0
1.
02
0.
84
>8
0
In
d.
>6
0
>9
0
>6
0
In
d.
>4
0
>3
0
In
d.
>0
0.
95
0.
99
In
d.
In
d.
In
d.
In
d.
In
d.
In
d.
>5
0
>6
0
In
d.
>2
0
0.
96
0.
95
In
d.
In
d.
>9
0
In
d.
>8
0
In
d.
>5
0
>4
0
In
d.
>1
0
0.
97
0.
85
>5
0
>7
0
>4
0
>6
0
>4
0
>8
0
>2
0
>2
0
>8
0
>0
0.
89
1.
00
>7
0
>7
0
>7
0
>7
0
>7
0
In
d.
>4
0
>3
0
In
d.
>1
0
0.
90
0.
95
>7
0
>7
0
>6
0
>7
0
>5
0
In
d.
>3
0
>2
0
>9
0
>0
0.
91
0.
85
>4
0
>5
0
>3
0
>4
0
>3
0
>6
0
>2
0
>1
0
>5
0
>0
Fo
r 
ev
er
y 
sc
en
ar
io
 th
e 
m
in
im
um
 s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
is
 g
iv
en
 u
nd
er
 w
hi
ch
 it
 is
 n
o 
lo
ng
er
 e
ffe
ct
iv
e 
(ie
. Q
AL
Ys
 a
re
 lo
st
) a
nd
/o
r 
co
st
-e
ffe
ct
iv
e 
(ie
. 1
20
,0
00
 p
er
 Q
AL
Y 
ga
in
ed
) t
o 
of
fe
r 
se
lf-
sa
m
pl
in
g 
to
 n
on
-a
tt
en
de
es
. T
he
 s
w
itc
hi
ng
 p
er
ce
nt
ag
e 
va
ri
es
 b
et
w
ee
n 
0 
(ie
. e
ve
n 
w
he
n 
no
 w
om
en
 s
w
itc
h 
it 
is
 n
ot
 e
ffe
ct
iv
e 
an
d/
or
 c
os
t-
ef
fe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
, >
90
 (i
e.
 w
he
n 
m
or
e 
th
an
 9
0%
 o
f t
he
 w
om
en
 s
w
itc
h 
it 
is
 n
ot
 e
ffe
ct
iv
e 
an
d/
or
 c
os
t-
ef
fe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
 to
 in
de
pe
nd
en
t (
in
d.
; i
e.
 in
de
pe
nd
en
t o
f h
ow
 m
an
y 
w
om
en
 s
w
itc
h,
 it
 is
 
al
w
ay
s 
ef
fe
ct
iv
e 
an
d 
co
st
-e
ffe
ct
iv
e 
to
 o
ffe
r 
se
lf-
sa
m
pl
in
g)
.  
B
as
e-
ca
se
 a
ss
um
pt
io
ns
: U
til
ity
 lo
ss
 d
ue
 to
 c
yt
ol
og
y 
tr
ia
ge
 =
 0
.0
06
 p
er
 w
ee
k,
 e
xt
ra
 a
tt
en
da
nc
e 
= 
6 
pe
rc
en
ta
ge
 p
oi
nt
s,
 u
nd
er
ly
in
g 
ri
sk
 o
f h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
 a
s 
co
m
pa
re
d 
w
ith
 th
e 
re
st
 o
f t
he
 s
cr
ee
ni
ng
 p
op
ul
at
io
n 
= 
1.
7 
tim
es
 h
ig
he
r,
 %
 o
f h
ig
he
r 
pr
im
ar
y 
ri
sk
 w
om
en
 
in
 e
xt
ra
 a
tt
en
de
es
 =
 2
9%
. T
he
se
 v
ar
ia
bl
es
, i
f n
ot
 v
ar
ie
d,
 w
er
e 
he
ld
 c
on
st
an
t a
t t
he
ir
 b
as
e-
ca
se
 le
ve
l. 
* U
nd
er
ly
in
g 
ri
sk
 fo
r 
de
ve
lo
pi
ng
 c
er
vi
ca
l c
an
ce
r. 
**
B
ec
au
se
 a
 h
ig
he
r 
ut
ili
ty
 lo
ss
 fo
r 
pr
im
ar
y 
th
an
 tr
ia
ge
 te
st
in
g 
do
es
 n
ot
 s
ee
m
 r
ea
lis
tic
 w
e 
al
so
 a
ss
um
e 
no
 u
til
ity
 lo
ss
 fo
r 
pr
im
ar
y 
te
st
in
g.
 
**
* A
ve
ra
ge
 =
 E
qu
al
 to
 th
e 
re
st
 o
f t
he
 s
cr
ee
ni
ng
 p
op
ul
at
io
n.
 
When is it effective to offer self-sampling to non-attendees? 141
percentages of switching (Figure 7.1-3b). Considering a cost-effectiveness 
threshold of 20,000 per QALY gained, the switching limit was up to 30 
percentage points lower (Table 7.1-5). Therefore, offering self-sampling was 
not effective or cost-effective when more than 40% of the women switch and 
test characteristics of self-sampling were inferior to those of office-based 
sampling. 
The effect of the level of utility loss associated with cytology triage was 
negligible (Table 7.1-4). Varying the extra attendance or underlying risk of 
higher primary risk women had more influence. When the extra attendance 
was halved (from 6 to 3 percentage points) or if higher primary risk women 
did not have an elevated underlying risk, QALYs were lost when more than 
50% of the women switched and test characteristics were slightly inferior. 
When they were inferior, it was no longer effective if more than 30% of 
the women switched. The most influential parameter was the attendance 
of higher primary risk women. When they did not attend, it was not ef-
fective to offer self-sampling when more than 60% of the women switched 
and test characteristics were equal. In case they were inferior, this threshold 
decreased to 10%. For offering self-sampling to be cost-effective, these 
switching thresholds were even lower (Table 7.1-5).
DiSCuSSioN
The number of QALYs gained by offering HPV self-sampling to non-
attendees was influenced by self-sampling test characteristics, the extra 
attendance via self-sampling, and the risk of extra attendees. When none 
of the regular attendees switched to self-sampling, it was always effective to 
offer HPV self-sampling. Switching resulted in fewer QALYs gained because 
the probability of being lost to follow-up after a positive self-sampling test 
was higher than after a positive office-based sampling test. If in addition the 
sensitivity of self-sampling was lower than that of office-based sampling, the 
number of QALYs gained decreased even more. However, even when test 
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characteristics were inferior, up to 60% of the regular attendees could switch 
before the QALYs gained by the 6 percentage points extra attendance were 
annulled by the QALYs lost by switching. This percentage dropped to 30% 
when the extra attendance halved from 6 to 3 percentage points or when 
higher primary risk women did not have an elevated underlying risk. It 
dropped to 10% if higher primary risk women did not attend self-sampling. 
When also considering a cost-effectiveness threshold of €20,000 per QALY 
gained, these switching thresholds were 10 to 20 percentage points lower. 
Our base-case assumption of 6 percentage points extra attendance was 
based on the Dutch PROHTECT trial in which a self-sampling kit was sent 
to 85% of all non-attendees (ie. the remaining 15% opted-out via a letter)
(73). Using another strategy will probably result in another extra attendance 
rate. If this rate will be lower than 3 percentage points (almost) no women 
can switch before more QALYs are lost than gained. 
We assumed that a subset of the unscreened women have a 1.7 times higher 
underlying risk on cervical cancer (ie. higher primary risk women) than the 
rest of the screening population, which was based on model calibration. 
Dugué and colleagues’ results have shown that non-attendees of cervical 
cancer screening (ie. no cervical smear taken in the past eight years) had a 
3.8-fold increased risk of dying from non-cervical (ie. non-screened) HPV-
associated cancers(190), which seems to confirm our assumption that at 
least part of the non-attendees have an increased underlying risk. Although 
the PROHTECT study showed that unscreened women (ie. invited for 
screening at least once but never attended) attended via self-sampling(176), 
it is uncertain whether this is the subset with an increased underlying risk. 
If these higher primary risk women do not attend via self-sampling, 10% 
to 60% of the women can switch before QALYs are lost by offering HPV 
self-sampling to non-attendees. 
The relative sensitivity and specificity of self-sampling as compared with 
office-based sampling will depend on the type of HPV DNA test used(185, 
191). However, even when a validated PCR is used (eg. GP5+/6+ or the real-
time hrHPV test), it is possible that the sensitivity and specificity of self-
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sampling are both inferior to that of office-based sampling. In fact, relative 
test characteristics of self-sampling might even be worse than we assumed 
in our sensitivity analyses(185). In that case, the maximum percentage of 
women that can switch before QALYs are lost is also lower. 
Studies in Sweden(192), Finland(193), the United Kingdom(194), and 
Italy(195) have also shown that offering self-sampling to non-attendees 
increased screening participation rates. We expect that our conclusions 
to a large extent apply to other countries and regions with well-organized 
invitational screening programmes with a high compliance and an optimal 
age range and screening frequency. Even if this would mean that HPV 
self-sampling would be offered to non-attendees of a primary cytology 
instead of a primary HPV programme. For countries and regions with a 
lower underlying risk and/or a more intensive screening programme as 
compared to the Netherlands, benefits of increased participation due to 
self-sampling are probably lower. In countries without a highly organized 
invitational programme, it may not be feasible to offer a self-sampling test 
to unscreened women. Instead, it could be offered to the general population 
by selling it over the counter. However, when screening is not reimbursed 
by the government, it is questionable to what extent unscreened women will 
use self-sampling. Indeed, a discrete choice experiment in the USA showed 
that vulnerable adults valued costs higher than the kind of screening offered 
or the travel distance to obtain screening(196). When non-attendance is 
driven by other factors than feeling uncomfortable or having little time (ie. 
factors that can be overcome by using self-sampling instead of going to the 
clinician(197), the success of offering self-sampling may be limited.
To our knowledge, this is the first study on the harms and benefits of provid-
ing a self-sampling test to non-attendees of a cervical cancer screening pro-
gramme. One of our key assumptions (ie. extra attendance via self-sampling) 
was based on observations from the PROHTECT trials(73, 176, 180). We 
extensively studied the effect of the level of switching in combination with 
the test characteristics of self-sampling and the underlying cervical cancer 
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risk of its users, which were important and uncertain parameters for the 
effectiveness of offering self-sampling. 
A limitation of our study is that we only focused on unvaccinated women. 
Screening programmes will probably be adapted when vaccinated cohorts 
reach the start age of screening. A separate analysis for this future situation 
is beyond the scope of the present analysis. However, we expect that of-
fering self-sampling to non-attendees will be less (cost-)effective, because 
we expect that fewer health effects can be gained by increasing attendance 
because of a lower underlying risk. Another drawback is the limited trans-
posability to other health systems. We expect lower benefits of increased 
participation due to self-sampling in screening programmes that are more 
intensive than the Dutch future programme will be (ie. 5 lifetime screens at 
ages 30, 35, 40, 50, and 60 years). Moreover, we might have overestimated 
the colposcopy compliance after a positive self-sampling test, as this may be 
lower than after a positive office-based sampling test. This may have resulted 
in a slight overestimation of the effectiveness of self-sampling. In addition, 
the relative CIN II+ specificity as described in our study will be somewhat 
higher when regular attendees switch, as the prevalence of high-risk HPV 
infections in women without a CIN II+  is slightly lower in regular attendees 
as compared with non-attendees attending self-sampling. Furthermore, we 
did not account for other healthcare that women may get while attending 
clinic-based screening. This may have underestimated health losses in regu-
lar attendees switching to self-sampling, as well as health gains in the small 
group of extra attendees with a positive self-sampling test complying with 
their triage invitation.
Offering self-sampling to non-attendees clearly offers an opportunity to in-
crease health benefits in cervical cancer screening if health providers make 
sure that (i) the relative CIN II+  sensitivity is at least 0.95, (ii) unscreened 
attendees are recruited with self-sampling, and (iii) the total attendance 
increases by at least 6 percentage points. Otherwise, switching of regular 
attendees to self-sampling may annul the benefits of self-sampling and even 
decrease the effectiveness of a primary HPV screening programme.
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SuPPlEmENTARy iNfoRmATioN
This Supplementary Material was provided by Steffie K. Naber, Kirsten 
Rozemeijer, Inge M.C.M. de Kok, Joost van Rosmalen and Marjolein van 
Ballegooijen. Here, we describe the model inputs of the MISCAN model 
for cervical cancer(181). This model can be used to assess the harms and 
benefits of different screening programmes for cervical cancer, as well as 
HPV vaccination. The model has been used previously for cost-effectiveness 
analyses of cervical cancer screening and HPV vaccination(84, 85, 188, 198). 
The MISCAN model (Figure 7.1-S1) consists of the following four parts: 
demography, natural history, screening, and cost-effectiveness. The assump-
tions used in each of these parts are described below.
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figure 7.1-S1. Structure of the MISCAN model
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Demography
The MISCAN model generates a simulated population of Dutch women 
born between 1953 and 1992. Women born after 1992 are eligible for HPV 
vaccination and are therefore not considered here. The relative sizes of 
the birth cohorts are based on the age distribution of women living in the 
Netherlands. 
For each woman, a time of death from other causes (ie. causes other than 
cervical cancer) is generated; this time of death is independent of the cervical 
cancer disease model. In the model, a woman’s lifetime cannot exceed 100 
years. The time of death from other causes is generated using a life table for 
women from Statistics Netherlands(199). The assumed hysterectomy rates 
vary by age and by year of birth. These rates are based on data from Statistics 
Table 7.1-S1. Model assumptions for the age-specific probability of having had a hysterec-
tomy for reasons other than cervical cancer, for women with birth years 1953-1992.
Age Birth years 1953-1958 Birth years 1959-1992
20 0.0000 0.0000
25 0.0003 0.0002
30 0.0030 0.0017
35 0.0134 0.0076
40 0.0372 0.0213
45 0.0755 0.0432
50 0.1138 0.0735
55 0.1367 0.0916
60 0.1484 0.1009
65 0.1601 0.1102
70 0.1732 0.1217
75 0.1862 0.1330
80 0.1963 0.1419
85 0.2023 0.1468
Linear interpolation is used to determine the probability of having had a hysterectomy at 
intermediate ages.
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Netherlands and Information Centre for Health Care and are presented in 
Table 7.1-S1(200, 201). 
Natural history
During her lifetime, each woman has an age-specific risk of acquiring high-
risk HPV infections (ie. an infection caused by an HPV type that can cause 
cancer and that can be detected by the HPV test) and CIN lesion without a 
(detectable) high-risk HPV infection. Most HPV infections clear or regress 
naturally, some HPV infections can progress to CIN I, CIN II, CIN III, 
cervical cancer, and death from cervical cancer.
To account for the fact that HPV infections and CIN may clear or regress 
naturally, six disease pathways are distinguished in MISCAN. Each instance 
of these disease pathways represents an HPV infection or a ‘lesion’ (ie. CIN 
of a certain grade or a stage of cervical cancer). Each disease pathway starts 
as either an HPV infection or as an HPV negative CIN I lesion. The natural 
history (ie. in the situation without screening) of these six disease pathways 
is shown in Figure 7.1-S2 and can be described as follows.
A) HPV infections that clear naturally without ever leading to CIN
B) HPV infections that progress to CIN I and then regress
C) HPV infections that progress to CIN I and CIN II and then regress
D) HPV infections that progress to CIN I, CIN II, and CIN III and then 
regress
E) HPV negative CIN I lesions that regress naturally or become HPV nega-
tive CIN II and then regress naturally
F) HPV infections that progress to CIN I, CIN II, CIN III, preclinical FIGO 
1A (micro-invasive) cervical cancer, and preclinical FIGO 1B cervical 
cancer. Preclinical FIGO 1B cervical cancer can either become clinically 
detected FIGO 1B cervical cancer or progress to preclinical FIGO 2+ 
cervical cancer and then to clinical FIGO 2+ cervical cancer. Clinically 
detected cervical cancer can progress to death from cervical cancer or 
remain in that state forever (if the woman is cured from cervical cancer).
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A woman can acquire multiple lesions and HPV infections during her life-
time, and multiple lesions and HPV infections may be present at the same 
time. In each simulated life history (ie. between ages 0 and 100), the number 
of lesions of each type follows a Poisson distribution. The annual probability 
of acquiring an HPV infection or CIN lesion is age-dependent and depicted 
in Figures 7.1-S3a (regressive disease pathways) and 7.1-S3b (progressive 
disease pathway). The transitions and sojourn times of the HPV infections 
or lesions are simulated based on a continuous-time semi-Markov process. 
A CIN 0 HPV+ Cleared/regressed
B CIN 0 HPV+ CIN I, HPV+ CIN I, HPV- Cleared/regressed
CIN 0 HPV+
C CIN 0 HPV+ CIN I, HPV+ CIN II, HPV+ CIN II, HPV- Cleared/regressed
CIN 0 HPV+
D CIN 0 HPV+ CIN I, HPV+ CIN II, HPV+ CIN III, HPV+ CIN III, HPV- Cleared/regressed
CIN 0 HPV+
E CIN I HPV- CIN II, HPV- Cleared/regressed
F CIN 0 HPV+ CIN I, HPV+ CIN II, HPV+ CIN III, HPV+
Preclinical FIGO 1A 
cervical cancer
Preclinical FIGO 1B 
cervical cancer
Preclinical FIGO 2+ 
cervical cancer
Clinical FIGO 1B 
cervical cancer
Clinical FIGO 2+ 
cervical cancer
Cervical cancer 
death
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19 
figure 7.1-S2. Schematic representation of the MISCAN model, with disease pathways A 
through F.
Notes: There are six disease pathways (types A through F) in MISCAN. All lesions start as 
either an HPV infection without CIN (disease pathways A, B, C, D, and F) or as a CIN I lesion 
without HPV infection (disease pathway E). Cleared/regressed denotes the absence of CIN 
and HPV infection; CIN 0 denotes the absence of CIN and cervical cancer. All cervical can-
cer states are HPV positive. The arrows between the states show which types of transitions 
can occur; the numbers refer to the duration distributions shown in Table 7.1-S2. In every 
state before death, a transition to “other-cause death” can occur, and in every state before 
cancer, a transition to “hysterectomy” can occur; in these cases, the transition applies to 
all HPV infections and CIN lesions of that person simultaneously.
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The sojourn times of most states in the model have either an exponential or 
a Weibull probability distribution (Table 7.1-S2).
The mean number of lesions of each type does not depend on the birth year, 
as we do not assume any cohort effects on the underlying risk of developing 
HPV infections, CIN, and cervical cancer for the cohorts included in this 
model. However, we do account for the possibility that the underlying risk 
may be higher for women who do not attend screening.
In the model, women who do not have cervical cancer have an age-specific 
probability of getting a hysterectomy for reasons other than cervical cancer. 
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figure 7.1-S3. Annual probability of acquiring A) a regressive HPV infection or CIN lesion, 
and B) a progressive HPV infection.
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A hysterectomy is assumed to remove all prevalent HPV infections and CIN 
lesions. Women with a hysterectomy will no longer acquire HPV infections 
or CIN lesions and are also no longer invited for screening tests. 
The assumptions for the probability and the duration of survival after a 
clinically detected (ie. detected because of symptoms) cervical cancer are 
based on data from the Dutch Cancer Registry for the period 1989-2009. 
We assumed that all cervical cancer mortality occurs in the first ten years 
after diagnosis. The assumed probability of long-term survival depends 
on age and stage (FIGO 1B or FIGO 2+); in the model, FIGO 1A cervical 
cancer cannot be clinically detected. Table 7.1-S3 shows what percentage of 
clinically detected cancers is detected in stages FIGO 1B and FIGO 2+. The 
model assumptions for the long-term survival probabilities are shown in 
Table 7.1-S4 and the assumed duration distributions are shown in Table 7.1-
S5.
Table 7.1-S3. Age-specific stage distribution of a clinically detected cervical cancer.
Age
Clinical detection in stage:
FIGO 1B FIGO 2+
0 25.4% 74.6%
25 25.4% 74.6%
40 35.0% 65.0%
55 61.4% 38.6%
70 75.4% 24.6%
100 75.4% 24.6%
Percentages in the table are estimated in the model calibration. Linear interpola-
tion is used to determine the probabilities at intermediate ages.
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Table 7.1-S4. Model assumptions for the age-specific probability that clinical FIGO 1B and 
FIGO 2+ cervical cancer will lead to death from cervical cancer (ie. 100% - probability of long-
term survival), in the absence of other-cause mortality. 
Age Clinical FIGO 1B Clinical FIGO 2+
0 9.7% 45.5%
30 9.7% 45.5%
45 10.8% 51.1%
60 22.9% 55.4%
80 34.5% 68.7%
100 34.5% 68.7%
Linear interpolation is used to determine the probabilities at intermediate ages. Source: 
observed age-specific and stage-specific survival for the periods 1989-2002 and 2003-2009, 
obtained from the Dutch Cancer Registry.
Table 7.1-S5. Model assumptions for the duration distribution of clinical FIGO 1B and FIGO 
2+ cervical cancer, if the transition to death from cervical cancer occurs. 
Years after detection Clinical FIGO 1B Clinical FIGO 2+
1 10.4% 37.6%
2 36.5% 64.6%
3 47.9% 78.1%
4 61.5% 84.5%
5 78.3% 88.5%
6 84.4% 90.5%
7 90.3% 93.3%
8 93.1% 96.4%
10 100.0% 100.0%
The values in this table represent the percentages of cervical cancer deaths that occur 
within a given number of years after the moment of clinical diagnosis. It is assumed that 
no cervical cancer mortality occurs more than ten years after clinical diagnosis. Source: 
observed age-specific and stage-specific survival for the periods 1989-2002 and 2003-2009, 
obtained from the Dutch Cancer Registry.
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Screening
Screening can change the life histories of women. In the current analysis, 
women are invited for primary HPV screening at the age of 30, 35, 40, 
50, and 60. In some strategies, a self-sampling HPV test is offered to non-
attendees of office sampling (ie. collected in the general practitioner’s office). 
Women aged 45, 55 and 65 years are only invited for screening if they had a 
positive test or did not respond in the last screening round. 
Table 7.1-S4 shows the assumed age-specific attendance rates, which were 
based on the current Dutch screening programme. We assumed that 10% of 
the female population never attends screening via office sampling (ie. office-
sampling refusers or higher primary risk women). Based on the proportion 
of cancers that are clinically detected in the Netherlands, we estimated that 
the women who never attend screening have a 1.71 times higher underly-
ing risk than the other 90% of the female population (ie. women who are 
inclined to attend office sampling). The compliance in different stages of the 
follow-up is shown in Figure 7.1-1.
If an HPV test is applied, each HPV infection prevalent at the time of screen-
ing has a probability of producing a positive test (ie. the sensitivity). If the 
HPV test is positive, cytological inspection determines whether the woman 
is referred for colposcopy or invited for cytological triage after 6 months. 
The test characteristics of the office sampling HPV test and of the cytologi-
cal inspection used in the triage are shown in Table 7.1-S5. The sensitivity 
of office-based sampling was based on the difference in CIN III+ detection 
rates between cytology and HPV testing found in the POBASCAM study 
(9). The test characteristics of the HPV self-test are varied and the possible 
values are described in the methods of the main manuscript.
In case a woman is referred for colposcopy, she will visit the gynaecologist 
with a certain probability (see Figure 7.1-1). At the gynaecologist, all preva-
lent CIN lesions are assumed to be diagnosed and successfully removed (in 
the costs we accounted for the requirement of repeated CIN treatment in 
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Table 7.1-S6: Assumed age-specific attendance rates at primary HPV screening.
Age
Women who are inclined to attend 
office sampling
(90% of the women)
Office-sampling refusers1
(10% of the women)
Overall
30 61.4% 0% 55.2%
35 69.6% 0% 62.6%
40 72.9% 0% 65.6%
45 77.9% 0% 70.1%
50 79.4% 0% 71.5%
55 75.0% 0% 67.5%
60 76.2% 0% 68.6%
652 76.2% 0% 68.6%
1 Defined as higher primary risk women in the main manuscript. 
2  In the current screening programme, women aged 65 are not invited for screening. We 
assumed their attendance to be the same as for women aged 60.
Table 7.1-S7. Model assumptions for test characteristics of HPV office-based sampling and 
cytological inspection
Test Parameter Value
HPV office-
based 
sampling  
Probability of positive HPV test if HPV positive 85%
Probability of positive HPV test if HPV negative 0%1
Cytology
Probability of at least ASCUS/LSIL for CIN 0 2.4%
Probability of at least HSIL for CIN 0 0.03%
Probability of at least ASCUS/LSIL for CIN I 40.0%
Probability of at least HSIL for CIN I 3.6%
Probability of at least ASCUS/LSIL for CIN II 50.0%
Probability of at least HSIL for CIN II 18.0%
Probability of at least ASCUS/LSIL for CIN III 75.0%
Probability of at least HSIL for CIN III 55.9%
Probability of at least ASCUS/LSIL for preclinical cervical cancer 75.0%
Probability of at least HSIL for preclinical cervical cancer 59.7%
1  The specificity of the HPV test is assumed to be 100%; a possible lack of specificity is 
modeled as fast-clearing HPV infections.
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15% of the cases, but no cancer development will take place after CIN de-
tection). HPV infections without CIN are not treated. For screen-detected 
cervical cancer, a stage-specific improvement (compared to the situation 
without screening) in the probability of cure is assumed.   
The effects of early detection on survival 
For screen-detected invasive cancers, survival was modelled as a reduc-
tion in the risk of dying compared with that risk in the situation without 
screening, when the cancer would have become clinical. This improvement 
of prognosis (89.4%, 50%, and 20% for FIGO IA, IB, and 2+, respectively) 
was calibrated to reproduce recently observed stage specific survival given 
observed screening [Dutch Cancer Registry (NKR)].
Calculation of health effects and costs of screening
For each simulated woman who is alive, MISCAN can determine the state, 
which can be Normal, HPV infected, CIN I, CIN II, CIN III, FIGO 1A, 
FIGO 1B, and FIGO 2+. A woman can have multiple HPV infections or CIN 
lesions at the same time. Her state is determined by the most severe disease 
stage present, using the order HPV infection, CIN I, CIN III, CIN III, FIGO 
1A cervical cancer, FIGO 1B cervical, and FIGO 2+ cervical cancer; if no 
HPV infections or CIN lesions are present, the woman’s state is Normal. 
The model produces the number of life-years spent in each state as well as 
the number of certain events (eg. screenings and cervical cancer diagnoses) 
in a lifetime. For each of these events, Table 7.1-1 presents the associated 
costs and disutility. To calculate the total costs of a screening strategy, a sum 
is taken over all the numbers of events multiplied by their associated costs. 
The same holds for the total disutility of a strategy. 
In the current analysis, the number of life-years gained is calculated as the 
difference in total years lived by the population between the situation with 
and without offering self-sampling to non-attendees of office sampling. To 
determine the number of QALYs gained (or lost), we computed the dif-
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ference in the total number of QALYs between both situations. Similarly, 
the net costs were determined. From these numbers, the incremental cost-
effectiveness ratio (ICER) of offering HPV self-sampling to non-attendees 
could be calculated by dividing the additional costs by the additional QALYs 
gained.
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Our paper of chapter 7.1 evoked a response by dr. Castle that the editorial 
board of Cancer Epidemiology, Biomarkers & Prevention allowed us to 
provide with an answer. In his letter, dr. Castle expressed his concern on 
the performance of HPV self-sampling as compared to office-based sam-
pling(202). He stated that the real-world performance of HPV self-sampling 
is likely to be less accurate than its performance in the artificial setting of 
a clinical study. Moreover, he could imagine that 20% to 30% of attendees 
switch from office-based to self-sampling, while the loss in sensitivity for 
cervical precancer and cancer is larger than 10%. Our response is repro-
duced in this chapter. 
wHEN iS iT EffECTiVE To offER SElf-SAmPliNG To NoN-
ATTENDEES—RESPoNSE
Kirsten Rozemeijer, inge mCm de Kok, Steffie K Naber, folkert 
J van Kemenade, Corine Penning, Joost van Rosmalen, and 
marjolein van ballegooijen
We appreciate Dr. Castle’s concern that a loss in CIN II+ sensitivity, when 
using self-sampling instead of office-based sampling, may still be an is-
sue(202), even though data of a recently published meta-analysis reported 
otherwise(185). 
Data of the Dutch PROHTECT study strongly suggested that the CIN II+ 
sensitivity of HPV self-sampling was non-inferior to that of HPV office-
based sampling(73). As self-sampling was offered to non-attendees at home, 
it is unlikely that the sensitivity profile in this study was biased because of 
“in office procedures”, although the PROHTECT study estimates may have 
been biased due to higher risk profiles in the non-attendees. Therefore, 
studies are needed to validate self-sampling test characteristics in regular 
responders with lower risk profiles in case they switch from office-based 
sampling to self-sampling.
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In our article, we showed that even if the loss in CIN II+ sensitivity is 10%, 
and 20 to 30% of the regular attendees switch to self-sampling, it is still 
both effective and cost-effective to offer self-sampling to non-attendees as 
long as unscreened women attend, and the extra attendance rates is at least 
6 percentage points(203). Results of the Dutch PROHTECT studies, where 
self-sampling was offered via an opt-out procedure (ie. a self-sampling 
kit was sent to all non-attendees except when they opted-out via a letter), 
showed that both assumptions were realistic(73, 176). However, as opt-in 
procedures (ie. involving a request for a self-sampler) may reduce response 
rates(71), the chosen strategy could be crucial in whether or not offering 
self-sampling is (cost-)effective. Therefore, we fully concur with Dr. Arbyn 
and Dr. Castle that the introduction of self-sampling strategies should be 
carefully prepared and evaluated in pilot studies integrated in well-organized 
settings before general rollout(71).
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AbSTRACT 
Background. Lower socioeconomic status (SES) women are more often 
diagnosed with cervical cancer, which might solely be attributed to 
their lower screening participation rate, but could also be partly due to 
other factors. Therefore, we determined whether low SES women have an 
increased underlying risk to be diagnosed with cervical cancer, indepen-
dent of differences in screening history and screening uptake. 
Methods. Retrospective data were obtained from the Dutch nationwide 
network and registry of histo- and cytopathology (PALGA). First-time 
attendees without any history of cervical examinations were included 
in the study to eliminate influences of differences in screening history 
and uptake. We performed logistic regression analyses to compare the 
cervical cancer risk between women living in low, intermediate, and high 
SES neighbourhoods (ie. neighbourhood status is indicative of their SES) 
attending the organized cervical cancer screening programme between 
2000 and 2007. We adjusted for differences in age distribution. For every 
postal code, SES was determined based on income, education and unem-
ployment rate. 
results. We included 404,761 first-time attendees of whom 254 (0.06%) 
were diagnosed with cervical cancer. As compared to women living in 
high SES neighbourhoods, those in low and intermediate SES neighbour-
hoods had a similar cervical cancer risk [ie. OR of 0.98 (95% CI: 0.70, 
1.39) and 1.07 (95% CI: 0.79, 1.45), respectively]. 
Conclusions. SES seems not to be associated with an increased underlying 
cervical cancer risk, although it cannot be ruled out. Any differences in 
cervical cancer risk between different SES groups, if present, are therefore 
probable caused by differences in screening participation. 
Keywords. Socioeconomic status; Cervical cancer; Screening; Underlying 
risk
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bACKGRouND
Having a lower socioeconomic status (SES) is considered to be a risk factor 
for developing cervical cancer(86, 87), which can be (partly) explained by 
the fact that women with lower SES are less likely to attend screening(90, 
204, 205). One of the factors causing this difference in uptake is that lower 
SES women have a more negative attitude towards screening (ie. lower SES 
women anticipate a higher distress of screening)(206). In countries without 
organized screening, a lack of health insurance, and therefore less access 
to health care, also contributes to this difference in uptake between SES 
groups(87). 
Benard et al. have found that lower education and higher poverty rates are 
associated with increased vaginal and penile cancer incidence rates(207). 
As both types of cancers are non-screened human papillomavirus (HPV) 
associated cancers, it suggests that lower SES is associated with an increased 
underlying (ie. background) risk of HPV related cancers. If true, and 
given that there is a causal relationship between the development of cervical 
cancer and a high-risk HPV infection(4, 5), one would expect that lower 
SES women also have an increased underlying risk for developing cervical 
cancer, independent of differences in former and current screening uptake. 
To test this hypothesis, we compared the cervical cancer rate between first-
time attendees without any history of cervical examinations living in low, 
intermediate, and high SES neighbourhoods (ie. neighbourhood status is 
indicative of a woman’s SES). We thereby eliminated the influence of differ-
ences in screening history and uptake between the SES groups (ie. ensuring 
that a possible risk difference was not caused by differences in former and 
current screening uptake). 
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mETHoDS
Since 1996, the Dutch cervical cancer screening programme consists of 
5-yearly cytological screening in women aged 30 to 60 years. The par-
ticipation rate ranges from 65% to almost 70% (programme only) and the 
coverage rate ranges from 77% to almost 80% [source: Dutch Network and 
National Database for Pathology (PALGA)](94). For a detailed screening 
protocol see Figure 8-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMD 
Triage cytology test at 6 months 
 
No cytological abnormalities 
Return to routine 
screening  
>BMD  Referral to 
gynaecologist 
 
Referral to 
gynecologist 
 
Triage cytology test at 18 months 
 
Primary cytology test 
 
≥BMD  
Referral to 
gynaecologist 
 
Return to routine  
screening  
 
No cytological 
abnormalities 
No cytological  
abnormalities  
≥BMD  
A 
figure 8-1. Triage protocol consisting of triage cytology (A) without HPV testing, and (B) 
with HPV testing. HPV = Human papillomavirus; BMD = Borderline and mildly dyskaryotic 
smears.
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From 1990 onward, all cervical cytology and histology tests taken in the 
Netherlands, within and outside the screening programme, are registered 
in PALGA. Every woman in the database receives an identification code 
based on her birth date and the first four letters of her (maiden) family 
name, which enables linkage of the tests belonging to the same woman, and 
thus allowing us to follow individual women. However, the linkage is not 
unique and certainly with common last names, administrative fusions occur 
quite often. To correct for these false identity matches(208), we excluded 
test results of women with the 0.5% most common surnames, which cor-
responds with approximately 30% of the women registered in the PALGA 
database(167). 
 
Retrospectively, we retrieved information from PALGA on all cervix uteri 
cytological and histological tests registered from January 2000 until March 
2009. To ensure enough follow-up time we only included women with a first 
episode taken within the national screening programme between January 
2000 and December 2007 (ie. almost all cervical cancers are detected within 
15 months following an abnormal cervical smear). Histologically confirmed 
cervical cancer cases were identified by selecting all PALGA records that 
included corresponding pathology codes.
The status score of the four-digit postal code of the woman’s place of resi-
dence at the time of the primary test was used to determine the SES of the 
woman’s neighbourhood(95). Status scores per four-digit postal code were 
provided by the Netherlands Institute for Social Research(96). They were 
based on: (i) mean income, (ii) percentage of households with a low income, 
(iii) percentage of households with, on average, a low education, and (iiii) 
unemployment rate per postal code in 2006. These variables were merged 
into one score (ie. status score) using principal components analysis(209). 
Status scores were ranked and low SES was defined as having a status score 
in the first (ie. lowest) quartile; intermediate SES as having a status score in 
the second and third quartile; and high SES as having a status score in the 
fourth (ie. upper) quartile. For our study intake period 2000 to 2007, status 
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scores were also available based on income, education and employments 
rates in 2002. In a sensitivity analysis, we used this alternative set of scores. 
Statistical analyses
As cervical cancer risk varies by age, it was considered a candidate for con-
founding(97, 98). Since women are invited in the year they turn 30, 35, .., 
60, the woman’s age was categorized as: 29-38, 39-48, and 49-63, at the time 
of the primary smear (ie. first test of the episode). We used a Pearson Chi-
Square test to test whether the distribution of age differed between the three 
SES groups. Thus, we tested whether age was indeed a potential confounder. 
We performed logistic regression analyses to compare the cervical cancer 
risk between the three SES groups, unadjusted and adjusted for confounding 
factors. The odds ratio (OR) was interpreted as relative risk since the cervi-
cal cancer prevalence was lower than 10%(99). The software programme 
SPSS (version 20) was used to perform the statistical analyses. 
RESulTS
Status scores per four-digit postal code ranged from -6.09 to 2.65. The 
lowest quartile ranged from -6.09 to -0.59 and the upper quartile ranged 
from 0.60 to 2.65. Thus, low SES corresponded with a status score of ≤-0.59, 
intermediate SES with a status score of >-0.59 and <0.60, and high SES cor-
responded with a status score of ≥0.60. 
A total of 404,761 first-time attendees without any history of cervical exami-
nations were included in our study; 26.4% lived in a low (106,747 women), 
48.2% in an intermediate (195,003 women) and 25.4% in a high SES neigh-
bourhood (103,011 women) (Table 8-1). Cervical cancer rates were similar 
between the three SES groups (61.8 versus 64.6 versus 60.2 cervical cancer 
cases per 100,000 women living in low, intermediate and high SES neigh-
bourhoods, respectively) (p = 0.891). First-time attendees living in low SES 
Association between SES and underlying screen-independent cervical cancer risk 169
neighbourhoods were more likely to attend at an older age than those in 
intermediate and high SES neighbourhoods (ie. 25 versus 21 and 20% were 
aged 39 years or older, respectively). Given these differences, and age being 
a risk factor for the development of cervical cancer, we considered age as a 
potential confounding factor. 
As compared to first-time attendees living in high SES neighbourhoods, 
those in low and intermediate SES neighbourhoods had a similar cervical 
cancer risk [i.e. OR of 1.03 (95% CI: 0.73, 1.45) and 1.07 (95% CI: 0.79, 
Table 8-1. Population characteristics. The distribution of cervical cancer detection and age 
per socioeconomic status group. 
Low 
SES
Intermediate 
SES
High 
SES
P value
No. of women 106,747 195,003 103,011
No. of cervical cancers 
(per 100,000 women)
66 
(61.8)
126 
(64.6)
62
(60.2)
0.891
Age <0.001
   29-38, n (%) 80,532  (75.4) 154,664 (79.3) 82,493 (80.1)
   39-48, n (%) 16,333 (15.3) 24,440 (12.5) 13,140 (12.8)
   49-63, n (%) 9,882 (9.3) 15,899 (8.2) 7,378 (7.2)
SES = Socioeconomic status 
Table 8-2. Comparing cervical cancer risk between first-time attendees living in different 
socioeconomic status neighbourhoods. Odds ratios are given, unadjusted and adjusted for 
differences in the distribution of age.
Model Low versus High Intermediate versus High
SES 1.03 (0.73, 1.45) 1.07 (0.79, 1.46)
SES, adjusted for age 0.98 (0.70, 1.39) 1.07 (0.79, 1.45)
The odds ratio can be interpreted as relative risk since the cervical cancer prevalence is 
less than 10%. The 95% confidence intervals are given in brackets. A p value of <0.05 was 
considered to be statistically significant. No significant differences were detected. 
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1.46), respectively] (Table 8-2). When adjusted for age, cervical cancer risks 
were still equivocal between the SES groups [ie. OR of 0.98 (95% CI: 0.70, 
1.39) and 1.07 (95% CI: 0.79, 1.45), respectively, when comparing first-time 
attendees in low and intermediate versus high SES neighbourhoods]. 
Sensitivity analysis
Status scores from 2002 ranged from -7.21 to 2.62. Low SES corresponded 
with a status score of ≤-0.79, intermediate SES with a status score of >-0.79 
and <0.22, and high SES corresponded with a status score of ≥0.22. We 
found that the age-adjusted OR of being diagnosed with cervical cancer 
was 1.10 (95% CI: 0.79, 1.52) and 0.91 (95% CI: 0.67, 1.23) for first-time 
attendees living in low and intermediate SES neighbourhoods as compared 
to first-time attendees living in high SES neighbourhoods, respectively. 
DiSCuSSioN
Our results showed no difference in cervical cancer risk between first-time 
attendees without any history of cervical examination living in low and 
intermediate versus high SES neighbourhoods. As we eliminated differences 
in former and current screening uptake, this indicates that the underlying 
cervical cancer risk is not associated with the SES of the neighbourhood 
the woman lives in, at least for the women considered: ever attending to 
screening. Therefore, any differences in cervical cancer risk between differ-
ent SES groups, if present, are probably caused by differences in screening 
participation.
This finding contrasted to our expectation that the underlying cervical can-
cer risk was associated with a woman’s SES. As a high-risk HPV infection is 
a necessary condition for the development of cervical cancer, an additional 
risk would result from a higher incidence of high-risk HPV infections, a 
higher probability for a high-risk HPV infection to progress into cancer, 
or a combination thereof. While a higher incidence can be caused by an 
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earlier sexual debut and more sexual partners(9-11), a higher probability 
of progression can be influenced by factors such as smoking, long-term 
contraceptive use and the incidence of sexual transmitted diseases (STD)
(9). Thus, it seems that no significant differences in sexual behaviour and/
or these factors were present between women living in different SES neigh-
bourhoods. Another possibility is that differences were present, but that 
they levelled each other off (eg. the effect of an increased smoking incidence 
was compensated by the effect of a decreased STD incidence). In addition, 
the number of cervical cancer cases was such that a maximal 39% increased 
underlying cervical cancer risk (ie. upper bound 95% CI) for women liv-
ing in neighbourhoods with a status score within the lowest quartile of all 
neighbourhoods compared to women living in a neighbourhood with a 
status score in the highest quartile cannot be ruled out. 
Status score of a neighbourhood (ie. defined by postal code) was based 
on income, education, and employment rates of inhabitants living in that 
neighbourhood. Obviously, it is possible that high SES women live in low 
SES neighbourhoods and the other way around. However, if a woman’s 
SES is not associated with her underlying cervical cancer risk difference, as 
indicated by our results, our effect estimates are unaffected when comparing 
SES on an individual instead of ecological level. If a woman’s SES is inversely 
correlated with the cervical cancer risk (ie. lower SES is associated with an 
increased underlying cervical cancer risk) our effect estimates would be 
underestimated. If positively correlated (ie. lower SES is associated with 
a decreased underlying risk), our effect estimates would be overestimated 
when comparing SES on an individual instead of ecological level.
While it is possible that lower SES non-attendees are a different group in 
terms of sexual behaviour and exposure to other risk factors than lower SES 
attendees, this probable also applies for higher SES non-attendees versus at-
tendees. Therefore, we expect that our findings (ie. lower SES is not associated 
with an increased underlying risk in first-time attendees) can be extrapolated 
to lower SES women in general. However, as in PALGA no data are available 
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on non-attendees without any cervical examinations taken, performing such 
a comparison was not possible without risking selection-bias.   
SES was defined according to status scores in 2006. As first lifetime cervical 
examinations were included from 2000 to 2007 this may have caused bias 
if women were misclassified because of changes in status scores over time. 
Knol et al. have shown that the average status score per postal code has 
increased from -0.26 in 1998 to +0.17 in 2010(209). However, we found 
that differences in status scores over time did not bias our results as our 
conclusions were still valid when SES was based on 2002 instead of 2006 
status scores. 
While the association between SES and the underlying cervical cancer risk 
was not found in this Dutch study, this does not automatically mean it is 
absent in other countries. For instance, the study of Benard et al. suggested 
that lower education and higher poverty rates are associated with an in-
creased underlying risk of HPV related cancers, and thus cervical cancer, in 
the United States.
Although multiple studies have shown that lower SES women have a higher 
cervical cancer risk and are more reluctant to attend screening, this is the 
first study that determined whether they still have an increased risk after 
eliminating differences in screening uptake. 
Nonetheless, our study has some limitations. First, liquid-based cytology 
tests SurePath and ThinPrep have gradually been implemented in most 
laboratories processing primary screening tests. As the few studies which 
compared cervical cancer detection rates between liquid-based cytology and 
conventional cytology did not find significant differences(49, 58, 117), we 
believe it is unlikely that possible differences in the distribution of the type 
of cytology test used biased our results. Second, no data are present whether 
cytology triage testing at six months was combined with HPV testing, and 
whether this was correlated with SES. Even so, Siebers et al. have shown 
that additional HPV triage testing shortens follow-up without altering the 
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detection of cervical intraepithelial neoplasia grade III or cancer(39). Third, 
we could only include cervix uteri cytological and histological tests taken 
until March 2009 as it was impossible to correct for false identity matches 
thereafter. However, we believe it is highly unlikely that our conclusion is 
time-dependent. 
Our results do not show that SES is associated with a woman’s underlying 
cervical cancer risk, at least for the women considered: ever attending to 
screening. Therefore, any differences in cervical cancer risk between dif-
ferent SES groups in the Netherlands, if present, are probably caused by 
differences in screening participation.
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In this thesis, we studied the impact of recent and future implementation 
of new screening tests in the Dutch cervical cancer screening programme. 
First, we will focus on the effect of using liquid-based cytology (LBC) tests 
SurePath and ThinPrep as compared to conventional cytology. Second, we 
will focus on offering human papillomavirus (HPV) self-sampling to non-
attendees in order to increase attendance rates. Thereafter, we will discuss 
monitoring of the future programme and future directions of Dutch cervical 
cancer prevention, followed by our conclusions and recommendations. 
PART i: PRimARy liquiD-bASED CyToloGy TESTiNG
Question 1: What is the effect of using Surepath and thinprep as 
primary test method on CIN II+ detection rates?
Our research showed that the use of SurePath as compared to 
conventional cytology led to an increased detection of CIN II+ by 8%, 
although it simultaneously increased the detection of CIN I by 14%. 
The use of ThinPrep did not affect CIN II+ or CIN I detection rates.
These findings correspond with literature. In chapter 2, we showed that 
our observed CIN II+ detection rate ratio of 0.99 (95% CI: 0.96, 1.02) was 
compatible with CIN II+ detection rate ratios of other studies comparing 
ThinPrep with conventional cytology. In addition, our observed CIN II+ de-
tection rate ratio of 1.08 (95% CI: 1.05, 1.12) when comparing SurePath with 
conventional cytology was compatible to the only other CIN II+ detection 
rate ratio provided by literature, although their conclusion differed from 
ours [ie. they found similar CIN II+ detection rates between these two tests: 
ratio of 1.01 (95% CI: 0.76, 1.33)]. 
As described in Table 1-2 there are multiple differences in preparation and 
protocol present between LBC tests SurePath and ThinPrep which may 
affect their performances’. First, the protocol concerned with handling of 
the collecting device is likely to be associated with the cell yield(100, 101) 
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and therefore, with the probability of transferring abnormal cells from 
the cervical specimen (if present) to the slide. Differences in this protocol 
could therefore be the cause of the differences in CIN II+ sensitivity found 
between the tests. In addition, the difference in the method of cells transfer 
is possible associated with the risk on an unsatisfactory smear. Zhao et al. 
suggested that debris like blood and mucus can attach to the filter used 
for processing ThinPrep samples. As a consequence, this could reduce 
the number of cells transferred to the slide resulting in for instance more 
unsatisfactory smears(53). This was confirmed in other studies which simu-
lated the preparation of smears of cervical samples containing excess blood 
and mucus(210, 211). They found that SurePath was able to handle larger 
amounts than ThinPrep. These results correspond with our own data. We 
found that the unsatisfactory rate was higher when using ThinPrep than 
using SurePath [odds ratio (OR) of 1.41 (95% CI: 1.38, 1.45)] (data not 
shown). Whether the method of cell transfer is associated with the sensitiv-
ity to detect CIN II+ is currently unknown, as is the effect of using different 
types of preservative fluid and collecting devices. Thus, more research is 
needed to examine which differences in preparation of the smears cause 
the difference in CIN II+ sensitivity between the different types of LBC 
tests. Then, it might be possible to adjust the ThinPrep protocol in order to 
improve its performance. 
It is not only meaningful to know whether the use of SurePath or ThinPrep 
affected CIN II+ detection rates, but also whether it affected the ability of 
cytologists to distinguish between women with and without a CIN II+ lesion. 
This is important as the aim of screening is to prevent as many cervical 
cancers against as little inconvenience for the women as possible. When 
comparing SurePath with conventional cytology, we found that the finding 
of cell abnormalities (ie. Pap ≥ 2) more often resulted in the detection of 
CIN II+ detection rates [ie. OR of 1.11 (95% CI: 1.07, 1.15)]. Thus, the posi-
tive predictive value (PPV) of a positive smear was higher and cytologists 
were better able to distinguish between women with and without CIN II+ 
lesions when using SurePath. When comparing ThinPrep with conventional 
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cytology, the PPV was similar or even lower [ie. OR of 0.97 (95% CI: 0.93, 
1.00)].  
Question 2: are increasing CIN detection rates caused by 
implementation of LBC tests?
We found that from 2003-2005 to 2009, trends of increased detection 
were present for all CIN grades. After adjusting for demographic 
factors, CIN I, CIN II, and CIN III detection rates were 2.11, 1.79, and 
1.59 times higher in 2009 as compared to 2003, respectively. When 
also adjusted for the type of cytology test used, detection rates were 
still 1.90, 1.48, and 1.55 times larger in 2009 as compared to 2003. 
Thus, the gradual implementation of LBC over time contributed to the 
increased detection of CIN I, CIN II, and CIN III but it was not the only 
cause. 
CIN I and CIN II detection rates decreased with 0.21 (ie. 2.11 to 1.90) and 
0.31 (ie. 1.79 to 1.48) when correcting for the type of cytology test used, 
which was larger than expected. Based on results from chapter 2, we foresaw 
a maximal decrease of 0.14 for both CIN I and CIN II (which would have 
been the decrease if all women switched from using conventional cytology 
in 2003 to using SurePath in 2009). On the other hand, the 0.04 decrease 
in CIN III detection rates (ie. 1.59 to 1.55) was as expected, namely below 
0.06 [which would have been the decrease if all women switched from 
using conventional cytology in 2003 to using SurePath in 2009 (Chapter 
2)]. This discrepancy on the effect of CIN I and CIN II detection rates is 
caused by the inclusion of two two-way interaction terms between: (i) the 
type of primary cytology test and age, and (ii) the type of primary cytology 
test and screening region. Thus, the effect of implementing SurePath or 
ThinPrep differs per age group, which was confirmed by Matjka et al.(64). 
This can be explained by the fact that the sensitivity of conventional cytol-
ogy is probably age-dependent(83, 212, 213). Moreover, it is likely that the 
effect of implementing SurePath or ThinPrep differs per laboratory, as we 
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used screening region as a proxy for the laboratories involved. This may 
be explained by the following three factors. First, differences in protocol 
could be present between laboratories. Second, implementation of auto-
mated reading in some of the laboratories could have affected their ability 
to detect CIN lesions when using LBC tests, although studies have shown 
heterogeneous results(61-64). Third, it is likely that the interobserver agree-
ment of conventional cytology is lower than that of SurePath and ThinPrep 
as the quality of cell transfer, and therefore the quality of the conventional 
cytology smear, might differ between clinicians. Thus, how much there is to 
gain when replacing conventional cytology by another primary test method 
possibly differs between clinicians and therefore, between laboratories. 
Also, it is possible for the interobserver agreement of ThinPrep to be lower 
than that of SurePath as the thoroughness of rinsing the brush in the vial 
with preservative fluid might differ between clinicians and therefore, the 
cell yield might also differ(101). A possible explanation for the finding of 
a larger decrease in CIN I and CIN II detection rates than expected, while 
the decrease in CIN III detection rates was in line with our expectations, 
is that the detection of mild cell abnormalities has a lower interobserver 
agreement than severe cell abnormalities. Therefore, the effect of switching 
to LBC testing on mild cell abnormalities, and therefore CIN I and CIN 
II, can differ more per lab than the effect on severe cell abnormalities, and 
consequently CIN III. 
If the effect of switching to either SurePath or ThinPrep differs per labora-
tory, this would probably mean that we under- or overestimated the con-
tribution of LBC implementation on the trend in increased CIN detection 
rates because: (i) no data per laboratory were available, and (ii) laboratories 
switched to either SurePath or ThinPrep on different points in time. Thus, 
the gradual implementation of LBC over time could have contributed for a 
larger part to the CIN increase than estimated. 
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question 3: is there a difference in sensitivity to detect progressive 
CiN lesions between SurePath, ThinPrep, and conventional cytology?
To assess whether the ability to detect progressive CIN lesions differed 
between SurePath, ThinPrep, and conventional cytology, we compared 
interval cancer rates (ie. a cervical cancer diagnosed after a negative 
primary screening smear) between the three types of cytology tests. 
When adjusted for confounders, the overall risk of interval cancer was 
17% lower after a negative Surepath smear and 20% higher after a 
negative ThinPrep smear than after a negative conventional cytology 
smear. This strongly suggests that the sensitivity to detect progressive 
CIN lesions is highest when using SurePath and lowest when using 
ThinPrep as primary test method.
The use of SurePath seemed more effective in finding progressive CIN le-
sions than ThinPrep and conventional cytology, both based on differences 
in CIN II+ detection rates and interval cancer rates (Chapters 2 and 4). Based 
on differences in CIN II+ detection rates, the use of ThinPrep seemed equally 
effective as the use of conventional cytology (Chapter 2). However, when 
using the same data but replacing the detection of CIN II+ by the detection 
of interval cancers as outcome measure, we found  strong indications that 
ThinPrep was less effective as conventional cytology in finding progressive 
CIN lesions. Thus, the use of surrogate measures led to the general con-
sensus that ThinPrep was equally effective in preventing cervical cancer by 
finding equal numbers of CIN II+, while the use of interval cancers showed 
that fewer cervical cancers were prevented by finding fewer progressive CIN 
lesions. Meanwhile, ThinPrep has been implemented in multiple countries 
with and without organized cervical cancer screening programmes, such 
as the Netherlands, Denmark, the UK, and the USA(92, 93), based on this 
consensus. Therefore, it is most important to carefully monitor the effect of 
implementing ThinPrep in these countries. 
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When implementing new screening tests or strategies one should not only 
focus on the benefits (ie. how many cervical cancer cases and associated 
deaths have been prevented) but also on the harms (ie. the loss in quality of 
life due to screening and associated treatments). For a screening programme 
to be effective the benefits need to outweigh the harms, which can be ex-
pressed by the number of quality-adjusted life-years (QALYs) gained and 
calculated using microsimulation. A good indicator for the negative effect of 
screening is the overdiagnosis rate (ie. the number of excess diagnoses when 
comparing the situation with versus without screening).
Question 4: What is the amount of overdiagnosis in the Dutch 
cervical cancer screening programme?
In general, more (pre-invasive) disease is found by screening. This 
excess in diagnosis by screening is defined as overdiagnosis (ie. 
number of extra diagnoses with screening divided by total number 
of diagnoses with screening). When assuming that conventional 
cytology was used as primary test method in the current primary 
cytological programme, the percentage of excess diagnoses was 
70.6% (ie. including all CIN grades). When CIN II, CIN III, and cervical 
cancer were defined as excess diagnoses, this percentage was 63.2%. 
When CIN III and cervical cancer were defined as excess diagnoses, 
this percentage was 50.0%. As cervical cancers are prevented by the 
diagnosis and treatment of pre-invasive CIN lesions, the incidence of 
cervical cancer decreased by 55.2% with screening. Thus, when only 
cervical cancer was defined as excess diagnosis, no overdiagnosis 
was present. In contrast, breast cancer screening is aimed at finding 
breast cancer in an earlier stage. Therefore, the percentage of excess 
diagnoses is 1.5%. 
Thus, the use of conventional cytology as primary test method results in 
an overdiagnosis rate of 70.6%, when including all CIN grades. The use of 
ThinPrep as primary test method will probably lead to a decreased sensitiv-
ity of the programme as the sensitivity to detect progressive CIN lesions is 
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decreased. Simultaneously, the number of detected CIN lesions is not sig-
nificantly affected. Thus, the number of detected CIN per prevented cervical 
cancer will probably rise and therefore the overdiagnosis rate. Hence, the 
use of ThinPrep as primary test method will probably also lead to a decrease 
in the QALYs gained and consequently, in a decreased effectiveness of the 
programme. Therefore, its sensitivity should probable be improved in order 
to guarantee a similar harm-benefits ratio and effectiveness of the original 
programme. The use of Surepath as primary test method will probably lead 
to an increased sensitivity of the programme as more cervical cancers are 
prevented by detecting more progressive CIN lesions. An increased sensitiv-
ity often leads to a decreased specificity which is expressed by the finding of 
3.1 extra CIN I (30.1 / 9.7), 3.2 extra CIN II (31.2 / 9.7) and 3.1 extra CIN 
III (30.3 / 9.7) diagnoses per extra prevented interval cancer (Table 9-1). 
Thus, the percentage of overdiagnosis will probably increase when using 
SurePath as primary test method and when including CIN diagnoses in the 
definition. However, it is possible that part of these extra detected CIN I 
and CIN II lesions are actually due to introduction of HPV triage testing 
instead of primary screening with SurePath(39). Especially since it is likely 
that the introduction of HPV triage testing is correlated to the use of LBC 
testing (ie. the possibility of co-testing is one of the advantages of LBC over 
conventional cytology(41, 44)). However, even then, the percentage of over-
diagnosis will probably still increase when using SurePath as compared to 
Table 9-1. The difference in CIN lesions and interval cancers per 100,000 SurePath and 
ThinPrep versus 100,000 conventional cytology smears. 
SurePath versus CC ThinPrep versus CC
Extra CIN I lesions detected 30.1 -3.5 
Extra CIN II lesions detected 31.2 9.4
Extra CIN III lesions detected 30.3 -12.2
Extra interval cancers prevented 9.7 -11.1*
Bold = Significant. A p value of <0.05 was considered to be statistically significant.  CC = 
Conventional cytology. 
*Thus, the use of ThinPrep leads to 11.1 extra interval cancers per 100,000 smears. 
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conventional cytology. Whether this will result in a decrease in the number 
of QALYs gained and therefore in a decreased effectiveness of the Dutch 
cervical cancer screening programme is unknown.
Microsimulation can be used to estimate the impact of using SurePath 
as compared to conventional cytology as primary test method on the ef-
fectiveness of the Dutch cervical cancer screening programme using: (i) 
observed short-term indicators (eg. number of women referred to triage, 
number of women referred directly to the gynaecologist, and the number 
of detected CIN lesions), and (ii) long-term outcomes (eg. interval cancer 
rates). In addition, sensitivity analyses can be included as regards to the 
cause (of part) of the extra detected CIN I and CIN II lesions. Moreover, 
cost-effectiveness analyses can be performed to assess whether SurePath is 
cost-effective besides being effective. In an earlier microsimulation study it 
was shown that using LBC is cost-effective if the sensitivity is at least 3 to 5 
percentage points higher than conventional cytology for CIN I, CIN II, CIN 
III, cervical cancer FIGO stage 1A, 1B, and 2+(214). However, we found a 
similar sensitivity to detect cervical cancer, while the sensitivity to detect 
CIN II and CIN III lesions is 1.14 and 1.06 times higher, leading to 17% 
fewer interval cancers. Thus, we recommend performing new microsimula-
tions, based on our recent findings, in order to assess whether the use of 
SurePath as primary test method is (cost-)effective or not. 
Additional analyses
In light of all the new evidence gathered within this first part of this thesis, 
we performed two additional analyses. First, we were interested in whether 
the sensitivity of the programme was affected by implementing screening 
tests SurePath and ThinPrep. We compared the risk on an interval cancer 
after a negative primary screening test (which is an important indicator for 
the sensitivity of the programme) between the periods 2006-onward and 
2000-2005 using Cox regression analyses. We did not find any changes in 
risk over time [the ratio was 0.92 (95% CI: 0.84, 1.02)]. Thus, we found no 
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indications that the interval cancer risk or the sensitivity of the programme 
was affected by gradual implementation of SurePath and ThinPrep over 
time. However, it cannot be ruled out that the sensitivity of the programme 
was altered while data to support this are not (yet) present. As the distribu-
tion of both LBC tests was similar until 2006 (Figure 9-1), it is possible that 
the negative effect of using ThinPrep on the sensitivity of the programme 
was levelled off by the use of SurePath. In addition, the effect of ThinPrep 
is time-dependent and the risk on an interval cancer is only increased after 
approximately four years. Thus, the first negative effects on the screening 
programme would appear somewhere in 2011. As data until March 2013 are 
present and interval cancers are rare, it is possible that not enough data are 
present yet to observe an increase in interval cancers. In addition, a decrease 
in the underlying risk of screened women could in theory have biased our 
results, although our data support the contrary (Chapter 3). Importantly, 
figure 9-1. Percentual distribution of the type of primary cytology test used in the Dutch 
cervical cancer screening programme.
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even when the sensitivity of the programme did not decrease over time, it is 
likely that the number of QALYs gained by screening did decrease because 
of: (i) the increase in women being referred to triage, (ii) the increase in 
women being referred directly to the gynaecologist, and (iii) the increase 
in CIN detection rates (Chapter 3). Thus, even when the sensitivity of the 
programme did not alter, the effectiveness of the programme probably did. 
In our second additional analysis, we assessed whether the cervical cancer 
incidence rate in the Netherlands increased, as was suggested in Figure 1-1, 
using the Joinpoint Regression Programme(108). We found that the inci-
dence rate non-significantly decreased by 1.2% (95% CI: -2.4, +0.0) annually 
from 1989-1998, followed by a non-significant decrease of 5.9% (95% CI: 
-17.8, +7.7) from 1998-2001 and a significant increase of 1.5% (95% CI; 
+0.7, +2.3) from 2001-2013. As it is not likely that this increase is caused by 
an increase in interval cancer rates, as shown earlier, it is probable caused 
by an increase in screen-detected and/or clinically detected cancer rates. 
Our finding that cervical cancer detection rates were nonsignificantly lower 
when using ThinPrep as compared to conventional cytology, and unaffected 
when using SurePath (Chapter 2), does not support the theory that screen-
detected cancer rates increased over time. However, it is possible that the 
underlying cervical cancer risk of the general Dutch population increased, 
which was also pointed out in Chapter 3. This could have caused an increase 
in both screen-detected and clinically detected cancers. Comparison of 
the prevalence of high-risk HPV infections over time in the eligible Dutch 
screening population could indicate whether this is the case or not. An-
other factor which could have contributed to a possible increase in both 
screen-detected and clinically detected cancers is compensation of the rapid 
decrease in cervical cancer incidence from 1998 to 2001, which was caused 
by an increased screening intensity from 1996 to 1998(109). However, we 
we doubt it was the main cause for a 12-year period of increase. As cervi-
cal cancer screening programme coverage rates were stable from 2004 to 
2013(79, 80), they can be excluded as possible explanation for a possible 
increased clinically detected cancer rate. 
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PART ii: iNCREASiNG ATTENDANCE by offERiNG HPV 
SElf-SAmPliNG To NoN-ATTENDEES
A study examining the screening history of Dutch women with cervical 
cancer revealed that more than half of the cervical cancers occurred in 
women who did not participate in screening in the previous six years while 
they were invited. In addition, less than 10% of the women had a previous 
negative screening smear within the previous six years(74). Thus, according 
to this study increasing the attendance has more potential in preventing 
cervical cancers than implementing a more sensitive screening test.
Question 5: how many cervical cancer cases in young women can 
potentially be prevented using a more sensitive screening test at 
age 30? 
We analyzed the screening history of 30 to 35 year old women 
diagnosed with cervical cancer between 2004 and March 2009. 
Accordingly, we assessed the percentage of cervical cancer cases 
that were preceded by a negative cytology test under the age of 35, 
which is the age of the second screening round, and the percentage of 
cervical cancer cases without a history of cervical cancer screening. 
If we assume that the lesion was already present 10 years before 
the cancer was diagnosed, 23% of the cancers can maximally be 
prevented by using a more sensitive screening test under the age of 
35, while 67% of the cancers occurred in women who did not have a 
history of cervical cancer screening. When assuming that the lesion 
was already present 5 years before the cancer was diagnosed, these 
percentages were 18% and 67%, respectively. Thus, the majority of 
cancers in women aged 30-35 years would still occur when applying 
a more sensitive screening test at first screening age 30, although 
increasing the attendance rate could make an important contribution 
in preventing them.
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The study of Gok et al. showed that offering HPV self-sampling to non-
attendees of Dutch cervical cancer screening is a promising method to 
increase participation rates, of invited women in general and of young 
women at their first screening age(73, 180). Thus, offering self-sampling to 
non-attendees could be an effective way in reducing the incidence and mor-
tality of cervical cancer. As HPV testing can be performed on self-collected 
samples(69, 70, 215) and primary HPV testing is expected to replace pri-
mary cytology testing in the Dutch cervical cancer screening programme 
from 2016 onward, we estimated we estimated under which circumstances 
it would be effective (ie. QALYs are gained) to offer self-sampling to non-
attendees of organized primary HPV screening. 
Question 6: When is it effective to offer self-sampling to non-
attendees of organized primary hpV screening?
Without “switching” of regular attendees from HPV office-based to 
HPV self-sampling, offering self-sampling is (cost-) effective under 
every studied condition. If all regular attendees switch, offering 
self-sampling is (cost-)effective if simultaneously the attendance 
increases by at least 6 percentage points, women with at least a 1.7 
higher underlying risk are recruited by self-sampling and the relative 
CIN II+ sensitivity and specificity of HPV self-sampling (as compared 
to office-based sampling) are at least 0.95. If the relative sensitivity 
decreases to 0.90 combined with either the absence of these higher 
underlying risk women or a 3 percentage points extra attendance, the 
effectiveness of the programme already decreases when more than 
20% to 30% of the regular attendees switch. 
The following variables are most influential in determining whether offering 
HPV self-sampling to non-attendees is effective or not: the relative CIN II+ 
sensitivity of HPV self-sampling, the increase in attendance, the ability to 
target higher underlying risk non-attendees, and the percentage of regular 
attendees switching from office-based to HPV self-sampling. 
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The largest uncertainty about offering HPV self-sampling to non-attendees 
is how many women will switch from office-based to HPV self-sampling. As 
we believe it is likely that women will actually switch, it is important that 
the following conditions are met in order to ensure an equal or increased 
effectiveness of the future HPV programme when offering HPV self-
sampling to its non-attendees: (i) the relative CIN II+ sensitivity is at least 
0.95, (ii) women with at least a 1.7 higher underlying risk are recruited by 
self-sampling, and (iii) the total attendance increases by at least 6 percentage 
points.
A recent meta-analysis has shown that a relative sensitivity of 1.00 can be 
met when using a validated polymerase chain reaction (PCR) test(185). 
However, as these results are uncertain (based on its confidence intervals) 
it is possible that the relative sensitivity of a validated PCR is lower than 
0.95. Moreover, as many of these studies were done in clinical settings, these 
relative sensitivities may be overestimated and they may even be lower than 
0.90 (ie. the real-world performances of HPV self-sampling might be lower 
than the performances of HPV self-sampling in the artificial setting of clini-
cal studies)(202). Thus, whether the first criterion will be met is uncertain. 
However, even when the relative CIN II+ sensitivity is 0.90, 70% of the 
regular attendees could switch before the effectiveness of the programme 
is decreased, as long as the second and third condition are met (Chapter 
7). Therefore, women with at least a 1.7 higher underlying risk need to be 
identified and recruited by self-sampling and the total attendance needs to 
increase by at least 6 percentage points. 
Question 7: Is lower socioeconomic status associated with an 
increased underlying cervical cancer risk?
 We found no difference in cervical cancer risk between first-time 
attendees without any history of cervical examination living in low 
and intermediate versus high SES neighbourhoods. As we eliminated 
differences in former and current screening uptake, this indicates 
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that the underlying cervical cancer risk is not associated with the 
SES of the neighbourhood the woman lives in, although it cannot be 
ruled out. As the SES of a neighbourhood is based on income levels, 
education levels and employment rates of its inhabitants, we expect 
most women to have similar SES statuses as the neighbourhood they 
live in. Therefore, we conclude that not only women living in lower SES 
neighbourhoods, but also lower SES women, probably do not have an 
increased underlying risk to be diagnosed with cervical cancer. 
The number of cervical cancer cases was such that a maximal 39% increased 
underlying cervical cancer risk (ie. upper bound 95% CI) for low as com-
pared with high SES women cannot be ruled out (Chapter 8). Compared to 
the general population this maximal increase will probably even be lower. 
Thus, the second criterion (ie. women with at least a 1.7 higher underlying 
risk as compared to the general population are recruited by self-sampling) 
will not be met by focussing on lower SES non-attendees. 
Another important target group for offering HPV self-sampling can be 
underscreened and unscreened women, since it was indicated that at least 
a part of them have an increased underlying risk(190). Results of the Dutch 
PROHTECT trial showed that these women indeed attended via self-
sampling when it was offered to them(176), although it is unknown whether 
this is the subset with an increased underlying risk. Moreover, self-sampling 
was offered via an opt-out procedure (ie. a self-sampling kit was sent to all 
non-attendees except when they opted-out via a letter), while the use of 
an opt-in procedure (ie. involving a request for a self-sampler) may reduce 
response rates (71). This would mean that fulfilment of the second criterion 
(ie. the recruitment of women with a 1.7 higher underlying risk) also de-
pends on the chosen strategy. Thus, whether the second criterion will be met 
is uncertain. Then, the effectiveness of the programme decreases when more 
than 30% of the regular attendees switch. If in addition the first criterion 
is also not met, this percentage decreases to 20%. If the cost-effectiveness 
is also taken into account, any woman switching will result in a decreased 
effectiveness of the programme (Chapter 7). 
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Results of the Dutch PROHTECT trial have also shown that the extra at-
tendance rate is at least 6 percentage points when self-sampling was offered 
to non-attendees(73). Therefore, fulfilment of the third criterion seems 
realistic, although this may also depend on the chosen strategy (ie. opt-in or 
opt-out). In case the criterion is not met, the effectiveness of the programme 
decreases when more than 50% of the regular attendees switch. If in addi-
tion, the first criterion is not met, this percentage decreases to 30%. When 
all three criteria are not met, this percentage decreases to less than 20%. 
Furthermore, it will be questionable whether it is cost-effective to offer HPV 
self-sampling to non-attendees even if no women switch at all (Chapter 7). 
In conclusion, it is unknown whether all conditions for offering HPV self-
sampling to be (cost-)effective are met in real-practice. Therefore, it is essen-
tial to carefully monitor the effects, both on the short term and on the long 
term, in order to guarantee equal or increased effectiveness when adding 
HPV self-sampling to the programme. Short term effects are defined as the 
extra attendance via HPV self-sampling, the percentage of regular attendees 
switching, the findings of self-sampling versus office-based sampling (eg. 
the number of women referred to triage, the number of women who comply 
to the given advice, CIN I, and CIN II+ detection rates), and the attendance 
of underscreened and unscreened women. Long term effects are defined as 
interval cancer incidence (which is an important indicator for the sensitivity 
of the programme) and mortality rates. 
future cervical cancer screening programme
It is expected that from 2016 onward, primary cytology screening will be 
replaced by primary HPV screening, combined with an extended screening 
interval from five to ten years at the ages of 40, 50, and 60. This decision was 
based on microsimulations which showed a mortality reduction of approxi-
mately 11%, while saving costs, when comparing the future with the current 
programme(216). However, assumptions of the HPV test characteristics 
could be overestimated as they were based on premature information, while 
at the same time an increased underlying risk of the screening population 
192 Chapter 9
cannot be ruled out. In combination with extending the screen interval to 
ten years, it is therefore essential to carefully monitor and evaluate the short 
and long term effects in order to guarantee equal or increased sensitivity 
and effectiveness of the future programme. Short term effects are defined 
as the number of women referred for triage testing, false-positive referrals, 
CIN I, and CIN II+ detection rates. Long term effects are defined as interval 
cancer incidence and mortality rates. In general, careful monitoring and 
evaluation of the effects of implementing new screening tests or new screen-
ing strategies is necessary to guarantee the effectiveness of the programme. 
Especially, as such decisions are often based on microsimulations and there-
fore, on assumptions which might differ from real-life settings. For instance, 
implementation of colon cancer screening in the Netherlands resulted in a 
referral rate for a colonoscopy of more than 12%, which was much higher 
than anticipated(217, 218). By carefull monitoring and evaluation of the 
programme there could be intervened in time (namely an increase of the 
threshold from 88 ng/mL to 275 ng/mL) in order to ensure that QALYs were 
still gained and screening for colon cancer was still effective.  
future directions of cervical cancer prevention
Since 2009, HPV vaccination has been implemented in the Dutch National 
Immunisation Programme. Twelve year old girls are vaccinated with the 
bivalent Cervarix vaccine against high-risk HPV types 16 and 18, while a 
catch-up campaign was organized for girls born between 1993 and 1996(75). 
Vink et al. estimated that the average HPV-16 reduction will be 44% for 20-
30 aged women, 15% for 30-40 aged women, 4% for 40-50 aged women and 
1% for 50-60 aged women by 2029, assuming current circumstances (ie. a 
coverage of 60% under 12-year old girls)(219). By 2059, these average HPV-
16 reductions were estimated to be 42, 15, 26, and 39%, respectively(219). 
Estimated reductions for HPV-18 in the Netherlands are not (yet) available. 
Naturally, increasing the coverage in 12-year old girls would improve these 
numbers. Another solution could be the additional vaccination of 12-year 
old boys. Bogaards et al. have estimated that this would result in the preven-
tion of one extra cancer case in males (ie. anal, penile, or oropharyngeal 
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cancer) per 795 boys vaccinated(220), while girls and women experience 
an increased protection against cervical cancer via herd-immunity(219). 
Furthermore, as men have a wider age preference for their sexual partners as 
compared to women(221, 222), older age cohorts will also be protected(219). 
However, as 35% of cervical cancers are estimated to be caused by oncogenic 
types other than HPV-16 and HPV-18(8), cervical cancer screening could 
still be effective. Whether this would be cost-effective and which screening 
strategy should be used needs to be determined. It probably depends on 
the vaccination coverage, herd-immunity levels, and distribution of unvac-
cinated women in the eligible screening population. 
CoNCluSioNS 
• The effect of using liquid-based cytology as primary test method for cer-
vical cancer screening depends on the type of liquid-based cytology test 
used. Our results strongly suggest that SurePath has a higher sensitivity 
to detect progressive CIN lesions as compared to conventional cytology, 
accompanied by an increased detection of CIN I, while ThinPrep has a 
lower sensitivity to detect progressive CIN lesions. 
• The gradual implementation of liquid-based cytology was responsible 
for a small but significant part of the increase in CIN I, CIN II, and CIN 
III detection rates as observed in the Dutch cervical cancer screening 
programme. Therefore, other factors must also have played an important 
role.
• More than 70% of the cervical cancers diagnosed within young women 
aged 30 to 35 years could not have been prevented by using a more 
sensitive screening test at the first screening at age 30. As most of these 
cervical cancers occurred in women who did not have a history of cervi-
cal cancer screening, increasing the attendance rate for screening at age 
30, for instance by offering non-attendees HPV self-sampling, can make 
an important contribution in preventing cervical cancers within young 
women. 
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• Lower socioeconomic status women do not seem to have an increased 
underlying cervical cancer risk to be diagnosed with cervical cancer, 
although it cannot be ruled out. 
• The following variables are most influential in determining whether of-
fering HPV self-sampling to non-attendees is effective: the relative CIN 
II+ sensitivity of HPV self-sampling, the extra attendance rate gener-
ated by HPV self-sampling, the ability to target higher underlying risk 
non-attendees, and the percentage of regular attendees switching from 
office-based to HPV self-sampling. In the absence of switching, offering 
self-sampling is effective under every studied condition. If all regular 
attendees would switch, offering self-sampling is effective if simultane-
ously (i) the attendance rate increases by at least 6 percentage points, (ii) 
women with at least a 1.7 higher underlying risk are recruited by self-
sampling, and (iii) the relative CIN II+ sensitivity of HPV self-sampling 
as compared to office-based sampling is at least 0.95. 
• The effect of using new screening tests on preventing cervical cancers 
can be estimated incorrectly when using surrogate endpoints such as 
CIN detection rates instead of interval cancer rates.
RECommENDATioNS 
• If the decision which primary cytology test to use depends on the ability 
to prevent cervical cancer cases, the use of SurePath in the Dutch cervi-
cal cancer screening programme is to be preferred. 
• The sensitivity of ThinPrep to detect progressive CIN lesions should be 
improved in order to guarantee an equal harm-benefits ratio and effec-
tiveness of the original Dutch cervical cancer screening programme. 
• It is unknown whether all conditions for offering HPV self-sampling to 
be (cost-)effective are met in real-practice. Therefore, it is essential to 
carefully monitor the effects, both on the short term and on the long 
term, in order to guarantee the effectiveness of the Dutch cervical 
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cancer screening programme when offering HPV self-sampling to non-
attendees. 
• Careful monitoring of the effects of implementing new screening tests 
or new screening strategies using population-based data is necessary to 
guarantee the effectiveness of the programme.
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SummARy
Cervical cancer is the fourth most common cancer in women all over the 
world, mainly affecting young women between 40 and 55 years. It was esti-
mated that 528,000 women were diagnosed with cervical cancer worldwide 
in 2012 and 266,000 women died because of it. In the Netherlands, cervical 
cancer incidence and mortality have decreased towards 5.9 and 1.4 cases per 
100,000 women in 2013, standardized to the world’s age distribution.
Cervical intraepithelial neoplasia (CIN) are considered as asymptomatic 
prestadia of cervical cancer and they are ranked to the severity of the le-
sion (CIN I, II, or III). This preclinical detectable phase of cervical cancer 
is estimated to last on average more than 10 years which makes it ideal for 
screening. In the Netherlands cervical cancer screening already exists since 
the 1970s. Since 1996, women are invited every five years from the ages of 
30 to 60 years to be tested by primary cytology and cytology triage, with or 
without addition of human papillomavirus (HPV) testing. 
PRimARy liquiD-bASED CyToloGy TESTiNG 
Within the last 10 to 15 years, most Dutch laboratories processing primary 
screening tests switched from using conventional cytology to liquid-based 
cytology (LBC) tests SurePath or ThinPrep. It was believed that the CIN II+ 
sensitivity of LBC was similar to that of conventional cytology, although 
no studies have been published comparing CIN detection rates between 
different types of LBC tests and conventional cytology. In chapter 2, we 
demonstrated that the use of SurePath as primary test method led to an 
increased detection of CIN II+  by 8%, although it simultaneously increased 
the detection of CIN I by 14%. The use of ThinPrep did not affect CIN detec-
tion rates. In chapter 3, we showed that from 2003-2005 to 2009 trends of 
increased detection were apparent for all CIN grades. Although implemen-
tation of LBC tests SurePath and ThinPrep contributed to this trend, it was 
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not the only cause. Therefore, an increased underlying risk cannot be ruled 
out. However, as it is likely that the effect of switching to either SurePath or 
ThinPrep differs per laboratory, and no data per laboratory were available, 
it is possible that we underestimated the contribution of LBC implementa-
tion on the trend in increased CIN detection rates. Based on results from 
chapter 2, one could argue that SurePath seems more effective in preventing 
cervical cancers than ThinPrep and conventional cytology (ie. because of 
their increased CIN II+ detection), while ThinPrep and conventional cytol-
ogy seemed equally effective (ie. because of their similar CIN II+ detection). 
However, as in the absence of screening and associated treatment only a 
fraction of CIN lesions would progress to cervical cancer, detecting an equal 
or increased CIN rate is not necessarily equivalent to preventing equally 
or increased numbers of cervical cancers. Indeed, in chapter 4 we showed 
that the effect of using new screening tests on preventing cervical cancers 
can be estimated incorrectly when using surrogate endpoints such as CIN 
detection rates instead of interval cancer rates (ie. cervical cancer diagnosed 
after a negative primary screening smear). The risk of an interval cancer 
was lowest when using SurePath as primary test method and highest when 
using ThinPrep as primary test method. This difference in interval cancer 
rates strongly suggests that the sensitivity to detect progressive CIN lesions 
is highest when using SurePath and lowest when using ThinPrep as primary 
test method. Thus, SurePath is likely to be more effective in preventing cer-
vical cancers than conventional cytology, which in turn is likely to be more 
effective than ThinPrep. However, when implementing new screening tests 
or strategies one should not only focus on the benefits (how many cervical 
cancers have been prevented) but also on the harms (the loss in quality of 
life due to screening and associated treatments). A good indication for the 
negative effect of screening is the overdiagnosis rate, which is defined as: the 
number of excess diagnoses when comparing the situation with screening 
versus without screening divided by the number of diagnoses with screen-
ing. In chapter 5, we estimated the overdiagnosis rate to be 70.6% in the 
current programme, when including all CIN grades and assuming that 
conventional cytology is used as primary test method. The use of ThinPrep 
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as primary test method will probably lead to a higher overdiagnosis rate 
as fewer cervical cancers are prevented while the number of detected CIN 
lesions are not affected. Therefore, it is likely that fewer quality-adjusted 
life-years (QALYs) are gained and thus the effectiveness of the programme 
decreases by using ThinPrep as primary test method. The use of SurePath as 
primary test method will probably also lead to a higher overdiagnosis rate 
as we estimated that 3.1 extra CIN I, 3.2 extra CIN II, and 3.1 extra CIN III 
lesions are detected per extra prevented interval cancer. In what way this 
will affect the number of QALYs gained and thereby the effectiveness of the 
Dutch cervical cancer screening programme needs to be estimated using 
microsimulations. 
iNCREASiNG ATTENDANCE by offERiNG HPV SElf-
SAmPliNG To NoN-ATTENDEES
A study examining the screening history of Dutch women with cervical can-
cer revealed that more than half of the cervical cancers occurred in women 
who did not participate in screening in the previous six years. In addition, 
less than ten percent of the women had a previous negative screening smear 
within the previous six years. This was confirmed in chapter 6 where we 
found that the majority of cancers in women aged 30-35 would still occur 
when applying a more sensitive screening test at first screening age 30, while 
part of them could have been prevented by increasing the attendance rate. 
A promising method to enhance screening participation rates is by offering 
HPV self-sampling to non-attendees of primary HPV screening, which is 
expected to be implemented in the Netherlands from 2016 onward. How-
ever, this could result in a decrease of the effectiveness of the programme 
if too many regular attendees would “switch” from office-based sampling to 
self-sampling, given a loss in CIN II+ detection (ie. more loss to follow-up 
and a possible lower self-sampling sensitivity). In chapter 7, we showed 
that as long as women do not switch it is effective to offer self-sampling to 
non-attendees in every scenario studied. Otherwise, there has to be ensured 
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that (i) the relative CIN II+ sensitivity is at least 0.95, (ii) women with at 
least a 1.7 higher underlying risk are recruited by self-sampling, and (iii) the 
total attendance increases by at least 6 percentage points. In chapter 8, we 
found no association between socioeconomic status (SES) and the under-
lying cervical cancer risk, although an 39% increased underlying cervical 
cancer risk for low as compared with high SES women cannot be ruled out. 
However, compared to the general population this maximal increase will 
probably be lower. Thus, the second criterion (ie. women with at least a 1.7 
higher underlying risk as compared to the general population are recruited 
by self-sampling) will not be met by focussing on lower SES non-attendees. 
As we believe it is likely that women will switch, and because it is unknown 
whether all conditions will be met in real-practice, it is essential to carefully 
monitor the effects, both on the short term and on the long term, in order to 
guarantee equal or increased effectiveness when adding HPV self-sampling 
to the programme.
CoNCluSioNS 
• The effect of using liquid-based cytology as primary test method for cer-
vical cancer screening depends on the type of liquid-based cytology test 
used. Our results strongly suggest that SurePath has a higher sensitivity 
to detect progressive CIN lesions as compared to conventional cytology, 
accompanied by an increased detection of CIN I, while ThinPrep has a 
lower sensitivity to detect progressive CIN lesions. 
• The gradual implementation of liquid-based cytology was responsible 
for a small but significant part of the increase in CIN I, CIN II, and CIN 
III detection rates as observed in the Dutch cervical cancer screening 
programme. Therefore, other factors must also have played an important 
role.
• More than 70% of the cervical cancers diagnosed within young women 
aged 30 to 35 years could not have been prevented by using a more 
sensitive screening test at the first screening at age 30. As most of these 
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cervical cancers occurred in women who did not have a history of cervi-
cal cancer screening, increasing the attendance rate for screening at age 
30, for instance by offering non-attendees HPV self-sampling, can make 
an important contribution in preventing cervical cancers within young 
women. 
• Lower socioeconomic status women do not seem to have an increased 
underlying cervical cancer risk to be diagnosed with cervical cancer, 
although it cannot be ruled out. 
• The following variables are most influential in determining whether of-
fering HPV self-sampling to non-attendees is effective: the relative CIN 
II+ sensitivity of HPV self-sampling, the extra attendance rate gener-
ated by HPV self-sampling, the ability to target higher underlying risk 
non-attendees, and the percentage of regular attendees switching from 
office-based to HPV self-sampling. In the absence of switching, offering 
self-sampling is effective under every studied condition. If all regular 
attendees would switch, offering self-sampling is effective if simultane-
ously (i) the attendance rate increases by at least 6 percentage points, (ii) 
women with at least a 1.7 higher underlying risk are recruited by self-
sampling, and (iii) the relative CIN II+ sensitivity of HPV self-sampling 
as compared to office-based sampling is at least 0.95. 
• The effect of using new screening tests on preventing cervical cancers 
can be estimated incorrectly when using surrogate endpoints such as 
CIN detection rates instead of interval cancer rates. 
RECommENDATioNS 
• If the decision which primary cytology test to use depends on the ability 
to prevent cervical cancer cases, the use of SurePath in the Dutch cervi-
cal cancer screening programme is to be preferred. 
• The sensitivity of ThinPrep to detect progressive CIN lesions should be 
improved in order to guarantee an equal harm-benefits ratio and effec-
tiveness of the original Dutch cervical cancer screening programme. 
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• It is unknown whether all conditions for offering HPV self-sampling to 
be (cost-)effective are met in real-practice. Therefore, it is essential to 
carefully monitor the effects, both on the short term and on the long 
term, in order to guarantee the effectiveness of the Dutch cervical 
cancer screening programme when offering HPV self-sampling to non-
attendees. 
• Careful monitoring of the effects of implementing new screening tests 
or new screening strategies using population-based data is necessary to 
guarantee the effectiveness of the programme.
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SAmENVATTiNG
Baarmoederhalskanker is de vierde meest voorkomende kanker bij vrouwen 
wereldwijd en het treft met name jonge vrouwen tussen de leeftijd van 40 
en 55 jaar. In 2012 werd wereldwijd bij circa 528.000 vrouwen de diagnose 
baarmoederhalskanker gesteld en circa 266.000 vrouwen overleden aan de 
gevolgen hiervan. In Nederland zijn de baarmoederhalskanker incidentie 
en mortaliteit gedaald naar 5,9 en 1,4 gevallen per 100.000 vrouwen in 2013, 
gestandaardiseerd naar de wereld leeftijdsdistributie. 
CINnen, oftewel cervical intraepithelial neoplasia, worden beschouwd als 
asymptomatische prestadia van baarmoederhalskanker die gerangschikt 
zijn naar de ernst van de lesie (CIN I, II en III respectievelijk). Deze 
preklinische, maar detecteerbare fase van baarmoederhalskanker duurt 
volgens schattingen gemiddeld meer dan 10 jaar, wat het ideaal maakt voor 
screening. In Nederland is screening naar baarmoederhalskanker daarom 
alreeds in de jaren 70 geïntroduceerd. Sinds 1996 worden vrouwen tussen 
de 30 en 60 jaar elke 5 jaar uitgenodigd voor primaire cytologie screening 
met cytologie triage, eventueel gecombineerd met het testen op humaan 
papillomavirus (HPV). 
DuNNElAAGCyToloGiE AlS PRimAiRE TEST mETHoDE
In de afgelopen 10 tot 15 jaar zijn de meeste Nederlandse laboratoria die 
primaire screeningstesten verwerken geswitcht van conventionele cytologie 
naar dunnelaagcytologie (DLC) (“liquid-based cytology”) testen SurePath 
en ThinPrep. Lange tijd werd aangenomen dat de CIN II+ sensitiviteit van 
DLC gelijk was aan dat van conventionele cytologie, alhoewel tot nu toe 
geen studies zijn gepubliceerd die CIN detectie rates tussen verschillende 
DLC testen en conventionele cytologie hebben vergeleken. In hoofdstuk 2 
hebben we laten zien dat het gebruik van SurePath als primaire test methode 
leidde tot een 8% toename in CIN II+ detectie rates, alhoewel het tegelijker-
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tijd leidde tot een 14% toename in de detectie van CIN I. Het gebruik van 
ThinPrep had geen effect op de CIN I en CIN II+ detectie rates. In hoofdstuk 
3 toonden we aan dat een trend in toenemende CIN detecties plaatsvond 
van 2003-2005 tot 2009. Alhoewel de implementatie van DLC testen Sure-
Path en ThinPrep heeft bijgedragen aan deze trend, was het niet de enige 
oorzaak. Een verhoogd achtergrondrisico kan hierdoor niet worden uitge-
sloten. Echter, het is mogelijk dat we de bijdrage van DLC implementatie 
hebben onderschat, aangezien het aannemelijk is dat het effect van switchen 
naar Surepath of ThinPrep verschilt per laboratorium en geen data per la-
boratorium beschikbaar zijn. Gebaseerd op resultaten van hoofdstuk 2 lijkt 
SurePath meer effectief in het voorkomen van baarmoederhalskanker dan 
ThinPrep en conventionele cytologie, terwijl ThinPrep en conventionele 
cytologie even effectief lijken. Echter, slechts een fractie van de CIN lesies 
zou zonder screening en de bijbehorende behandelingen doorgegroeid 
zijn tot baarmoederhalskanker. Het detecteren van een gelijk of toenemed 
aantal CINnen staat dus niet perse gelijk aan het voorkomen van evenveel of 
meer baarmoederhalskankers. Dit werd bevestigd in hoofdstuk 4 waar we 
hebben aangetoond dat het effect van nieuwe screeningstesten verkeerd kan 
worden ingeschat indien gebruik wordt gemaakt van surrogaat eindpunten, 
zoals CIN detectie rates, in plaats van intervalkanker rates (een baar-
moederhalskanker gediagnosticeerd na een negatief primair screenings-
uitstrijkje). Het risico op een intervalkanker is het laagst bij gebruik van 
SurePath als primaire test methode en het hoogst bij gebruik van ThinPrep 
als primaire test methode. Dit verschil in intervalkanker rates suggereert 
ten zeerste dat de sensitiviteit om progressieve CIN lesies te detecteren 
het hoogst is wanneer gebruik wordt gemaakt van SurePath en het laagst 
wanneer gebruikt wordt gemaakt van ThinPrep als primaire test methode. 
Daarom is de kans groot dat SurePath meer effectief is in het voorkomen 
van baarmoederhalskankers dan conventionele cytologie, wat op zijn beurt 
weer meer effectief is dan ThinPrep. Echter, de focus moet niet alleen liggen 
op de voordelen van het implementeren van nieuwe screeningstesten of 
strategieën (het aantal voorkomen baarmoederhalskankers), maar ook op 
de nadelen (het verlies in kwaliteit van leven door screening en bijbeho-
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rende behandelingen). Een goede indicator voor het negatieve effect van 
screening is de mate van overdiagnose, oftewel het aantal exces diagnoses in 
de situatie met screening versus de situatie zonder screening gedeeld door 
het aantal diagnoses met screening. In hoofdstuk 5 hebben we de mate 
van overdiagnose in het huidige programma geschat op 70,6%, indien alle 
CIN grades worden meegeteld en conventionele cytologie als primaire test 
methode wordt gebruikt. Het gebruik van ThinPrep leidt waarschijnlijk tot 
een hogere mate van overdiagnose aangezien minder baarmoederhalskan-
ker worden voorkomen en het aantal gedetecteerde CIN lesies gelijk blijft. 
Het is daarom aannemelijk dat minder levensjaren gecorrigeerd voor de 
kwaliteit van leven (“quality-adjusted life-years”) worden verkregen en dat 
de effectiviteit van het programma afneemt bij gebruik van ThinPrep als pri-
maire test methode. Het gebruik van Surepath leidt waarschijnlijk ook tot 
een hogere mate van overdiagnose aangezien we hebben berekend dat 3,1 
extra CIN I, 3,2 extra CIN II en 3,1 extra CIN III lesies worden gedetecteerd 
per extra voorkomen intervalkanker.  Echter, hoe het gebruik van SurePath 
het aantal verkregen levensjaren gecorrigeerd voor de kwaliteit van leven, 
en daarmee de effectiviteit van het Nederlandse bevolkingsonderzoek naar 
baarmoederhalskanker, zal beïnvloeden moet worden bepaald met gebruik 
van microsimulaties. 
ToENAmE iN oPKomST DooR HET AANbiEDEN VAN DE HPV 
zElfAfNAmESET AAN NiET-oPKomENDE VRouwEN
Een studie die de screengeschiedenis van Nederlandse vrouwen met 
baarmoederhalskanker onderzocht liet zien dat meer dan de helft van de 
kankers voorkomt in vrouwen die de afgelopen zes jaar niet deelnamen aan 
het Nederlandse bevolkingsonderzoek naar baarmoederhalskanker. En dat 
terwijl minder dan tien procent van de vrouwen met kanker een  voorgaand 
negatief screeningsuitstrijkje had. Dit werd bevestigd in hoofdstuk 6 waarin 
we hebben laten zien dat de meerderheid van de baarmoederhalskankers in 
30 tot 35-jarige vrouwen nog steeds zou plaatsvinden indien een sensitievere 
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screeningstest op leeftijd 30 zou worden gebruikt. Echter, een gedeelte van 
deze kankers had voorkomen kunnen worden door het verbeteren van de 
screeningsopkomst. Een veelbelovende manier om de screeningsdeelname 
te verhogen is door het aanbieden van de HPV zelfafnameset (ZAS) aan 
niet-opkomende vrouwen van primaire HPV screening, wat naar verwach-
ting vanaf 2016 zal worden ingevoerd. Dit zou echter ook kunnen resulteren 
in een afname van de effectiviteit van het programma indien teveel vrouwen 
zullen “switchen” van reguliere screening naar zelfafname, gegeven dat met 
behulp van de ZAS minder CIN II+ wordt gedetecteerd (door meer loss 
to follow-up en een eventueel lagere sensitiviteit). In hoofdstuk 7 hebben 
we laten zien dat het effectief is om de HPV ZAS aan te bieden aan niet-
opkomende vrouwen in elk bestudeerd scenario, zolang er geen vrouwen 
switchen. Anders moet er worden gegarandeerd dat (i) de relatieve CIN 
II+ sensitiviteit tenminste 0,95 is, (ii) vrouwen met tenminste een 1,7 keer 
verhoogd achtergrondrisico deelnemen en (iii) de deelname graad toeneemt 
met tenminste 6 percentage punten. In hoofdstuk 8 hebben we geen associ-
atie gevonden tussen sociaaleconomische status (SES) en het baarmoeder-
halskanker achtergrondrisico, alhoewel een 1,39 hoger achtergrondrisico 
voor lagere versus hogere SES vrouwen niet kan worden uitgesloten. In 
vergelijking met de algemene populatie zal dit cijfer waarschijnlijk nog wat 
lager uitvallen. Aan het tweede criterium (vrouwen met ten minste een 1,7 
keer verhoogd achtergrondrisico moeten deelnemen via de HPV ZAS) zal 
dus niet worden voldaan door te focussen op lagere SES vrouwen. Het is 
daarom essentieel dat de kortetermijneffecten en langetermijneffecten van 
het aanbieden van de HPV ZAS zorgvuldig worden gemonitored zodat op 
die manier de effectiviteit van het programma kan worden gewaarborgd. 
Helemaal aangezien het aannemelijk is dat vrouwen zullen switchen en het 
onbekend is of aan alle criteria wordt voldaan in de praktijk. 
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CoNCluSiES 
• Het effect van het gebruik van dunnelaagcytologie als primaire test 
methode hangt af van het type dunnelaagcytologie. Onze resultaten sug-
gereren ten zeerste dat Surepath een hogere sensitiviteit heeft om pro-
gressieve CIN lesies te detecteren dan conventionele cytologie, terwijl 
het tegelijkertijd meer CIN I lesies detecteert. ThinPrep lijkt daarentegen 
een lagere sensitiviteit te hebben om progressieve CIN lesies te detecte-
ren. 
• De geleidelijke implementatie van dunnelaagcytologie is verantwoorde-
lijk voor een klein, maar significant gedeelte van de toename in CIN I, 
CIN II en CIN III detectie binnen het Nederlandse bevolkingsonderzoek 
naar baarmoederhalskanker. Andere factoren moeten daarom ook een 
belangrijke rol hebben gespeeld. 
• Meer dan 70% van de baarmoederhalskankers gediagnosticeert in 30 
tot 35-jarige vrouwen had niet kunnen worden voorkomen door het 
gebruik van een sensitievere screeningstest op leeftijd 30. Een groot 
gedeelte van deze kankers komt echter voor in vrouwen zonder enige 
screeningsgeschiedenis. Het verhogen van de screeningsopkomst op 
screeningsleeftijd 30, bijvoorbeeld door het aanbieden van de HPV 
zelfafnameset, kan daarom een belangrijke bijdrage leveren aan het 
voorkomen van baarmoederhalskankers in jonge vrouwen. 
• Lagere sociaaleconomische status vrouwen lijken geen verhoogd ach-
tergrondrisico te hebben om baarmoederhalskanker te ontwikkelen, 
alhoewel dit niet kan worden uitgesloten.  
• De volgende variabelen zijn het meest invloedrijk in het bepalen of het 
aanbieden van de HPV zelfafnameset aan niet-opkomende vrouwen 
effectief is of niet: De relatieve CIN II+ sensitiviteit van de HPV zelf-
afnameset, de extra opkomst gegenereerd door de HPV zelfafnameset, 
het vermogen om vrouwen met een hoger achtergrondrisico te bereiken 
en het percentage vrouwen wat switcht van reguliere screening naar 
zelfafname. In elk bestudeerd scenario is het effectief om de HPV 
zelfafnameset aan te bieden aan niet-opkomende vrouwen zolang er 
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geen vrouwen switchen. Indien alle reguliere opkomende vrouwen 
zouden switchen, is het aanbieden van de HPV zelfafnameset effectief 
indien tegelijkertijd (i) de deelname graad toeneemt met tenminste 6 
percentage punten, (ii) vrouwen met ten minste een 1,7 keer verhoogd 
achtergrondrisico deelnemen en (iii) de relatieve CIN II+ sensitiviteit 
tenminste 0,95 is. 
• Het effect van nieuwe screeningstesten op het voorkomen van baarmoe-
derhalskanker kan verkeerd worden ingeschat indien gebruik wordt 
gemaakt van surrogaat eindpunten, zoals CIN detectie rates, in plaats 
van intervalkanker rates. 
AANbEVEliNGEN 
• Als de beslissing welke primaire cytologietest te gebruiken afhangt van 
het vermogen om baarmoederhalskanker gevallen te voorkomen, dan is 
het gebruik van SurePath in het Nederlandse bevolkingsonderzoek naar 
baarmoederhalskanker aan te raden. 
• De sensitiviteit van ThinPrep om progressieve CIN lesies te detecteren 
moet worden verbeterd om een gelijk nadeel-voordeel ratio en gelijke 
effectiviteit van het Nederlandse bevolkingsonderzoek naar baarmoe-
derhalskanker te garanderen.    
• Het is onbekend of aan alle condities voor de HPV zelfafnameset om 
(kosten)effectief te zijn wordt voldaan in de praktijk. Daarom is het 
essentieel dat de kortetermijneffecten en langetermijneffecten van het 
aanbieden van de HPV zelfafnameset zorgvuldig worden gemonitored 
zodat op die manier de effectiviteit van het Nederlandse bevolkingson-
derzoek naar baarmoederhalskanker kan worden gewaarborgd. 
• Monitoring van de effecten van het implementeren van nieuwe 
screeningstesten of nieuwe screeningsstrategieën, gebruik makende van 
populatie-data, is essentieel om de effectiviteit van het programma te 
waarborgen. 
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Daarnaast wil ik al mijn co-auteurs (Bert, Caspar, Corine, Folkert, Inge, 
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avondjes, terasjes, weekendjes weg, afterparty’s, koninginnedagavonturen, 
“diepzinnige” discussies met iets te veel drank op , pre-oud en nieuw party’s 
en ga zo maar door. Alles is bij ons reden om gezellig bij elkander te komen 
en zonder jullie was mijn leven half niet zo leuk!
Mijn lieve Leiden vriendjes en vriendinnetjes, schaapjes en schaappinetjes. 
Ook jullie mogen niet in dit dankwoord ontbreken. Wat hebben we toch een 
mooie tijden beleefd en wat gaan we nog een mooie tijden beleven! Mijn 
lieve PB-matties (het worden er teveel om hier persoonlijk te bedanken), 
wat heb ik genoten van al onze gekke en maffe avonturen in Hepatho, de 
Hut, in een random Nederlandse stad of ergens in het verre buitenland! 
Mijn studentenleven had niet mooier kunnen zijn! Ik kan niet wachten tot 
we alweer op de 3e lustrumreis gaan! Ik stem wederom als locatie op die 
rokende vulkaan. Ooit zal ik toch eens gelijk krijgen? Ook nog een speciaal 
woord richting mijn geliefde Club-de-Groep. Jullie hebben me onder jullie 
hoede genomen toen ik nog een klein, schattig en vooral erg druk sjaarsje 
was. Door jullie raakte ik al snel ingeburgerd in het Leidse leven en ik dank 
jullie voor alle mooie momenten die we samen hebben gehad en die er zeker 
ook nog gaan komen!! Op een mooie vriendschap. Proost!
Ook dank aan mijn lieve schone ouders en zus! Ik ben erg blij dat ik jullie in 
mijn leven heb, ik had me geen lievere schoonfamily kunnen wensen!
En nu, last but not least, dank aan mijn geliefde family (Paps & Mams, en 
natuurlijk ook Björn & Cynthia, en niet te vergeten: de liefde van mijn leven, 
Marijn). De afgelopen vier jaar, en ook de jaren daarvoor, hebben jullie me 
op elk mogelijke manier gesteund. Jullie boden een luisterend oor als een 
van mijn papers weer eens was afgewezen, jullie stelden doordachte vragen 
over mijn onderzoek (waar ik soms het antwoord nog niet eens op wist) 
230 Appendices
en jullie proostten mee toen mijn 1e papers eindelijk werden geaccepteerd. 
Dank je wel dat jullie er altijd voor me zijn, deze is voor jullie! 
Lieve Marijn, als allerlaatst (nu echt) richt ik me tot jou persoonlijk. Wat 
hebben we de afgelopen 10 jaar toch een hoop meegemaakt en wat vullen 
we elkaar toch goed aan. Door jou heb ik geleerd minder te plannen en 
het leven meer te nemen zoals het is. Ik kan niet wachten om de rest van 
mijn verdere leven met jou te delen. Ik hou van je. Op naar ons volgende 
avontuur!
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Kirsten Rozemeijer was born on the 23th of March 1987, in Rijnsburg, the 
Netherlands. In 2005, she completed her secondary education at the Scala 
College in Alphen a/d Rijn and she started studying Biomedical Sciences 
in Leiden. During her bachelor internship at the department of Clinical 
Epidemiology in the LUMC, she compared the performance of two different 
test methods to measure kidney function. This resulted in a co-authorship 
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international conference for epidemiologists and students, respectively. 
During her research master in the Biomedical Sciences, she decided to 
focus more on the epidemiology and public health of scientific research. She 
wrote an essay about the advantages of including men in studies on female 
related risk factors which both resulted in a paper that has been submitted 
to an international scientific journal and a presentation at an international 
student conference. She performed laboratorial research comparing the 
antigen capacity of naïve versus Epstein-Barr virus transformed non-human 
primate B-cells at the Biomedical Primate Research Centre at Rijswijk. In 
addition, she compared the immune response after yellow fever vaccination 
between young and old vaccinees at the department of Infectious Diseases 
at the LUMC.  She obtained her Master of Science degree in 2011. 
From 2011 to 2015, she was employed as researcher at the department 
of Public Health at the Erasmus MC in Rotterdam where she evaluated the 
Dutch cervical cancer screening programme by using the nationwide net-
work and registry of histo- and cytopathology (PALGA). During this period 
she also obtained her Master of Public Health degree at the Netherlands 
Institute for Health Sciences.
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